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ABSTRACT
DNA methylation is one of the epigenetic mechanisms that controls gene
expression and is vulnerable to early life environmental toxicant exposures. Our goal
was to use two fish models, Fundulus heteroclitus and Danio rerio (zebrafish), to study
the benzo(a)pyrene (BaP) effects on DNA methylation status and whether the
alterations could contribute to BaP-mediated reproductive and developmental toxicities.
Initially, we used Fundulus to study BaP effects on glycine N-methyltransferase (GNMT)
expression throughout development. Fundulus embryos were exposed to waterborne
BaP at nominally 10 or 100 μg/L and both GNMT mRNA expression and enzyme activity
were measured. Quantitative PCR and whole mount in situ hybridization showed
significant GNMT mRNA induction by BaP, whereas enzyme activity was significantly
inhibited in the Fundulus embryos. In zebrafish embryos, however, neither significant
changes in GNMT gene expression nor enzyme activity were detected after BaP (1, 10
or 100 μg/L) exposure. Similarly, BaP exposure did not change DNA methyltransferase
1 (DNMT1) mRNA expression at 48, 60 or 96 hours post fertilization (hpf) or nuclear
DNMT1 enzyme activity at 96 hpf. Direct waterborne BaP treatment at 100 μg/L from
2.5 to 96 hpf to zebrafish embryos did significantly decrease global DNA methylation by
55% and gene-specifically reduced promoter CpG methylation in vasa by 17%. As a
result, vasa mRNA expression was significantly increased by 33% after exposure.
However, BaP at 100 μg/L did not change CpG island methylation or gene expression in
Ras-association domain family member 1 (RASSF1), telomerase reverse transcriptase
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(TERT), c-Jun and c-Myca at 96 hpf. Teratogenic effects (e.g. delayed hatching,
pericardial edema, head and tail deformity) were observed in the BaP-treated embryos.
Parental zebrafish were also exposed to 23 ± 2.3 or 42 ± 1.9 μg/L BaP to measure the
adverse impact on fish reproduction. Although BaP was detected in the exposed fish
ovaries, egg production was not affected. However, when the offspring were
continuously exposed, they demonstrated DNA hypomethylation, high mortality and
various deformities (e.g. pericardial edema, tube heart, head and tail deformity). In
conclusion, BaP can cause global and gene specific DNA methylation changes in
zebrafish embryos, which may play a role in BaP-induced reproductive and
developmental toxicities.
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CHAPTER 1. INTRODUCTION
1. Polycyclic aromatic hydrocarbons (PAHs) and benzo(a)pyrene (BaP)
1.1 PAHs in the environment
PAHs are hydrocarbons that contain at least two fused aromatic rings and do not
have any substituent or heteroatom. PAHs with two to three-member rings are often
known as low molecular weight (LMW) PAHs, and those with more than four rings are
high molecular weight (HMW) PAHs (National Oceanic and Atmospheric Administration
(NOAA)

http://ccma.nos.noaa.gov/stressors/pollution/nsandt/bs_contaminants.aspx).

HMW PAHs are more lipophilic and less volatile compared to LMW PAHs. LMW PAHs
can react with sunlight, ozone or NO2 and break down in days or weeks. HMW PAHs
are more persistent and can adhere to sediments for weeks or months before they may
be degraded by microorganisms.
PAHs are ubiquitous organic pollutants in the environment that include more than
100 different compounds and 32 of them (including BaP) are listed as priority pollutants
by

the

United

States

Environmental

Protection

Agency

(EPA,

http://www.epa.gov/region1/npdes/permits/generic/prioritypollutants.pdf). PAHs exist in
natural and processed fossil fuels, such as crude oil, coal, tar, etc. PAHs arise from
incomplete burning of carbon-containing materials, such as diesel, gas, petroleum, coal,
wood, fat and tobacco. Combustion of different types of material at different
temperatures can generate different mixtures of PAHs, which enter the environment and
widely spread in air, water, soil and sediment. Volatile PAHs from combustion can
adhere to fine or ultrafine particulate matter (Wichmann 2007), become suspended in
the air and ultimately deposit in the soil. Water running off asphalt (or tar) roads or roof
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shingles can carry PAHs to the creeks, rivers and finally settle into sediments (Ahrens
and Depree 2010). Because of rapid urbanization, anthropogenic sources of PAHs are
increasing dramatically. Likewise, PAH deposition in urban and lake sediments is also
increasing. This is in contrast to other classes of persistent environmental pollutants (e.g.
polychlorinated biphenyls (PCBs) and dichlorodiphenyltrichloroethane (DDT)) where
there have been in downward trends in deposition during 1970-2001 in the United
States (Van Metre and Mahler 2005).

1.2 Human exposure to PAHs
The primary human exposure routes to PAHs are inhalation and dietary
consumption. Humans are exposed to a variety of PAHs through breathing
contaminated air (Bostrom et al. 1994) including indoor smoke from fuel burning (Pott
and Heinrich 1990), and first hand and second hand tobacco smoke (DeMarini 2004;
Nelson 2001; Rodgman et al. 2000). Food is another major source of PAH intake during
everyday life (Guillen et al. 1997; Phillips 1999). One study claimed that more than 90%
of the daily PAH exposure was associated with food (Stahl et al. 2004). PAHs in the food
are introduced from contamination or formed during the cooking process. Char-grilled
food contains high amounts of PAHs (Lijinsky 1991). Laboratory tests have found that
hamburgers can have up to 38 ng/g PAHs (Knize et al. 1999). In addition, PAHs can
also be absorbed through the skin by contact with air, water or soil near hazardous sites
(Moody et al. 2007; Phillips et al. 1990).
Workers in coal power plants, coal mining, petroleum industry, smeltering, iron and
steel foundries, trash incineration, asphalt production plants, smoke houses, coking
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plants, fire fighting, road paving and roofing have a higher likelihood to exposure to
PAHs at the workplace (Boffetta et al. 1997; Bosetti et al. 2007). The Occupational
Safety and Health Administration (OSHA) sets a limit of 0.2 mg/m3 of PAHs in the air.
The National Institute for Occupational Safety and Health (NIOSH) recommends that
the average air levels for coal tar products should be below 0.1 mg/m3. Other guidelines
for PAH containing material (e.g. mineral oil, coal, and coal tar) in the workplace are
also available.

1.3 PAHs as a human health concern
Epidemiological studies have shown that PAH exposures are linked to cancer, birth
defects,

immunodeficiency,

Organization

International

respiratory
Agency

and

for

nervous

Research

on

disorders
Cancer

http://monographs.iarc.fr/ENG/Classification/index.php;

USEPA

(World

Health

(IARC)

2009,
2007,

http://www/epa.gov/ttn/atw). The most important health concerns for PAHs are their
carcinogenic, mutagenic and teratogenic toxicities. IARC classified benzo(a)pyrene
(BaP), coal tars, coal-tar pitches and tobacco as group 1, carcinogens to human
(ATSDR, 2009); dibenz(a,h)anthracene, dibenzo(a,l)pyrene and creosotes were listed
as

group

2A,

benzo(b)fluoranthene,

probably

carcinogens

to

benzo(c)phenanthrene,

human.

Benz(a)anthracene,
benzo(j)fluoranthene,

benzo(k)fluoranthene, dibenzo(a,h)pyrene, dibenzo(a,i)pyrene, indeno(1,2,3-cd)pyrene,
chrysene, and naphthalene were listed as group 2B, possibly carcinogens to human.
Generally speaking, the HMW PAHs are more likely to be carcinogenic. A number of
PAHs, such as benzo(e)pyrene and pyrene, are non-carcinogenic. The site of
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carcinogenesis is usually related to the route of exposure. Following inhalation,
ingestion, and dermal contact of PAHs, lung cancer (Bruske-Hohlfeld 2009), colorectal
cancer (Alexandrov et al. 1996) and skin cancer (Kubasiewicz et al. 1991; Kubasiewicz
and Starzynski 1989) can develop, respectively. Other cancers, such as liver cancer
(Chen et al. 2002), esophageal cancer (Gustavsson et al. 1998), laryngeal cancer (Elci
et al. 2003), renal cancer (Karami et al. 2011), and bladder cancer (Geller et al. 2008)
were also reported after occupational or environmental PAH exposure.
In addition to cancers, reproductive and developmental toxicities are associated with
human PAH exposure. PAH exposure was associated with increased male idiopathic
infertility risks (Xia et al. 2009b) through damaging sperm DNA (Gaspari et al. 2003;
Han et al. 2011) and impairing human semen quality (Xia et al. 2009a).

Human

primordial germ cell (PGC) formation was disrupted after exposure to PAHs (Kee et al.
2010). In smoking women, the PAHs present in cigarettes were found in the serum and
follicular fluid. High levels of BaP in the follicular fluid (1.79 ng/ml) were associated with
women who did not conceive (Neal et al. 2008). PAHs also enter the placenta (Gladen
et al. 2000) and adversely affect pregnancy outcomes (Dejmek et al. 2000) including:
increased risk of early pregnancy loss (Wu et al. 2010a); reduced fetal growth (Choi et
al. 2008; Perera et al. 2005); preterm delivery (Singh et al. 2008); and low birth weight
(Choi et al. 2006). In utero PAH exposure delayed the cognitive development in the
fetally exposed children at 3 (Perera et al. 2006) and 5 years of age (Edwards et al.
2010). Higher cord blood levels of PAH-DNA adducts were associated with more
symptoms of anxiety/depression in 4.8 year-old children and attention problems in 7
year-olds (Perera et al. 2011). Prenatal PAH exposure was also associated with
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childhood asthma (Perera et al. 2009). Even paternal preconceptional exposure to PAH
increased the risk of childhood brain tumors, such as neuroectodermal tumors (Cordier
et al. 1997) and astroglial tumors (Cordier et al. 2004).

1.4 BaP as a model PAH
Due to the environmental complexity, humans are usually exposed to PAH mixtures
both in work and life. However, it is extremely difficult to characterize mixture toxicities
and their mode of action. Therefore, pure compounds are widely used in laboratories to
investigate PAH toxicity. BaP is one of most used surrogate genotoxic and carcinogenic
PAHs. BaP has five aromatic rings (Figure 1) and is the first pure chemical recognized
as a carcinogen (Miller 1970). BaP is the main contributor to the carcinogenesis of
environmental PAH mixtures, ranging from 37-70% (Delgado-Saborit et al. 2011). A
potency equivalence factor (PEF) risk approach was develop to relate individual PAH
carcinogenic potency to that of BaP (Collins et al. 1998). Adjustments such as
administration routes can be factored in to the PEF for better prediction outcomes
(Knafla et al. 2006; Schneider et al. 2002). However, the method was based on the
assumption of additive effects of PAH carcinogenicity and did not adequately predict

Figure 1. Bio-transformation of BaP to its toxic metabolite BPDE.
5

synergistic and antagonistic interactions between different PAHs, thus lead to under- or
overestimation of carcinogenic potency in some cases (Billiard et al. 2008; Bostrom et al.
2002; Culp et al. 1998).
Like all PAHs, BaP is ubiquitously found in fossil fuels, all smoke released from
incomplete combustion of organic materials (including tobacco smoke), and processed
food. For non-smoke, non-occupational exposed populations, inhalation of polluted air
and ingestion of contaminated food are the major sources of BaP exposure. Airborne
BaP concentrations can be as high as 9.6 μg/m3 in traffic tunnels (De et al. 1994). In UK
and Sweden, the regulatory goal of airborne total PAH level is lower than what is
equivalent to 0.25 ng/m3 BaP and 0.1 ng/m3 BaP, respectively. Currently, there is no US
EPA regulatory limit for BaP in ambient or indoor air. BaP dietary intake was estimated
to be 0.16 to 3.3 μg/day (for a 60 kg person) or 0.05 μg/kg/day by WHO
(http://inchem.org/documents/jecfa/jecmono/v28je18.htm).

In

general,

BaP

concentrations in food ranged from 0.004 to 1.2 ng/g (Lioy et al. 1988). However, in
smoked, fried, and charcoal cooked food, much higher concentrations of BaP can be
detected. For example, BaP from 5.25 to 5.55 ng/g were found in fried chicken (Lee and
Shim 2007) and 62.2 ng/g in charcoal grilled beef (Aygun and Kabadayi 2005). Although
BaP has low water solubility (2.3 to 4 μg/L) (ATSDR 1995; Mackay and Shiu 1977), it
can be found dissolved in drinking water or suspended with particulate matter in surface
water. The EPA Maximum Contaminant Level (MCL) for BaP in concentrations drinking
water is 0.2 μg/L (http://water.epa.gov/drink/contaminants/index.cfm#1). The EPA
Maximum Contaminant Level Goal (MCLG) for BaP concentrations in drinking water is 0.
As mentioned previously, BaP binds strongly to sediments and soil. Therefore, children
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may have greater daily BaP intake than adolescents and adults because of more handto-mouth activity (Falco et al. 2003).

1.5 BaP as a carcinogen
Humans are always exposed to complex mixtures of PAHs, yet BaP has served as
a key marker to represent the entire PAH mixture. IARC has concluded that there was
adequate evidence to list BaP as a known human and animal carcinogen in 2009.
However currently, BaP is classified by the US EPA as B2: a probable carcinogen to
human.
There is extensive evidence showing that BaP is carcinogenic to laboratory animal
models including mice (Rabstein et al. 1973), rats (Stefanou et al. 1998), guinea pigs,
hamsters (Thyssen et al. 1981), rabbits, primates, and fish via dietary (Neal and Rigdon
1967), gavage (Brune et al. 1981), inhalation, intraperitoneal injection (Friemann et al.
1996), dermal contact (Knafla et al. 2006), subcutaneous, or water borne exposure
(Wang et al. 2010). The incidence of total tumors, tumors at the site of administration,
and distant site tumors is significantly increased after subchronic or chronic exposure
(Culp et al. 1998). Other routes of BaP administration, such as intravenous injection
(Rees et al. 1979), injection to pelvis, vaginal painting, implantation in stomach wall,
lung

and

brain

are

also

carcinogenic

(EPA,

IRIS,

http://www.epa.gov/iris/subst/0136.htm). Thus, BaP is usually used as a positive control
in carcinogenesis studies or as a chemical tool to develop cancer in animal models.
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1.6 BaP as a reproductive and developmental toxicant
BaP significantly compromises the success of reproduction and development. BaP
exposure in humans was linked to altered sperm morphology, decreased sperm
(Cordier et al. 1997) and egg numbers (Zenzes et al. 1998). BaP adducts have been
detected in preimplantation embryos from parents who both the father and mother, or
mother alone, or father alone, smoked cigarettes (Zenzes et al. 1999). BaP has also
been found in adult reproductive organs (Zenzes et al. 1998), maternal blood, placenta,
cord blood and human breast milk (Madhavan and Naidu 1995).
The reproductive and developmental toxicity by BaP is well established in animal
studies. BaP is an endocrine disruptor because it altered testicular steroidgenesis and
decreased plasma testosterone concentrations in male rats (Inyang et al. 2003). BaP
also decreased plasma progesterone, estrogen and prolactin concentrations in female
rats (Archibong et al. 2002). Our lab found that BaP exposure significantly reduced
aromatase expression, an enzyme that converts testosterone to estrogen, in Fundulus
brain (Dong et al. 2008). In addition, BaP reduces the weights of gonads, damages
ovarian follicles, and leads to infertility in animal models (Mohamed et al. 2010).
Transplacental distribution of BaP was reported in mice (McCabe and Flynn 1990),
rats (Withey et al. 1993), guinea pigs (Kihlstrom 1986), and primates (Lu et al. 1993).
BaP exposure during pregnancy resulted in increased fetal death (Archibong et al. 2002;
Wu et al. 2003), low birth weight, and abnormalities (Barbieri et al. 1986; Legraverend et
al. 1984).
BaP exposure has profound health effects on the offspring of BaP exposed parents.
In utero BaP exposure increased incidence of lung adenomas in five subsequent
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generations of mice (Turusov et al. 1990). Male offspring were more prone to develop
liver tumors compared to female offspring in later life (Wislocki et al. 1986). In mice,
reduced numbers of sperm and egg follicles were found in the offspring of exposed
adults (Kristensen et al. 1995; MacKenzie and Angevine 1981). Paternal BaP exposure
also adversely impacted sperm function and fertility in at least three generations of mice
(Mohamed et al. 2010).

1.7 BaP modes of action
BaP is metabolism dependent and has a genotoxic mode of action (Xue and
Warshawsky 2005). The bay-region dihydrodiol epoxide pathway is the major
mechanism that bioactivates BaP to the anti-7β,8α-dihydroxy-9α,10α-epoxy-7,8,9,10tetrahydrobenzo(a)pyrene (BPDE) (Levin et al. 1982). BPDE is the most carcinogenic
BaP metabolite and is responsible for the formation of stable, pro-mutagenic DNAadducts. Initially, BaP is oxidized to epoxides by the monooxygenase system, e.g.
cytochrome P450s (CYP1A1 and CYP1B) (Kleiner et al. 2004) and prostaglandin H
synthase (Marnett 1981). Then, the epoxide ring at the angular benzo-ring, aka “bayregion”, opens up by epoxide hydrolase, forming the electrophilic bay-region diolepoxide (Figure 1). At last, BaP metabolites conjugate with glutathione and are excreted
primarily through the urine.
In the cytoplasm, BaP binds to both 8S and 4S PAH binding proteins (Raha et al.
1990). The 8S PAH binding protein is more commonly known as the aryl hydrocarbon
receptor (AhR). Simply, the BaP-AhR complex translocates to the nucleus,
heterodimerizes with ARNT and then transactivates genes, including CYP1A1, CYP1A2,
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CYP1B1 and some Phase II enzymes. Paradoxically, CYP1A1 has duel functions in the
BaP metabolism: CYP1A1 bioactivates BaP to BPDE but also detoxifies BaP for
excretion (Uno et al. 2001). The detoxification role outweighs the activation role
because knocking out or down CYP1A1 potentiated BaP toxicities.
DNA damage by BaP is through formation of bulky DNA-adducts (covalent binding
to DNA) and reactive oxygen species (ROS). BPDE primarily binds to the N2 position of
deoxyguanosine, forming BPDE-N2-deoxyguanosine (BPDE-N2-dG), which makes up
~80 to 90% of all DNA-adducts (Arce et al. 1987; Yang et al. 1991). BPDE-N7-dG,
BPDE-N6-deoxyadenosine (BPDE-N6-dA) and BPDE-N3-deoxycytidine (BPDEN3-dC)
are minor adducts (Osborne et al. 1981). Stable-DNA adducts may become apurinic
sites (Melendez-Colon et al. 2000), leading to deletion, base substitution and frameshift
mutations (Lenne-Samuel et al. 2000). Moreover, DNA-adducts may cause strand
breakage, micronucleus formation and chromosome instability (Harper et al. 1989).
Bulky DNA-adducts interfere the fidelity of DNA replication and result in mistakes like
deletion, GC-TA transversion (Olsen et al. 2010) and mis-match (Wei et al. 1991). DNAadducts can be spontaneously released, reduced by hepatic glutathione S-transferase
(Thapliyal et al. 2002) or be repaired by nucleotide excision repair machinery (Zou et al.
2001). However, it might take weeks or months to remove all adducts (Talaska et al.
1996) and some lesions are resistant to DNA repair (Wani et al. 2002). If DNA adduct
formation occurs on and mutates oncogenes (Vousden et al. 1986), tumor suppressor
genes (Wani et al. 2000) and other signaling genes, carcinogenesis may be initiated.
DNA-adducts can be quantitated (Boysen and Hecht 2003; Santella et al. 1984) and
used as biomarkers for BaP exposure (Machella et al. 2004) and disease risk (Phillips
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2005). Induction of DNA adducts is correlated with tumor development in breast, spleen,
liver, lung and bladder (de Vries et al. 1997; Poirier and Beland 1994; Rundle 2006).
BaP-DNA adducts were also linked to induced gene mutation in spermatogonial cells
(Verhofstad et al. 2011) and DNA damage in ovaries (Ramesh et al. 2010), which may
be related to impaired fertility and transmission to future generations.
In addition to BPDE adducts, 8-hydroxydeoxyguanosine (8-OH-dG) and its keto
form, 7, 8-dihydro-8-oxodeoxyguanosine (8-oxo-dG) are identified in tissues after BaP
exposure (Malins et al. 2006; Malins and Haimanot 1990). During the oxidation of BaP
in the endoplasmic reticulum, ROS can be released, leading to oxidative stress
(Machella et al. 2004), which is often associated with carcinogenesis and teratogenesis
(Valko et al. 2004; Wells et al. 2009). ROS attack the electrophilic DNA molecules
(Marnett 2000; Wang et al. 1998) and result in base pair damage, e.g. 8-OH-dG
(Valavanidis et al. 2009) and 8-ox-dG (Wallace and Selman 1985). Both lesions have
been well characterized as premutagenic to humans and are involved in tumor initiation
and progression (Olinski et al. 2003). ROS also can cause DNA single strand breaks
and genome instability (Dianov and Parsons 2007). Proteins and lipids can be oxidized
by ROS and form DNA adducts as well (Chevion et al. 2000; Wells et al. 2009).

2. Epigenetic mechanisms
Epigenetics refers to heritable variations in gene expression that are not caused by
changes in DNA sequences (e.g. one genotype can express several phenotypes without
genetic alterations). Epigenetic mechanisms regulate almost all biological processes
from conception to death, including genome wide reprogramming during early
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embryogenesis and gametogenesis, cell differentiation, and maintenance of a
committed lineage (Delcuve et al. 2009). The epigenome which controls genome
transcription includes the interaction between chromatin modification, DNA methylation
at the dinucleotide sequence CG, and the expression of non-coding microRNAs
(miRNAs) (Choudhuri et al. 2010).

2.1 Histone modification
The histone is an alkaline structural protein found in eukaryotic cell nuclei. DNA
wraps around histone proteins to form condense units called nucleosomes, which are
the basic building blocks of chromatin. Histones are highly conserved proteins and can
be grouped into two super-classes: core histones (H2A, H2B, H3 and H4) that serve as
spools for the DNA to wrap around (Finch et al. 1977); and linker histones (H1 and H5)
that connect the nucleosomes and allow the DNA to form higher order structure (VargaWeisz and Becker 2006). Histones are positively charged due to the amine groups,
which can facilitate the interaction with the negatively charged phosphate groups in DNA
molecules (Kuo and Allis 1998). The H3 and H4 have long N-terminal tails protruding
from the nucleosome, which can undergo extensive posttranslational modifications,
such as acetylation (Wade et al. 1997), methylation (Jenuwein 2001), phosphorylation
and ubiquitination (Shilatifard 2006). Histone modifications are involved in gene
regulation, DNA repair and chromosome condensation during mitosis (Sarma and
Reinberg 2005). Histone acetylation and methylation are believed to be predominant
marks for the status of chromatin configuration, which determines the accessibility of
chromosomal proteins or transcriptional machinery to the genome (Lee et al. 1993).
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Histone acetyltransferases (HATs) add acetyl groups (O=C-CH3) to the lysine (K)
residues in the histone tail, changing the positive charged amine groups to neutral
charged amide groups, and thus, diminish the electrical attraction between the histone
and

DNA.

Therefore,

histone

hyperacetylation

is

associated

with

chromatin

decondensation (euchromatin) and gene activation (Tse et al. 1998). In contrast, histone
deacetylases (HDATs) deacetylate histone tails, resulting in chromatin condensation
(heterochromatin) and gene silencing. As histone acetylation is usually a permissive
transcription mark, histone methylation can be either active or repressive. For example,
di- or trimethylation of K4 of H3 (H3K4me2, H3K4me3) is indicative of gene activation
whereas H3K9me2/3 and H3K27me3 indicate inactive genes (Peterson and Laniel 2004;
Sims, III and Reinberg 2006). Histone methyltransferases (HMT) catalyze histone
methylation and histone demethylases remove the methyl groups (Shi et al. 2004;
Tsukada et al. 2006). Therefore, histone modifications are reversible which is critical for
the genome to be accessible according to the dynamic physiology and environment.
Histone-modification enzymes are not specific to any genes. However, specific
transcription activators and repressors recruit the right histone-modification enzymes to
the particular genome loci in certain cell types at a given point in time, and thus,
precisely control target gene expression (Jenuwein and Allis 2001).
Genetic mutations in the histone modification machinery can cause severe
diseases. Mutation in the RSK2 gene is associated with abnormal histone
phosphorylation and can lead to a rare disease called Coffin-Lowry syndrome. Similarly,
mutation in CREB-binding protein results in aberrant histone acetylation and is linked to
a disease named Rubinstein-Taybi syndrome. In addition, aberrant histone acetylation
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and methylation patterns are found in many tumor types (Ozdag et al. 2006). For
example, the inhibition of tumor suppressor genes in cancer was associated with a
combination of abnormal histone marks, such as loss of permissive marks (H3, H4
acetylation, H3K9me and H3K27me3) and gain of repressive marks (H3K4me3) (Jones
2007). Because abnormal recruitment of HDACs is often seen in cancer cells (Marks et
al. 2000), HDAC inhibitors are under active investigation as potential anti-cancer drugs
and some of them have already been approved by FDA. Moreover, HDAC inhibitors
also have a promising role in anti-schizophrenia therapy (Simonini et al. 2006).

2.2 MicroRNA (miRNA)
miRNA are non-coding, ~22-nucleotide (nt) RNA molecules that are found in all
eukaryotic cells of various multicellular organisms. They are involved in posttranslational
regulation of gene expression either by degrading target mRNA or inhibiting translation.
miRNAs are highly conserved and are more abundant in cells compared to typical
mRNA. miRNAs are highly regulated and have temporal and spatial expression patterns.
The vertebrate genome may encode hundreds if not thousands of miRNAs (Berezikov
et al. 2005) that potentially regulate 30-60% of the genes (Friedman et al. 2009; Lewis
et al. 2005). However, the biological functions of many miRNAs are still currently
unknown.
miRNA can be transcribed from either noncoding RNA genes or noncoding
sequences in introns of host genes (Rodriguez et al. 2004). In the latter case, many
miRNAs coexpress with their host genes and expression of both are driven by the same
promoter regulation (Baskerville and Bartel 2005). The biogenesis of miRNAs is initiated
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by RNA polymerase II, and is transcribed into a 70-100 nt pri-miRNA (Cai et al. 2004;
Lee et al. 2004). Subsequently, the precursor is processed into a hairpin RNA precursor
(pre-miRNA) by a ribonuclease called Drosha (Cullen 2004). Pre-miRNA is exported
from the nucleus to the cytoplasm by a transporter named Exportin 5/Ran GTP. After
that, the pre-miRNA is cleaved into 18-24 nt duplex by a ribonucleoproteic complex,
which contains the RNase III enzyme Dicer (Ketting et al. 2001). One strand of the
miRNA duplex interacts with the RNA-induced silencing complex (RISC) and becomes
the mature miRNA, which directs the RISC to the 3’ UTR of target mRNAs. In
vertebrates, the majority of miRNA recognize target mRNA by imprecise base pairing
(imperfect Watsonian match) and generally lead to inhibition of mRNA translation
through a still unknown mechanism (Saxena et al. 2003). If miRNA binds precisely to
the 3’UTR (perfect Watsonian match), the resulting double-stranded RNA activates the
RISC to break down the target mRNA (Doench et al. 2003; Zeng et al. 2003). By either
means, miRNA functions to repress target gene expression. Each miRNA can target
hundreds of different genes and each mRNA can be targeted by one or a few miRNAs
(Vatolin et al. 2006). Thus, the combination of miRNAs is able to regulate thousands of
mRNAs (Bartel and Chen 2004).
miRNA expression undergoes the same epigenetic regulatory mechanisms (e.g.
histone modification and DNA methylation) like many other protein-coding genes (Saito
et al. 2009; Saito et al. 2006). Interestingly, a small set of miRNAs (named epi-miRNA)
directly target the expression of effector proteins in the epigenetic machinery (e.g.
HDAC and DNMT), and thus, indirectly affect the expression of genes that are
controlled by the targeted effectors (Fabbri et al. 2007; Garzon et al. 2009; Noonan et al.

15

2009). This evidence indicates that a complex intertwined network is behind the three
epigenetic mechanisms.
By regulating gene expression, miRNAs are involved in many biological processes,
including cell proliferation, apoptosis, development, and maintenance of particular
differentiation states (Harfe 2005). miRNAs are not essential for early vertebrate
development (Wienholds et al. 2003) because the majority of miRNAs are not
expressed during the earliest development (Chen et al. 2005). However, miRNAs have
high expression at later stages of development (Wienholds et al. 2005) and are
essential for morphogenesis, such as heart, hematopoietic lineage, liver and adipocyte
development (Wienholds and Plasterk 2005).
More than half of the miRNAs are mapped to the cancer-associated genomic
regions, suggesting the link between aberrant miRNA expression and cancer
development (Calin et al. 2004). Indeed, alterations of the miRNome (the full spectrum
of miRNA transcription) are found in almost all human tumors (Fabbri and Calin 2010).
Signature deregulated miRNA patterns have been identified in different types of tumors
(Barbarotto et al. 2008; Calin and Croce 2006). miRNA are sometimes upregulated but
more commonly downregulated in tumor tissues (Lu et al. 2005). Altered miRNA
expression is also involved in cardiomyopathies (Tatsuguchi et al. 2007; Thum et al.
2007; van Rooij et al. 2006) and schizophrenia (Beveridge et al. 2010).

2.3 DNA methylation
Compared to histone modification and miRNA, DNA methylation is the best studied
and the only epigenetic pathway that can covalently modify the DNA molecules. DNA
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methylation is mostly found at cytosine residues that are followed by guanines (CpG
sites) (Gruenbaum et al. 1981). Approximately 2-5% of all cytosines are methylated in
mammalian genomes (Fuke et al. 2004). CpG islands (CGI) refer to regions with densly
clustered ‘CG’ dinucleotides that are typically unmethylated in active genes. In contrast,
more than 90% of DNA methylation occurs in transposable repetitive elements (aka
transposons) and do not directly relate to gene function. Alu and long interspersed
nuclear element-1 (LINE-1) are the most plentiful transposons representing 30% of the
human genome. Alu and LINE-1 are heavily methylated and often used as surrogate
markers to estimate global methylation levels (Yang et al. 2004). DNA methylation
patterns are established during early development by de novo DNA methyltransferase
(DNMT). The already established methylation pattern can be copied from the parental
strand into the daughter strand after cell each division by a semiconservative
maintenance DNMT (Razin and Riggs 1980). Therefore, DNA methylation marks are
stably memorized and have long-term impact on the phenotype without any changes in
the genotype. Although present at a lower level, DNA methylation is also found at
adenine bases (Hotchkiss 1948) and non CG cytosines (highly prevalent in embryonic
stem cells) (Ramsahoye et al. 2000) with unknown biological significance.
DNA methylation plays essential roles in many biological processes. DNA
methylation participates in cell differentiation during embryogenesis, and it is essential
for X chromosome inactivation (Riggs 1975), parental imprinting in mammals (Sapienza
1990) and silencing retrotransposons and parasitic elements that are integrated to the
genome (Bestor 1998). The DNA methylation pattern is cell-type specific, and thus,
provides cellular identity to the genome (Benvenisty et al. 1985). In addition, DNA

17

methylation is critical for the genomic stability because the global loss of DNA
methylation by demethylating agents can lead to elevated mutation rates (Chen et al.
1998), widespread chromosomal rearrangements (Ji et al. 1997) and P53 induced
apoptosis (Stancheva et al. 2001).

2.3.1 DNA methyltransferases (DNMTs)
The DNA methylation pattern is established and maintained by DNMTs. DNMTs are
responsible for transferring a methyl group from the universal methyl donor Sadenosylmethionine (SAM) to the 5’ position of cytosine forming 5-methylcytosine
(Figure 2). DNMT1 prefers hemimethylated DNA (one DNA strand is methylated and the
other one is not) and methylates the newly replicated daughter DNA strand, maintaining
the methylation patterns in a replication-dependent manner in all somatic cells (Bestor
et al. 1988). However, DNMT1 also has some de novo methyltransferase activities.
DNMT1 is rapidly recruited to sites of DNA damage where it participates in de novo
methylation (Mortusewicz et al. 2005). Indeed, DNMT1 is responsible for ~90% of all
DNA methyltrasferase activity in mammalian cells (Rhee et al. 2000). DNMT2 has still
unclear interactions with DNA but is able to methylate tRNA substrates, which is critical

Figure 2. Enzymatic reaction of DNMT. DNMT transfers a methyl group (in red) from
universal methyl donor SAM to the C-5 position of cytosine forming SAH and 5methylcytosine.
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to protect tRNA from cleavage (Goll et al. 2006; Schaefer and Lyko 2010). The de novo
DNMT3a and DNMT3b are mainly involved in establishing new methylation patterns on
DNA because they methylate unmethylated and hemimethylated DNA in the same rate
(Okano et al. 1999). DNMT3L lacks the key methyltransferase domain but it is important
for maternal genomic imprints (Bourchis et al. 2001) and de novo methylation of
retrotransposons.

2.3.2 DNA methylation and gene regulation
Generally, promoter DNA methylation and gene expression are inversely correlated
(Kass et al. 1997) which means DNA hypermethylation will effectively repress gene
expression and vice versa. Two mechanisms of gene silencing by DNA methylation are
well established. The first theory is that methylated cytosines block transcription factors’
ability to bind to their recognition elements, and thus, inhibit transcriptional activation
(Comb and Goodman 1990). The second mechanism is that methyl cytosines are
recognized by methylated DNA binding domain proteins (MBD) (Nan et al. 1997), which
will recruit histone modification enzymes, such as HDACs and HMT, to the promoter
and leave repressive marks on the chromatin (Eden et al. 1998).
However, a lot of promoter methylation patterns do not correlate well with gene
expression. For example, hypomethylated promoters can sometimes be associated with
gene silencing (Weber et al. 2007). It is possible that gene expression is permissive by
DNA hypomethylation; however, transcription only occurs in response to specific
triggers such as transcription factors and hormones.
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2.3.3 Interactions of DNA methylation and histone modification
DNA methylation often works synergistically with histone modification to control
gene expression (Cervoni and Szyf 2001; Vaissiere et al. 2008). Active chromatin is
usually associated with DNA hypomethylation whereas inactive chromatin is generally
hypermethylated (Razin and Cedar 1977). As mentioned above, MBD recruits HDACs
and HMTs to methylated DNA to deposit repressive histone marks resulting in inactive
chromatin. In addition, the polycomb complex (PRC1) and histone methyltransferase
EZH2 guides DNMT1 and DNMT3a to specific sites in the genome to maintain or initiate
DNA methylation (Vire et al. 2006). DNMTs are also found in complexes with other
histone modifying enzymes including HDAC1 and HDAC2 (Fuks et al. 2000; Rountree
et al. 2000). Furthermore, HDAC inhibitors, such as sodium butyrate (Szyf et al. 1985),
trichostatin A (Selker 1998) and valproic acid (Gottlicher et al. 2001), can increase
histone acetylation and at the same time cause global loss of DNA methylation.
Therefore, DNA methylation and chromatin structure are interrelated.

2.3.4 CpG methylation in promoter and gene body
In the human genome, about 60-90% of CpG sites are methylated (Bird 1986) and
most of them are located in repetitive regions such as transposons (Bestor and Tycko
1996) or within gene bodies especially the exons. However, in some CpG-rich DNA
fragments like CGIs, most cytosines are unmethylated (Rollins et al. 2006). The criteria
for defining CGI are relatively arbitrary and use three parameters: sequence length, GC
content, and ratio of CpG observed to CpG expected (aka CpG ratio) (Gardiner-Garden
and Frommer 1987). Based on the classic criteria, many false-positive CGIs containing
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repetitive elements were detected. Therefore, more stringent CGI criteria were proposed,
which effectively reduced the chance of finding repetitive elements by 98%, but also
excluded 11% of true CGIs in the 5’ promoters (Takai and Jones 2002). CGIs are almost
exclusively located within or in the proximity of promoter regions and occasionally exist
in transcribed regions (Baylin and Herman 2000).
Approximately 70% of genes contain CGIs in their proximal promoter regions
(upstream of TSS) (Saxonov et al. 2006). The inverse correlation between CpG-rich
promoter methylation and gene expression is well established. However, the
relationship between DNA methylation in promoters with lower CpG contents and gene
activity is still inconclusive (Boyes and Bird 1992; Hsieh 1994). A recent study found
some interesting results by comprehensively analyzing 16,000 human promoters
(Weber et al. 2007). Based on CpG ratio, GC content and length of CpG-rich region,
they divided the promoters in categories of high-CpG promoters (HCP), intermediateCpG promoters (ICP), and low-CpG promoters (LCP). HCPs are strong CGIs, ICPs are
weak CGIs, and LCPs are non-CGIs. They found that the majority of HCPs (97%) had a
very low methylation percentage, ICP were more likely to be methylated (21%), and
LCP were almost exclusively methylated. Therefore, they concluded that the outcome of
gene methylation is linked to the CpG density in the sequence. The study also found
that about 66% of HCPs were associated with active genes, especially housekeeping
genes. The HCPs and ICPs methylation status were negatively correlated to the gene
activity. Interestingly, many HCPs remained unmethylated even when they were inactive,
indicating that DNA methylation is not necessary to silence a gene. In contrast, rarely
expressed tissue-specific genes were coupled with LCPs. LCPs were predominately
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methylated in both active and inactive states, suggesting low abundance of methylated
CpGs did not completely block gene activity. However, a small subset of LCPs was
hypomethylated and associated with highly expressed genes, implying unmethylated
LCPs were more permissive to gene expression.
The majority of previous studies were focused on 5’ promoter DNA methylation,
however, recent studies also acknowledge gene-body methylation. The majority of gene
bodies have low-density of CpG sites that are frequently extensively methylated in both
plants and animals (Ball et al. 2009; Feng et al. 2010b). However, a subset of genes
contain CGIs within their coding regions, and the CGIs have variable methylation
patterns (Suzuki and Bird 2008). In contrast to the negative correlation of promoter
methylation and gene expression, gene-body DNA methylation was positively correlated
with gene transcription in plants (Zhang et al. 1999; Zilberman et al. 2007). In
vertebrates, the function of gene body methylation is not yet clear. Evidence showed
that transcribed genes have extensive DNA methylation within their gene bodies,
supporting the positive correlation of intragenic methylation and gene expression (Lister
et al. 2009; Rauch et al. 2009). Furthermore, gene bodies were hypermethylated in
active X chromosomes, which normally contained hypomethylated promoters in active
genes (Hellman and Chess 2007). However, other studies found conflicting results.
From in vitro studies, methylation of the intragenic region was sufficient to repress gene
expression in the absence of promoter methylation (Graessmann et al. 1994; Keshet et
al. 1985). Moreover, alternative promoters were discovered in gene bodies, and their
methylation was associated with gene silencing, which played a major role in regulation
of cell specific gene expression (Maunakea et al. 2010). Furthermore, a recent study
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showed that gene-body methylation was more complex than previously thought (Brenet
et al. 2011). Biological significance differed when methylation occurred in different
intragenic regions. Methylation surrounding the TSS (promoter and first exon) was
tightly linked to transcriptional silencing whereas methylation in the more downstream
portion of the gene body had no or only modest negative association with the level of
gene expression. More strikingly, the data also suggested that the first exon methylation
was much more strictly associated with gene silencing than upstream promoter
methylation. Notably, they also found that exons usually had higher methylation than
introns, except that the first exons were relatively unmethylated. Interestingly, another
study found that in the absence of methylation, high CpG content in the coding region
significantly increased the copy number of mRNA being transcribed compared to the
CpG depleted counterpart (Bauer et al. 2010). High CpG content also improved mRNA
stability and prolonged mRNA half life (Duan and Antezana 2003).

2.3.5 CpG loss during evolution
Except in CGI clusters, CpG dinucleotides contents are statistically underrepresented (about 1/16 as would be predicted) within the genome of many species due
to higher mutation rates in CpG sites (Shen et al. 1994). An unmethylated cytosine can
be deaminated spontaneously and converted to a uracil, which is readily detected and
repaired by the DNA base excision repair system (Bestor 2000). However, deamination
of a methylated cytosine creates a thymine, which is not easily recognized by the DNA
repair machinery, thus resulting in C to T transition and a CpG loss. It has been
demonstrated that heavily methylated LCPs lose CpG significantly faster than the
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relatively lower methylated ICPs and HCPs, and ICPs lose CpG more frequently than
the unmethylated HCPs (Weber et al. 2007). Therefore, hypomethylation in CGIs
protects the sequence from CpG depletion during evolution.

2.3.6 DNA demethylation
There is a long standing notion that DNA methylation is irreversible and DNA
methylation can be only altered during mitosis when unmethylated daughter DNA is
newly synthesized. However, this concept is greatly challenged by studies that have
shown that demethylation occurred in post mitotic neurons (Feng and Fan 2009;
Levenson et al. 2006) and DNMT1 conditional knock out in post mitotic neurons leads to
hypomethylation (Feng et al. 2010a). Now, it is well accepted that both active and
passive demethylation in non-divided cells does exist and DNA methylation is a
reversible reaction (Ramchandani et al. 1999). DNA excision repair is believed to be
primary responsible for passive demethylation. Therein, 5-methylcytosine is cleaved by
a glycosylase (Jost and Jost 1994), and the resulting abasic site is repaired and
replaced by an unmethylated cytosine. Another mechanism is that methylated cytosine
is deaminated to a thymidine creating a G/T mismatch, which is recognized and
removed by a G/T mismatch-specific thymine glycosylase (MBD4) (Rai et al. 2008). The
DNA is then repaired with unmethylated cytosine by an enzyme named GAD45.
Because the repair based mechanisms are not rational to justify the genome-wide loss
of DNA methylation during early embryogenesis, active DNA demethylation by
demethylases is proposed although it is still controversial. The most possible
demethylase

candidate

is

methylated

DNA
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binding

protein

(MBD2)

whose

demethylation and gene reactivation activities have been well demonstrated in vitro
(Angrisano et al. 2006; Bhattacharya et al. 1999; Bruniquel and Schwartz 2003; Detich
et al. 2002). Another proposed demethylation mechanism is via oxidation of the methyl
group in cytosine, formation of 5-hydroxymethylcytosine (-CH2OH), and release of
formaldehyde (CH3OH) (Hamm et al. 2008). Soon after the mechanism was proposed,
5-hydroxymethylcytosine was discovered in mammalian DNA (Kriaucionis and Heintz
2009). 5-hydroxymethylcytosine was converted from 5-methylcytosine by an oxidative
enzyme named TET1 (Ito et al. 2010).

2.3.7 Methods to detect DNA methylation
Traditional assays to detect DNA methylation include: methyl sensitive southern
blotting (MSSB) (Shemer et al. 1990); sodium bisulfite sequencing (BS-seq) (Frommer
et al. 1992); and methylated-specific PCR (MSP) (Herman et al. 1996). MSSB assay
relies upon the characteristics of two restriction enzymes: HpaII and MSPI. Both
enzymes recognize CCGG sequence, but HpaIl is unable to digest DNA when the
central CpG is methylated. Enzyme treated DNA can be used for PCR or Southern
blotting to determine methylation in specific genes or sequences. BS-seq and MSP are
based on a chemical reaction between sodium bisulfite and DNA that converts
unmethylated cytosine to uracil followed by traditional Sanger sequencing or
quantitative PCR. BS-seq generates single nucleotide resolution of individual CpG
methylation status and MSP provides accurate measurement of methylation percentage
in target CpGs.
Newer

methods

are

being

developed
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to

measure

DNA

methylation.

Pyrosequencing of bisulfite treated DNA detects each nucleotide based on the unique
fluorescence signals emitted when it is added to the new strand during PCR and gives
us a percentage methylation per CpG (Tost and Gut 2007). The enzyme-linked
immunosorbent assay (ELISA) assay with 5-methylcytosine antibody is validated to
detect methylation percentage in all cytosines (Liu et al. 2008). A recent breakthrough
uses liquid chromatography electrospray ionization tandem mass spectrometry with
multiple reaction monitoring (LC-ESI-MS/MS-MRM) to simultaneously detect 5methylcytosine and 5-hydroxymethylcytosine (Le et al. 2011), which are not
distinguishable by all the methods mentioned above including bisulfite treatments
(Huang et al. 2010).
Large-scale DNA methylation analysis methods are also quickly evolving in the field,
making comprehensive and high-throughput methylation analysis possible. Most of
these methods combine DNA analysis by different types of microarrays or next
generation sequencing with methylated DNA enrichment or translating DNA methylation
patterns into DNA sequence information (Zilberman and Henikoff 2007). Specifically,
DNA

can

be

prepared

immunoprecipitation

by

(MeDIP);

four

ways:

methylated

enrichment

DNA capture

by
by

methylated
affinity

DNA

purification

(MethyCap); methylation specific treatment by sodium bisulfite conversion; or
methylation-specific fractionation (such as digesting DNA with HpaII and MSPI) (Bock et
al. 2010). Two major types of microarrays have been used: promoter arrays that target
5’ promoter regions; and tiling arrays that target all gene regions (promoter, exon and
intron) (Ladd-Acosta et al. 2010). Next generation sequencing, including 454,
Solexa/Illumina and SOLiD platforms, are used to sequence enriched methylated DNA

26

libraries or even whole genomic DNA treated with sodium bisulfite (Cokus et al. 2008;
Meissner et al. 2008). Multiplexing parallel sequencing can simultaneously measure
DNA methylation in many biological samples by tagging with sample specific barcodes
(Taylor et al. 2007; Varley and Mitra 2010). Although much more powerful, large scale
methylation studies are more demanding of resources and bioinformatics.

2.3.8 DNA methylation changes in life
DNA methylation is required for normal embryogenesis. The genetic deletion of
DNMT1, DNMT3a or DNMT3b individually all result in embryonic lethality at early stages
of development possibly due to aberrant DNA methylation and expression in
developmental imprinting or X inactivation-related genes (Li et al. 1992; Okano et al.
1999). Mutations that cause deficiency of effectors in the DNA methylation machinery
are linked to severe developmental diseases (see DNA methylation and disease below).
In mammals, DNA methylation patterns experience dramatic changes in the inner
cell mass (lineage-specific) during early development and in the early primordial germ
cell (PGC, germ-line specific) after sex determination (Anway and Skinner 2006). In the
beginning, sperm has higher DNA methylation than oocytes (Mayer et al. 2000b). After
fertilization, paternal DNA undergoes a rapid global loss of methylation before the first
replication occurs (Oswald et al. 2000). In contrast, the relatively unmethylated maternal
genome initially gains de novo DNA methylation prior to DNA replication and then loses
DNA methylation in the first several DNA replication cycles (Nafee et al. 2008; Sanz et
al. 2010; Weaver et al. 2009). In mammals, both parental genomes are at equally low
levels of DNA methylation by the 8-cell stage and hit the lowest point by the blastocyst
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stage (Mayer et al. 2000a). Notably, imprinted genes resist to this genome-wide DNA
demethylation process. At the morula and blastocyst stages, extensive acquisition of de
novo DNA methylation occurs and eventually about 70% or more of CpGs are rapidly
remethylated (Shi and Wu 2009). A second round of genome-wide methylation
reprogramming occurs in PGCs after sex determination. This wave of demethylation
affects the entire genome including the imprinting genes, which wipes the genome clean
of marks in the PGCs (Popp et al. 2010; Sasaki and Matsui 2008). The methylation level
remains low in the immature germ cells until de novo methylation occurs during germ
cell maturation and gametogenesis (Lees-Murdock and Walsh 2008; Rousseaux et al.
2005). Currently, the significance of the genome-wide methylation reprogramming is not
well understood but disruptions in this highly coordinated process may contribute to
developmental defects or embryo death (Haaf 2006).
DNA methylation

patterns

are

established

in

early

embryogenesis

and

subsequently remodeled during cell differentiation. Additional dramatic global DNA
methylation changes were not detected in promoter regions when embryonic stem cells
(ESCs) differentiate to somatic cells (Mohn et al. 2008). However, modest gains and
losses of CpG methylation were observed in the transition of ESCs to neuronal
progenitor cells (Meissner et al. 2008). A few more methylation changes occurred when
the cells further transformed to terminally differentiated neurons (Mohn et al. 2008). The
promoters that gained methylation during differentiation belong to pluripotent genes (e.g.
Oct4 and Nanog) (Hattori et al. 2004; Hattori et al. 2007), germ-line specific genes,
tissue-specific genes, and some other genes (Shen et al. 2007). Therefore, terminally
differentiated cell types develop unique methylation patterns that can contribute to their
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lineage specificity (Irizarry et al. 2009).
Although most epigenetic marks are maintained after birth, DNA methylation
patterns are still changeable by external environment interventions during postnatal
development. A recent study showed that, although monozygotic twins were
epigenetically indistinguishable in young age, they started to exhibit remarkable
differences in epigenetic marks that affected their gene expression later in life (Fraga et
al. 2005). Another study found that greater than 10% of DNA methylation patterns
changed over time within the same individual genome (Bjornsson et al. 2008). These
two studies reflect that life styles and environmental factors shape the epigenome
across the life-span. However, the epigenome is the most plastic in early postnatal
development when it can be more significantly impacted by the environment. For
example, early childhood is well known to be a critical period in mammals to shape a
panel of phenotypes that last into adulthood (Ruppenthal et al. 1976). In fact, maternal
care and early social and chemical environments play important roles in behavior
phenotype development independent of genetic determination (Francis et al. 1999).
Evidence has shown that epigenetics, especially DNA methylation, are responsible for
these phenotypic changes (see DNA methylation and disease below).
At the other end of the life spectrum, DNA methylation changes are part of the
aging process and associated with age-onset pathologic phenotypes (Gravina and Vijg
2010). DNMT1 expression and activity decline and errors of methylation maintenance
increase in aging individuals (Lopatina et al. 2002). As a result, global hypomethylation,
especially demethylation of repetitive elements, is detected in most vertebrate tissues
with aging (Barbot et al. 2002; Bollati et al. 2009; Wilson et al. 1987). There are also
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numerous reports on specific gene methylation changes during aging. The most
methylation instable genes are imprinted and X-linked genes. Imprinted genes refer to a
set of genes that are normally active in one parental allele and epigenetically
suppressed in the other allele (Ferguson-Smith and Surani 2001). X-linked genes are
located in X-chromosomes that one of the two copies present in females is silenced by
epigenetic mechanisms (Okamoto et al. 2004; Wareham et al. 1987). The relaxation of
epigenetic control of genes contributes to abnormal gene expression (Bennett-Baker et
al. 2003), functional decline in organs, and progression of aged related diseases such
as Alzheimer’s disease and cancer (Wang et al. 2008).

2.3.9 DNA methylation and disease
Mutations in the effectors of DNA methylation machinery are linked to severe
developmental diseases. Functional deficiency of DNMT3b causes a rare chromosome
breakage disease named immunodeficiency, centromeric region instability and facial
anomalies syndrome (ICF) (Ehrlich 2003; Ehrlich et al. 2008), which is characterized by
global DNA hypomethylation. In another case, mutational repression of MecP2, a methyl
DNA binding protein that facilitates gene silencing, results in lethality in most males and
causes a neurodevelopmental disorder named Rett syndrome predominantly affecting
females (Chahrour and Zoghbi 2007). It is also found that promoter hypermethylation in
MecP2 was associated with patients with autism spectrum disorder (Nagarajan et al.
2008). Increased copies of CGG trinucleotide repeat in an X-linked FMR1 gene caused
DNA hypermethylation and FMR1 gene silencing, leading to fragile X syndrome, which
is characterized by distinct facial features and mental retardation (Sutcliffe et al. 1992).
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Epimutations accumulate in life and possibly contribute to disease development.
Alterations of DNA methylation as the etiology and/or biomarkers for carcinogenesis are
well established in almost all cancer types (Iacobuzio-Donahue 2009). Tumor cells are
often characterized by a paradoxical alteration of DNA methylation pattern: global DNA
hypomethylation and local promoter hypermethylation of certain genes (Ehrlich 2002;
Esteller 2005). Actually, these two types of epigenetic abnormalities affect different DNA
sequences. Hypermethylation of promoter CGI has been associated with the silencing
of tumor suppressor genes and other tumor-related genes involved in cell cycle
regulation, DNA repair, apoptosis, and signal transduction (Esteller 2002). In contrast,
demethylation occurs in repetitive elements and unique genes such as imprinted genes,
proto-oncogenes and genes associated with invasion and metastases, causing genome
instability and desuppression of disease genes (Kisseljova and Kisseljov 2005; Zapisek
et al. 1992). In addition, DNMT1 is required to maintain DNA methylation and aberrant
gene repression in human cancer cells (Robert et al. 2003). DNMT1 is overexpressed in
several cancers (Belinsky et al. 1996; Le et al. 2006; Mortusewicz et al. 2005;
Robertson et al. 1999), mediating carcinogen-induced promoter hypermethylation and
transformation of normal cells (Damiani et al. 2008). Reducing DNMT1 activity results in
re-expression of silenced tumor suppressor genes (Rhee et al. 2002; Suzuki et al. 2004).
Besides cancer, epigenetic changes are common in many other complex chronic
diseases. DNA methylation mechanisms have been implicated in asthma, type 2
diabetes, metabolic disorders and autism (Szyf 2009), major psychotic disorders (e.g.
schizophrenia and bipolar disorder) (Rutten and Mill 2009), neurodegeneration diseases
(Marques et al. 2011), suicide and depression (Autry and Monteggia 2009),
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cardiovascular disease (Kim et al. 2010), obesity (Campion et al. 2009), autoimmune
and inflammatory diseases (Wilson 2008), lupus (Balada et al. 2007), kidney diseases
(Liakopoulos et al. 2011), infertility (Rajender et al. 2011) and perhaps many others.
Therefore, epigenetic DNA methylation changes could apply clinically for disease
prediction, prevention and treatment (Muraki et al. 2009; Relton and Davey 2010).

2.3.10 DNA methylation and fetal origin adult diseases
A variety of fetal/early postnatal developmental origins of adult-onset diseases are
often associated with altered epigenetic marks, especially the most stable DNA
methylation marks that are deposited in utero or during early postnatal development and
store lifelong molecular memories. These permanent epigenetic alterations lead to
persistent differential gene expression patterns, functional changes, and increased
susceptibility to disease in the later life.
Associations between in utero nutrition and increased risk to age-related diseases
(e.g. cardiovascular diseases (CVDs) and type 2 diabetes) have been demonstrated in
numerous human epidemiology studies and their causal relationship has been strongly
supported by animal studies (McMullen and Mostyn 2009). DNA methylation is often
found to be one of the mechanisms related to maternal nutrients and its lifelong impact
on health status (Thompson and Einstein 2010; Zeisel 2009). For example, children of
pregnant women exposed to the 1944-1945 Dutch famine had higher incidence of
obesity, diabetes and CVDs in the adulthood (Lumey and Stein 1997). Lower DNA
methylation of the imprinted gene, insulin-like growth factor 2 (IGF2), was found in those
prenatal nutritionally restricted individuals compared to their unexposed, same-sex
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siblings (Heijmans et al. 2008). In rats, low-protein diet during pregnancy caused
hypomethylation in PPARα, glucocorticoid receptors and angiotensin receptors, which
was associated with persistent up-regulation of those genes that may contribute to the
development of hypertension (Bogdarina et al. 2007; Lillycrop et al. 2005). When sheep
were fed with methyl deficient diet before conception and during early pregnancy, global
hypomethylation was observed in their offspring (Sinclair et al. 2007). Moreover, 4% of
1400 CGIs were differentially methylated in those fetal sheep livers. These sheep
offspring exhibit hypertension and insulin resistance in later life. In contrast to deficiency
induced hypomethylation, maternal supplement of the soy phytoestrogen genistein in
mice caused lifelong DNA hypermethylation and protected the offspring from obesity
(Dolinoy et al. 2006).
Epigenome changes caused by adverse environmental factors during early
postnatal development can also lead to persistent changes in gene expression and late
on-set disorders. In humans, childhood abuse increased methylation in the ribosome
RNA (rRNA, essential for protein synthesis) and decreased rRNA expression (McGowan
et al. 2008). Adult suicide victims that experienced childhood adversity had different
DNA methylation marks in the glucocorticoid receptor promoters compared to suicide
victims who did not have early social adversity (McGowan et al. 2009). Similarly, early
life stress and adversity in mice produced sustained DNA methylation changes in the
regulatory regions of arginine vasopressin (Murgatroyd et al. 2009) and brain-derived
neurotrophic factor (Roth et al. 2009). The offspring of low pup licking/grooming mothers
had DNA hypermethylation in the regulatory region of glucocorticoid receptor (Weaver
et al. 2004), subsequently decreased gene expression in the hippocampus, and higher
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stress sensitivity (Liu et al. 1997). In the mice studies, all the alterations can be reversed
by brain injection of trichostatin A, a HDAC inhibitor that also reduces DNA methylation
(Cervoni et al. 2001).
As mentioned above, the epigenome is extensively erased and reestablished
between generations, however, the erasure is incomplete and part of the epigenetic
marks are transmitted to the next generation. Therefore, epigenetic alterations
established in early life not only affect the full life span in one generation but also
potentially impact the health status of future generations by inheritance. A recent study
demonstrated that early life stress was able to induce transgenerational depressive
phenotype and was associated with DNA methylation changes in sperm and brain
(Franklin and Mansuy 2010).

2.3.11 DNA methylation and toxic chemicals
More and more drugs and/or environmental chemicals have been identified as
epigenetic modifiers that cause epimutations, particularly affecting DNA methylation
patterns. Although the precise mechanisms of DNA methylation deregulation are
unknown, possible explanations are changes in SAM concentrations, DNMT activity,
and/or HDAC activity. For example, chronic ethanol consumption altered DNA
methylation both globally and gene-specifically (Garro et al. 1991), possibly through
affecting liver SAM levels and DNMT3b expression (Bonsch et al. 2006; Garro et al.
1992; Purohit et al. 2007). Primary or secondhand cigarette smoke is linked to DNA
methylation changes (Ma et al. 2011; Wilhelm-Benartzi et al. 2011) possibly via
downregulation of DNMT3b (Liu et al. 2007a). Prenatal exposure to tobacco smoke also
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affected global and promoter CGI methylation in children (Breton et al. 2009). As
mentioned above, the HDAC inhibitor valproic acid causes neural tube defects similar to
abnormalities from methyl deficient diets and the toxicity can be counteracted with a
methyl rich diet (Ornoy 2009).
Many environmental toxicants are DNA methylation modifying agents that leave
permanent epigenetic changes in the genome (Bollati and Baccarelli 2010). Exposure to
some air pollutants, such as particular matter, black carbon and benzene is associated
with DNA hypomethylation either globally or gene-specifically (Baccarelli et al. 2009;
Bollati et al. 2007; Tarantini et al. 2009). Steel plant air caused hypermethylation in
mouse sperm DNA and the effect was persistent even after exposure (Yauk et al. 2008).
Some endocrine-disruptors such as bisphenol A (Kundakovic and Champagne 2011),
diethylstilbestrol (Li et al. 1997) and persistent organic pollutants (DDT, DDE, PCBs)
(Rusiecki et al. 2008) cause DNA hypomethylation either globally or gene specifically.
Other endocrine-disruptors like di-(2-ethylhexyl)-phthalate (Wu et al. 2010b) and dioxin
(Wu et al. 2004) induce DNA hypermethylation. Environmental metals including
cadmium, chromium, lead, nickel, methylmercury and particularly arsenic also mediate
their toxicity partially through changing DNA methylation patterns (Baccarelli and Bollati
2009). Most of the above mentioned chemicals are capable of inducing oxidative stress
in tissues. Oxidative DNA damage might disrupt interactions between methyl-CpG
binding proteins and DNA, thus altering CpG methylation (Valinluck et al. 2004).
Important to this study, BaP is also an epigenetic modifier. In the early 1980s, a few
epigenetic studies used BaP and BPDE to investigate the modulation of DNA
methylation in vitro (Wilson and Jones 1983; Pfeifer et al. 1884; Wilson and Jones
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1984). BPDE preferentially bound to methylated DNA (Augoustides-Savvopoulou et al.
2003; Denissenko et al. 1996; Hu et al. 2003), and modification of DNA with BPDE
resulted in impairment of DNMT activity (Pfeifer et al. 1984; Wilson and Jones 1984;
Wilson and Jones 1983; Wojciechowski and Meehan 1984). Furthermore, treatment of
murine cell lines with BaP caused a reduction in the 5-methylcytosine content of cellular
DNA (Wilson and Jones 1983). More recently, two studies described BaP-induced hypoand hypermethylation events in in vitro cell line models (Sadikovic et al. 2004; Sadikovic
and Rodenhiser 2006). Despite no alteration in mRNA expression of the maintenance
DNMT1 or the de novo DNMT3a or DNMT3b by BPDE, there was increased expression
of DNMT1 protein and promoter hypermethylation of several genes of the panel of 30
genes analyzed in immortalized bronchial epithelial cells (Damiani et al. 2008). In
contrast, when non-transformed cells were treated with BPDE in vitro, no significant
change in methylation status was noted (Tommasi et al. 2010). These studies guided
our investigations into the potential DNA methylation disruptions by an environmentally
relevant exposure to BaP in vivo during embryogenesis.

2.3.12 The implication of epigenetics in pharmacology and toxicology
The rapid growing field of epigenetics provides new research opportunities and
challenges to classical pharmacology approaches and toxicology explanations. The
reversibility of epigenetic changes and their prevalence and causative role in a variety of
diseases, especially cancer, has implied that the epigenome can be a promising drug
target. Several drugs have been developed to restore the normal DNA methylation.
Vidaza (5-azacytidine) and Decitabine (5-aza-2’-deoxycitidine) inhibit DNA methylation
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by incorporating into the DNA during replication in dividing cells and deplete DNMTs that
come in contact with the drugs (Constantinides et al. 1977). These demethylating
agents have been approved as treatments for the leukemia and myeloblastic syndrome
(Muller et al. 2006). Unfortunately, they do not have activity against solid tumors (Mack
2006). Other inhibitors of DNA methylation that do not incorporate into the DNA have
also been developed to treat different types of cancers (Cortez and Jones 2008).
The concept that one genotype can exhibit multiple phenotypes by having varied
epigenetic marks might add insights into the cause of the variability of responsiveness
to a same drug among individuals or even within the same person at different times
during the course of treatment. Therefore, it may eventually be useful to consider epipolymorphisms to further personalize medication. Epigenetics also brings a concern that
transient exposures to drugs or chemicals that are not mutagenic can cause persistent
phenotypic changes by influence on the epigenome. Thus, in addition to studying
immediate pharmacological impacts, it may be necessary to monitor latent phenotypic
changes long after the drug therapy (Szyf 2011). High-throughput epigenome toxic
screening assays should be developed to evaluate drug and chemical safety (LeBaron
et al. 2010). For reproduction tests, it is important to know whether the phenotype of an
organism could be stably changed by exposure to epigenomic modifiers during
gestation or early prenatal changes. Furthermore, it is critical to test compound toxicity
during very early embryonic development because it is an extremely important period
for establishing and maintaining epigenetic marks. Any disruption of these epigenetic
events by chemicals could have profound consequences on normal development or
even result in fetal based adult diseases (Haaf 2006).

37

3. Glycine N-methyltransferase (GNMT)
GNMT is the enzyme responsible for the transfer of a methyl group from Sadenosylmethionine (SAM) to glycine forming S-adenosylhomocysteine (SAH) and
sarcosine (Figure 3), thus it preserves the ratio of SAM/SAH, which is a sensitive
indicator of cellular methylation capacity. GNMT makes up 1% or more of cytosolic liver
proteins (Luka et al. 2009) and is a critical mediator in the methionine and folate cycles
(Figure 4) (Mato and Lu 2007). In mammals, the homotetramer form of GNMT is
enzymatically active and is the major folate binding protein in the liver (Cook and
Wagner 1984). The homodimeric form has been suggested to be the 4S PAH binding
protein (Bhat et al. 1997) which might mediate CYP1A induction by PAHs independent
of the AhR (Raha et al. 1995) though these results are controversial.
GNMT deficiency in humans is associated with various liver pathologies such as
hypermethioninemia and hepatomegaly (Luka and Wagner 2003; Mudd et al. 2001).
GNMT has been suggested to be a tumor suppressor gene and GNMT expression was
down-regulated

in

hepatocellular

carcinoma

(HCC)

(Tseng

et

al.

2003),

cholangiocarcinoma (Huang et al. 2008) and prostate cancer tissues (Huang et al.
2007). GNMT knockout mice spontaneously develop chronic hepatitis, glycogen storage
disease (Liu et al. 2007b), steatosis and HCC (Martinez-Chantar et al. 2008).

Figure 3. Enzymatic reaction of GNMT. GNMT transfers a methyl group (in red) from
universal methyl donor SAM to glycine forming SAH and sarcosine (aka Nmethylglycine).
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Although the controversy of GNMT and 4S PAH binding protein is not resolved,
recent studies continue to find interactions between GNMT and BaP. Docking studies
suggested a preference for BaP binding to the dimeric form of GNMT (Chen et al. 2004).
BaP exposure to GNMT transfected cells have decreased BPDE adduct formation and
CYP1A1 enzyme activity. It was also suggested that GNMT sequestered BaP, in turn,
diminished BaP’s effects to the liver detoxification pathways and prevented cytotoxicity
in HepG2 cells (Lee et al. 2006). Recently, one functional xenobiotic response element
(XRE) was identified in the 5’ regulatory region of human GNMT and was inducible by
BaP treatment in vitro (Lee et al. 2009). Therefore, it was suggested that GNMT may be
involved in the cellular defense mechanism against the environmental carcinogen BaP.
Based on the reported interactions with BaP and role in methylation regulation,
GNMT was selected in my study to measure BaP effects on its expression and activity.

Figure 4. The role of GNMT in folate (Luka et al. 2007) and methionine cycles (Mato and
Lu 2007). GNMT regulates the ratio of SAM and SAH (Martinez-Lopez et al. 2008). THF:
tetrahydrofolate, MTHF: methyl tetrahydrofolate.
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4. Primordial germ cells and vasa
PGCs are germline cells formed in early embryonic stages and then migrate to the
gonadal site where they start differentiating into gametes (Wylie 2000). PGCs are
monopotent and differentiate only to eggs or sperm. Therefore, PGCs are the only cell
type capable of acquiring totipotency and giving rise to future offspring. Any genetic or
epigenetic mutations in PGCs will be potentially inherited by the future generations.
Development of PGCs depends on the maternal RNAs and proteins that are originally
deposited in the germ plasm of the oocytes and further segregated to the PGCs
(Houston and King 2000; Raz 2003). Some of those maternal RNAs (e.g. vasa) are
highly expressed in germ cells with little or no expression in other tissues and thus have
been used in the identification of PGCs. PGCs migrate and colonize from the yolk sac to
the urogenital ridge under the control of precisely timed expression of signals by the
surrounding somatic cells (Kierszenbaum and Tres 2001). During development, PGCs
undergo various unique epigenetic changes that are different from the changes in
somatic cells, which might be crucial for the germ cells to acquire totipotency (Mochizuki
and Matsui 2010).
Vasa, first identified in Drosphila, is a germline marker for which human fetal ovary
and testis expression has recently been described (Albamonte et al. 2008; Anderson et
al. 2007). Vasa is a highly conserved protein among vertebrates and invertebrates. Vasa
expression is abundant in PGCs, mature spermatocytes and oocytes (Castrillon et al.
2000). Although at very low levels, extra-gonadal vasa expression has been reported in
many species, such as rainbow trout, Xenopus, honey bee and mouse (Ikenishi and
Tanaka 2000; Tanaka and Hartfelder 2009; Yoshizaki et al. 2000). Recent evidence
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indicates that vasa homologs play distinct roles in other cell types (Gustafson and
Wessel 2010). Functionally, vasa is a putative ATP-dependent RNA helicase that
belongs to the DEAD (Asp-Glu-Ala-Asp) box family (Hay et al. 1988). DEAD box
proteins are involved in RNA splicing, processing, translational regulation, nuclear
export and degradation (Luking et al. 1998). Vasa translationally regulates two
Drosophila mRNAs, gurken and oskar, which are important for the differentiation of
gonadal-specific cell types (Ephrussi and Lehmann 1992). Mutations in the helicase
domain of vasa strongly inhibit gurken and oskar translation, resulting in germ cell
defects and female infertility (Johnstone and Lasko 2004). Loss of vasa homolog mRNA
or protein leads to reduced numbers of PGCs, defective germ cell proliferation and
differentiation and altered gametogenesis (Gruidl et al. 1996; Ikenishi and Tanaka 1997;
Kuznicki et al. 2000). Orthologs of vasa are required for germ cell development in
mammals (Fujiwara et al. 1994). In Japanese medaka, vasa is necessary for migration
but not survival of PGCs (Li et al. 2009). Vasa is essential for ovarian differentiation in
zebrafish (Weidinger et al. 2003). Vasa mRNA expression is regulated by the interplay
of growth hormone, gonadotropin-releasing hormone and estradiol during oogenesis
(Cardinali et al. 2004).
Vasa and PGCs are implicated in environmental chemical toxicity and disease
states. Vasa expression and PGC number diminished after exposure to 9, 10dimethylbenz(a)anthracene (DMBA), which is a potent PAH (Kee et al. 2010). Vasa
expression is present in many types of germ cell tumors (Zeeman et al. 2002). In
Drosophila, ectopic expression of germline genes, including vasa, drives malignant
brain tumor growth, suggesting germline traits are necessary for tumor growth (Janic et
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al. 2010).
In zebrafish, vasa has also been used to identify PGCs and monitor their migration
during development (Braat et al. 1999; Yoon et al. 1997). This provides a unique
opportunity to test chemical toxicity on the PGC development. Two putative
environmental estrogens, nonylphenol and endosulfan, caused alterations in the
distribution of PGCs in 24 hpf zebrafish embryos (Willey and Krone 2001). Cyclopamine,
a teratogen isolated from corn lily, also strongly impaired PGC migration in zebrafish
embryos (Mich et al. 2009).

5. Ras association domain family 1 (RASSF1)
RASSF1 is a relatively newly discovered tumor suppressor gene located in the
human chromosome 3p12, a region that frequently undergoes loss of heterozygosity in
solid tumors (Dammann et al. 2000). RASSF1 is given the name because it encodes a
Ras-association domain in the C-terminus and is a Ras effector protein. In humans,
RASSF1 transcribes nine different splice variants, RASSF1A-1I, by using two different
CpG-rich promoters (Hesson et al. 2007). The first promoter regulates the expression of
RASSF1A, 1D, 1E, 1F and 1G whereas the second promoter controls RASSF1B and
1C. Only isoforms RASSF1A and 1C have been studied extensively. RASSF1A can be
inactivated by gene deletions or point mutations in up to 15% of tumors (Pan et al.
2005). However, RASSF1A expression is predominantly controlled by DNA methylation
in

its

CGI

promoter.

Although

RASSF1C

shares

many

similar

biochemical

characteristics with RASSF1A, it is not subject to epigenetic silencing and its function is
almost never lost in tumor tissues (Li et al. 2004; Vos et al. 2000).

42

RASSF1A lacks enzymatic domains and serves as a scaffold for the assembly of
multiple tumor suppressor complexes. Consequently, RASSF1A promotes cell cycle
arrest, mitotic aggression, genome stabilization, apoptosis and ultimately inhibits
tumorigenesis (Donninger et al. 2007). Silencing of RASSF1A expression by
inappropriate promoter hypermethylation occurs at least 40 tumor types or pre-tumor
tissues (Richter et al. 2009; van der Weyden and Adams 2007), making it one of the
most frequent epigenetic inactivated tumor suppressor genes ever identified in human
cancer.
RASSF1A knockout mice are viable, fertile and free of apparent pathophysiological
abnormalities (van der Weyden et al. 2005). However, RASSF1A null mice were more
prone to spontaneous carcinogenesis in later life and had a shorter life span compared
to wild-type mice. RASSF1A knockout mice also have increased tumor susceptibility
after exposed to mutagens including BaP (Tommasi et al. 2005). In the GNMT knockout
mice, RASSF1 promoter was hypermethylated, contributing to GNMT-deficiency
induced pathologies (Martinez-Chantar et al. 2008).

6. Telomerase reverse transcriptase (TERT)
TERT is a catalytic subunit of the enzyme telomerase, which is essential for
telomerase activity (Liu et al. 2000). Telomerase is a ribonucleoprotein polymerase that
maintains telomere ends by addition of the telomere repeat TTAGGG. TERT expression
is limiting in certain types of cells, such as stem cells and PGCs, and is essential for
normal embryogenesis (Coussens et al. 2006; Coussens et al. 2010). Telomerase
expression is normally repressed in postnatal somatic cells, resulting in progressive
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shortening of telomeres and cellular senescence.
Deregulation of telomerase expression in somatic cells is involved in tumorigenesis
(Nowak 2000; Sirera et al. 2011). Transcriptional upregulation of TERT is the major
mechanism for cancer-specific activation of telomerase. Epigenetic mechanisms,
including DNA methylation and histone modulation, have recently been suggested to be
important for regulation of the TERT promoter (Kyo et al. 2008). In addition, a number of
factors have been identified to directly or indirectly regulate the TERT promoter,
including transcriptional activators (c-Myc, JNK/c-Jun, ER, HIF-1, Sp1, Ets, etc.)
(Alfonso-De Matte et al. 2002) as well as the repressors PITX (Qi et al. 2011). TERT
expression can be stimulated by estrogen or androgens in ovarian cancer cells (Kimura
et al. 2004; Nourbakhsh et al. 2010). Elevated TERT expression in blood cells is
associated with chronic arsenic exposure (Mo et al. 2009) implying TERT expression is
susceptible to toxicant exposures.

7. Cellular Jun (c-Jun)
The Jun oncoprotein family has four members, c-Jun, viral Jun (v-Jun), JunB and
JunD. Jun and its partner Fos are the two major components of AP-1, a potent
transcription factor complex that regulates the expression of many specific target genes
(Bohmann et al. 1987). AP-1 activation has been implicated in many downstream
biological processes, such as cell proliferation, differentiation, apoptosis and malignant
transformation. Interestingly, the c-Jun enhancer contains two AP-1 binding sites that
can mediate positive autoregulation (Angel et al. 1988). c-Jun is also modulated by
other transcriptional regulators and is further controlled by Jun N-terminal kinase (JNK)
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and other various transduction pathways (Gottlicher et al. 1998). Being an immediateearly gene, c-Jun quickly converts external growth signals into the activation of cell
cycle machinery (Shaulian and Karin 2001). Genetic deletion of c-Jun leads to
embryonic lethality due to defects in the cardiac outflow tract or hemorrhage and edema
found in the liver (Eferl et al. 1999; Hilberg et al. 1993). In contrast, overexpression of cJun does not result in abnormal phenotypes in mice (Grigoriadis et al. 1993). However,
the role of c-Jun in later stages of development or postnatal life is still unknown.
c-Jun is usually not overexpressed in any particular tumors (Vogt 2001). However,
c-Jun is located at the end of signal cascades of numerous oncogene activation
pathways, and thus, it is involved in many different mechanisms of oncogenesis. c-Jun
participates in carcinogenesis by regulating oncogenic transformation, proliferation,
invasive growth and angiogenesis (Jochum et al. 2001). In contrast, downregulation of
c-Jun attenuates tumor growth and malignant transformation.
c-Jun expression is inducible by environment chemicals. In chlorinated acetic acid
induced murine tumors, c-Jun mRNA and protein levels were elevated (Tao et al. 2000).
In contrast, c-Jun promoter was hypomethylation at HpaII sites measured by using the
methylation-sensitive restriction endonuclease digestion and Southern blot assay.
Several studies have shown that BaP was able to induce c-Jun expression in vitro
(primary human macrophages, 2 μM for 24 h) (Sparfel et al. 2010) and in vivo (Wistar
rats, 3 mg/animal for 48 h) (Qin and Meng 2006). BPDE activated the JNK pathway and
subsequently activated the downstream activity of c-Jun (Dreij et al. 2010). However,
another study found that low dose BPDE (0.05 μM for up to 24 h) exposure inhibited cJun expression in normal human amnion epithelial cells (Lu et al. 2010).

45

8. c-Myc
c-Myc is a tightly regulated and multifunctional protein in both normal and
transformed cells in response to extracellular proliferative cues. Numerous signal
transduction mechanisms and regulatory pathways have evolved to control c-Myc
expression (Kelly et al. 1983; Marcu et al. 1992). The c-Myc promoter is a key
regulatory sequence for multiple signaling cascades to control expression (Wierstra and
Alves 2008). Mitogenic stimulations rapidly induce c-Myc mRNA while anti-proliferation
signals quickly reduce c-Myc expression (Dean et al. 1986). c-Myc mRNA and protein
are extremely short-lived, and their levels quickly fall and growth arrests if without
sustained proactive signal (Dani et al. 1984; Hann and Eisenman 1984). c-Myc is a
universal transcription regulator that participates in the activation or repression of
approximate 10-15% of all genes, including conventional protein encoding genes and
non-coding miRNAs (Dang et al. 2006; Patel et al. 2004). The c-Myc binding to genomic
loci is highly depending on the DNA methylation status and chromatin modifications
(Barsyte-Lovejoy et al. 2006; Guccione et al. 2006). In different cell types and
circumstances, c-Myc regulates different sets of genes, which are usually involved in
cell cycle, differentiation, cell growth, cell adhesion and migration, genomic stability,
angiogenesis, apoptosis, metabolism and transformation. Although the effect of c-Myc
on individual genes is usually very modest and requires co-regulators, c-Myc’s function
is essential for the proliferation of all somatic cells. Genetic deletion of c-Myc results in
embryonic death due to widespread failures in organ and tissue growth (Soucek and
Evan 2010). c-Myc is also essential in the normal development of haematopoietic and
neuronal stem cells.
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Different levels of c-Myc govern its biological output: low levels of c-Myc induce
normal cell proliferation, higher c-Myc drives cancer development, and substantially
elevated levels of c-Myc triggers apoptosis (Murphy et al. 2008). c-Myc is often
deregulated and overexpressed in most tumor cells (Adhikary et al. 2005; Leder et al.
1986; Nesbit et al. 1999). Deregulation of c-Myc expression is also critical for the
initation and maintenance of tumor stem cells (Lin et al. 2009; Wilson et al. 2004). In
contrast to gene upregulation, the third exon of c-Myc was hypomethylated in colorectal
cancers (Sharrard et al. 1992) and hepatocellular carcinomas (Shen et al. 1998)
measured by using the methylation-sensitive restriction endonuclease digestion and
Southern blot assay. In chlorinated acetic acids induced murine liver tumor models, the
c-Myc promoter was hypomethylated together with elevated c-Myc mRNA and protein
(Tao et al. 2000).
BaP exposure at 0.03-3 μM for 2-24 h dose-dependently increased c-Myc
expression in normal human bronchial epithelial cells (Fields et al. 2004). Similarly,
inhalation of BaP significantly induced c-Myc expression in the lungs of Wistar rats (3
mg/animal for 48 h) (Qin and Meng 2010). However, BaP exposure at 10 μM for 72 h
decreased c-Myc mRNA by 61% in human placental choriocarcinoma JEG-3 cells
(Zhang and Shiverick 1997). BPDE exposure between 0.01-3 μM for 2-24 h decreased
c-myc expression in normal human cell lines (Akerman et al. 2004; Lu et al. 2009).

9. Fish as model organisms
Fish have been extensively used in toxicology testing, biomonitoring, and
biomedical research. Fish develop similar organ systems and share common
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biochemical and molecular pathways with mammals. Fish are easy to maintain in the
laboratory because of their small size, hardiness, short generation time and low cost.
Fish produce lots of offspring in a short period of time. Fish embryos develop rapidly in
extrauterine and are easy for observation. Importantly, the chorion has tiny pores and
could allow compounds enter the embryos from water. Collectively, fish are excellent
models for developmental biology and toxicology studies. Notably, genome duplication
occurred in fish lineages about 300 million years ago (Braasch and Salzburger 2009).
The majority of duplicated genes lost their function or degraded during evolution (Brunet
et al. 2006). However, some genes remain in at least two copies and allow us to study
their physiological sub-functions (Postlethwait et al. 2004).
This study will use two types of fish, Fundulus heteroclitus, killifish and Danio rerio,
zebrafish, to investigate the hypotheses outlined below. Fundulus is a small teleost that
lives along the Atlantic coast of United States and Canada. They are non-migratory
species, which suggests their health condition will directly reflect their environmental
conditions. In some highly contaminated waterways, Fundulus develop relevant human
diseases including cancer and reproductive/developmental deficits. Surprisingly,
Fundulus are able to develop tolerance against creosote, PCBs and PAHs (Mulvey et al.
2003; Ownby et al. 2002), making it a unique model to study detoxification mechanisms.
The utility of Fundulus as a “premier teleost model in environmental biology” has been
highlighted in a recent review (Burnett et al. 2007).
Unfortunately, there are a few disadvantages in the Fundulus model when
compared to the better established zebrafish model (Table 1). Firstly, the genomic
resources in Fundulus are not as complete as they are for zebrafish (Woods et al. 2002).
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Secondly, developmental stages and the seven periods of embryogenesis have been
more precisely described for zebrafish (Kimmel et al. 1995). Thirdly, the spawn cycle
and generation time are significantly shorter in zebrafish. Fourthly, zebrafish have been
used as model organisms since 1981 and numerous molecular tools and mutants are
available. Indeed, zebrafish are an NIH recognized comparative model organism, which
play a key role in developmental and cancer biology (Feitsma and Cuppen 2008;
Spitsbergen and Kent 2003; Stern and Zon 2003; Stoletov and Klemke 2008).
My study initially used Fundulus due to our lab’s extensive experience of studying
PAHs effects in this species. However, as my research became more genetic, the
unsequenced Fundulus genome greatly impeded the studies of promoter methylation in
many genes. Therefore, most of my aims will use the genetically better established
zebrafish model.
Table 1. Comparison of Fundulus and zebrafish.

a

Latin name

Fundulus heteroclitus

Danio rerio

Living environment

Estuarine

Fresh water

Total length

10.5 cm

4 cm

Spawn cycles

Lunar cycles

2-3 days

Hatch time

~17 days

2-3 days

Age at maturity

8 months

3 months

Egg chorion

Hard

Soft

Tolerance to PAH

Yes a

Not reported

Genome

Not fully sequenced

Sequenced

Developmental biology

Limited studies

Better studied

(Mulvey et al. 2003)

49

10. DNA methylation in fish
DNA methylation is widespread in many species of fish (Aniagu et al. 2008; Varriale
and Bernardi 2006; Walter et al. 2002; Zemach et al. 2010). The DNA methylation
system in fish is generally conserved with mammals. Bisulfite sequencing has shown
that zebrafish genome is heavily methylated (80%) at CpG sites, mostly located in
repetitive elements and gene bodies (Feng et al. 2010b). Most CGIs in zebrafish are
unmethylated. Non-CpG methylation is relatively low and evenly spread across the
zebrafish genome. Zebrafish do not have gene imprinting or sex chromosome
inactivation, making it a simplified system to study DNA methylation mechanisms in
vertebrates (Streisinger et al. 1981).
Most of the effector proteins in the methylation machinery have been identified in
zebrafish (Goll and Halpern 2011). Due to the above-mentioned genome duplication
events, some of the genes exist in multiple copies. For example, the zebrafish genome
encodes 8 DNMT orthologs (Shimoda et al. 2005). Zebrafish has a single copy of
DNMT1 which is about 73% identical to human DNMT1. DNMT2 is also present as a
single copy in zebrafish and plays a conserved role in RNA methylation (Rai et al. 2007).
Six orthologs are present in zebrafish genome and potentially serve as de novo
DNMT3a and DNMT3b. Zebrafish DNMT6 and DNMT8 are the most similar to human
DNMT3a whereas zebrafish DNMT4 is most related to human DNMT3b. DNMT3 and
DNMT5 reside in a neighboring gene to DNMT4, suggesting they might appear from a
recent gene duplication event in zebrafish (Smith et al. 2005). The functions of
individual zebrafish DNMT3-like genes are not identified yet as the antisense
morpholino knockdowns of each mRNA did not change global DNA methylation, which
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suggests those orthologs may have redundant functions. Interestingly, DNMT3L
orthologs are not found in zebrafish genome (Yokomine et al. 2006).
There are conflicting reports on whether the dynamic developmental methylation
maintenance is conserved in fish. One initial study did not detect DNA methylation
changes at DANA repetitive elements or three randomly selected genes during
zebrafish development (Macleod et al. 1999). Another study also detected constant
levels of global DNA methylation between 16-cell and larval stages in Japanese medaka
(Walter et al. 2002). In contrast, recent studies have provided evidence for methylation
changes during development. For example, when methyl-sensitive digested zebrafish
genomic DNA was analyzed, the result showed that global DNA methylation was very
low in 1-2 cell stage embryos compared to blastula stage embryos (Mhanni and
McGowan 2004). Another study using 5-methyl cytosine antibody also detected little or
no methylation before the blastula stage of zebrafish (MacKay et al. 2007). Therefore,
global DNA erasure and reestablishment are conserved in fish. In fact, active DNA
demethylation by AID, MBD4 and GADD45 was found in zebrafish (Rai et al. 2008).
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CHAPTER 2. CENTRAL HYPOTHESES AND SPECIFIC AIMS
Because BaP has adverse impacts with DNA methylation, we hypothesized that
BaP developmental toxicity is partly mediated by affecting global and/or gene specific
DNA methylation status and the activities of DNA methylation related enzymes (Figure
5).

Figure 5. Central hypotheses.

Specific aims
Aim 1 BaP Effects on GNMT mRNA Expression and Enzyme Activity in Fundulus
Aim 1.1 Clone the full length GNMT cDNA in Fundulus using 5’ and 3’ RACE.
Aim 1.2 Measure BaP effects on GNMT mRNA expression by qPCR and in situ
hybridization (ISH).
Aim 1.3 Characterize GNMT enzyme kinetics and measure BaP effects on GNMT
enzyme activity.
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Aim 2 BaP Effects on DNA Methylation in Zebrafish
Aim 2.1 Measure BaP effects on DNMT and GNMT mRNA expression and enzyme
activity.
Aim 2.2 Measure BaP effects on global DNA methylation status.
Aim 2.3 Measure BaP effects on CpG methylation and mRNA expression of germ cell
specific gene: vasa.
Aim 2.4 Measure BaP effects on CpG methylation and mRNA expression of cancer
related genes: RASSF1, TERT, c-Jun, c-Myc.

Aim 3 BaP Effects on Zebrafish Reproduction
Aim 3.1 Measure egg production and offspring survival after a waterborne BaP
exposure of parental zebrafish.
Aim 3.2 Measure BaP effects on global DNA methylation status of offspring.
Aim 3.3 Measure BaP accumulation in ovary by GC-MS.
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CHAPTER 3. METHODS
1. Fundulus care
Parental Fundulus heteroclitus were collected from an uncontaminated site at the
Newport River near Beaufort Inlet, NC, USA and raised under the University Institutional
Animal Care and Use Committee (IACUC) approved conditions. Sexually mature fish
were bred and kept in salt water (20-25 parts per thousand (ppt), Instant Ocean,
Cincinnati, OH). The fish were maintained at 20-25°C, 14:10 light-dark cycle. Adult fish
were fed twice daily with tropical flake fish food (Tetramin, Tetra Werke, Germany) and
live brine shrimp (Salt Creek Inc., Salt Lake City, UT). First generation offspring, from
wild parents, were used for the studies described below.

2. Zebrafish care
AB line wild-type zebrafish were purchased from Zebrafish International Resource
Center (ZFIN, Eugene, OR) and raised under the IACUC approved conditions. Fish
were kept in Aquatic Habitats ZF0601 Zebrafish Stand-Alone System (Aquatic Habitats,
Apopka, FL) with zebrafish water (pH 7.0-7.5, 60 parts per million (ppm), Instant Ocean,
Cincinnati, OH) at 24-30°C, 14:10 light-dark cycle. Adult fish were fed twice daily with
tropical flake fish food and live brine shrimp. Larvae were fed with ArteMac-0 powered
food (20-80 micron size, Bio-Marine, Hawthorne, CA) and/or live brine shrimp
depending on their age (Appendix Protocol 2). Sexually mature fish were selected as
breeders and their eggs were collected for the studies described below (Appendix
Protocol 1).
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3. Fundulus embryo BaP exposure
Eggs and sperm were stripped from the wild caught parental Fundulus population
and mixed together for in vitro fertilization. Fertilized eggs were randomly sorted into
three treatment groups (3 replicates per group), namely control dimethylsulfoxide
(DMSO, 1 μl/mL), 10 and 100 μg/L (part s per billion, ppb) BaP (stock solution 0.1
mg/mL in DMSO; final DMSO concentration was 1 μl/mL in all treatment groups). The
pure water solubility of BaP ranges between 2.3 (ATSDR 1995) and 4 μg/L (Mackay and
Shiu 1977). BaP is highly lipophilic with an octanol-water partition coefficient (Kow) of
2.2 x 106 (Chiao et al. 1995). Therefore, the higher concentrations of BaP exposure
could be considered to mimic either the maternal transfer and/or concentration of
organic chemicals (e.g. organochlorine pesticides, polychlorinated dibenzo-p-dioxins,
dibenzofurans, and coplanar polychlorinated biphenyls) to the lipid-rich ova (Kadokami
et al. 2004). Ten eggs were pooled randomly and raised in 10 ml of salt water (20-25 ppt)
in glass scintillation vials. Exposures for each experimental sample began at
approximately 4.5 hours post fertilization (hpf). Eggs were inspected daily for deformity
and mortality. Water was changed and eggs were re-dosed every other day. For
embryos prepared for in situ hybridization (ISH), 1-phenyl-2-thiourea (PTU, 0.003%,
Sigma-Aldrich, St. Louis, MO) was added to the culture water from 5 dpf until the end of
the exposure to reduce pigmentation. After 10 days of exposure, some embryos were
returned to clean water prior to collection on day 14. Ten embryos per pool per timepoint were collected at different time-points (embryos would typically hatch at ~17 dpf).
For RNA extraction, embryos were stored in 0.5 ml RNAlater (Applied Biosystems,
Carlsbad, CA) at -80°C immediately. For ISH, embryos were fixed in 4% (w/v)
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paraformadehyde (PFA, Sigma-Aldrich) in phosphate buffered saline (PBS, pH 7.4)
overnight and stored at -20°C freezer after removal of the chorion membrane by
watchmaker’s forceps (Fine Science Tools, Foster City, USA). For GNMT enzyme
activity assays, embryos were frozen at -80°C in 1 ml HEGD buffer (HEPES 10 mM,
EDTA 1.5 mM, glycerol 10% v/v, DTT 1 mM, PMSF 0.5 mM and pH 8.0).

4. Zebrafish embryo BaP exposure
Fertilized eggs were cleaned and disinfected with 0.4 ppm methylene blue for 1-2
minutes and then randomly sorted into four treatment groups (3-6 replicates per group),
namely control dimethylsulfoxide (DMSO, 1 μl/mL), 1, 10 and 100 μg/L BaP (stock
solution 0.1 mg/mL in DMSO; final DMSO concentration was 1 μl/mL in all treatment
groups). Thirty fertilized eggs were pooled randomly and raised in 10 ml of zebrafish
water (60 ppm, pH 7.0-7.5) in glass scintillation vials. If necessary, methylene blue in 0.4
ppm was added to zebrafish water to inhibit fungus growth. Exposures for each
experimental treatment began at approximately 2.5 hpf. Water was changed and eggs
were re-dosed every day. Embryos were pooled at different time-points (embryos would
typically hatch at 48-72 hpf).
For RNA extraction, embryos were stored in 0.5 ml RNAlater at -80°C immediately.
For ISH, embryos were fixed in 4% (w/v) paraformadehyde (PFA) in phosphate buffered
saline (PBS, pH 7.4) overnight and stored at -20°C freezer after removal of the chorion
membrane by watchmaker’s forceps. For GNMT and DNMT enzyme activity assays,
embryos were frozen at -80°C in 1 ml HEGD buffer (HEPES 10 mM, EDTA 1.5 mM,
glycerol 10% v/v, DTT 1 mM, PMSF 0.5 mM and pH 8.0). For DNA extraction, embryos
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were put in 100% ethanol, snap frozen in liquid nitrogen for 5 min, and then kept in 80°C freezer.

5. Parental zebrafish exposure
Adult zebrafish (2 males x 4 females, N=3 replicate tanks for each treatment) were
selected for acclimation for 7 days in an 818 Low Temp Illuminated Incubator (Precision
Scientific, Chennai, India) at 28.5°C. Fish tanks were covered in dark all day except
from 8:00-9:00 in the morning to trigger spawning. Eggs were collected daily from each
tank to ensure successful reproduction by the parental fish. Thereafter, fish were
waterborne exposed to control, 22.5 ± 2.3 or 42.0 ± 1.9 μg/L (ppb) BaP (using ethanol
as vehicle solvent; final ethanol concentrations were 0.1 μl/mL (100 parts per million,
ppm) in all treatment groups) for 7 days. Before exposure or after the 7-day exposure,
eggs were collected, counted, and raised in normal conditions or continuously exposed
to BaP with 10-30 embryos in 10 ml zebrafish water until 3.3 and 96 hpf for global and
gene specific methylation status measurement. Embryos were checked daily to record
survival and deformity until 96 hpf. Parental zebrafish were euthanized in buffered MS222 and their brain, heart, liver and gonad were preserved in 100% ethanol or RNAlater
for further analysis. Water was changed and re-dosed every day during fish acclimation,
adult exposure and embryo exposure. Both control and BaP water were sampled once
from each tank for actual BaP measurement by gas chromatography-mass
spectrometry (GC-MS, Agilent Technologies, Santa Clara, CA).
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6. Measurement of BaP concentration in water samples by GC-MS
Water samples (20-200 mL) were collected 20 minutes after dosing and analyzed
to confirm control and BaP concentrations from each adult zebrafish exposure tank.
Water samples were passed slowly through Sep-Pak@Vac RC C18 catridge (500 mg)
(Waters Corp., Milford, MA) pre-washed with 50 ml of 75% methanol. Methylene
chloride (10 ml, 2X) was added to the columns to elute BaP. Solvents were evaporated
under a gentle flow of nitrogen gas. Samples were re-constituted in iso-octane. BaP
concentrations in the water extracts were measured by gas chromatography (Agilent
6890) coupled with mass spectrometry (Agilent 5973N) in selected ion monitoring mode
for ions 252 and 253. BaP standards (0.1, 0.2, 0.5, 1, and 2 ppm) were prepared in isooctane to build a standard curve.

7. RNA extraction, purification and reverse transcription
Pooled embryos, larvae or tissues were homogenized with pellet pestles cordless
motor (Sigma-Aldrich) in Trizol reagent or RNAzol (Molecular Research Center,
Cincinnati, OH). RNA was isolated and purified with RNeasy Mini Kit (Qiagen, Valencia,
CA) by following the manufacturer’s protocols. Total RNA (250 ng) was reverse
transcribed to double stranded cDNA libraries by using TaqMan® Reverse Transcription
Reagents (Applied Biosystems). Each reaction contained random hexamers, multiscribe
RT, RNase inhibitor, deoxynucleotide triphosphate mix, 25 mM MgCl2, and 10X RT
buffer.
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8. Genomic DNA isolation
Genomic DNA were isolated from tissues, zebrafish embryos (>3.3 hpf) and larvae
by using DNeasy Blood & Tissue Easy Kit (Qiagen) according to manufacturer’s
protocol except the following modifications: 1. Samples were homogenized in ALT buffer
with pestles motor for at least 2 min before proteinase K overnight digestion; 2. after
RNAase incubation, samples were centrifuged at 12,000X g at room temperature for 10
min to precipitate undigested debris; 3. DNA was eluted twice from the column with 20200 μl of AE buffer depending on the yield of DNA and final concentration of DNA
needed. Because of the low DNA abundance and high yolk to DNA ratio in early
zebrafish embryos, at least 100 embryos at 3.3 hpf were needed to pool for DNA
extraction. Embryos were dehydrated with 100% ethanol to decrease the sample
volume before they were digested overnight with high concentration proteinase K.
Protocols were optimized for 3.3 hpf zebrafish embryo DNA extraction by using
phenol/chloroform, DNAzol (Molecular Research Center) or DNeasy Blood & Tissue
Easy Kit (Appendix Protocol 7).

9. Cloning of Fundulus GNMT cDNA
Full-length Fundulus GNMT cDNA was cloned from two adult Fundulus livers. A
partial Fundulus GNMT (764 bp) EST was found in the Fundulus EST database
(FunnyBase, http://genomics.rsmas.miami.edu/funnybase/super_craw4/). 5’ and 3’ rapid
amplification of cDNA ends (RACE) PCR primers were designed based on this partial
sequence (Table 2). 5’ and 3’ RACE PCR was conducted to amplify the 5’ and 3’ ends of
the GNMT cDNA, following the protocol of GeneRacer kit (Invitrogen, Carlsbad, CA).
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PCR products were cloned and sequenced as described below. Based on the novel
gene sequence, primers were designed to amply the full-length GNMT cDNA and
sequencing (Table 2). Nine white colonies of fish 1 and thirteen colonies for fish 2 were
picked for sequencing. Because consistent sequence variations were found in the 3’
UTR between clones, genomic DNA was used as template to amplify the 3’ UTR of
GNMT with designed primers (Table 2). Sequence data were analyzed with DNAstar
(SeqMan). Homology searches were carried out using the BLAST (Basic Local
Alignment Search Tool) program at http://www.ncbi.nlm.nih.gov/BLAST/, whereas
sequence

alignment

was

performed

using

the

CLUSTAL

W

program

at

http://workbench.sdsc.edu.

10. Cloning and sequencing
PCR products were run in 1% agarose gel with ethidium bromide (Appendix
Protocol 5). DNA bands were cut out and extracted with Qiagen QIAEXII Gel Extraction
Kit (Qiagen). DNA was ligated into pGem-T easy vector system I (Promega, Madison,
WI) and transformed (Appendix Protocol 6) into DH5α E.coli competent cells (Invitrogen
or homemade by using Appendix Protocol 4) and then plated on the Luria-Bertani (LB)
broth + ampicillin (or carbenicillin) + Isopropyl-b-d-1-thiogalactopyranoside (IPTG) + 5bromo-4-chloro-3-indolyl-b-d-galactopyranoside (X-Gal) plates. White colonies were
picked by toothpicks or pipette tips and were grown in liquid LB broth overnight at 37°C
at 220 RPM. Plasmid DNA was extracted from the liquid culture with a Qiaprep Spin
Miniprep Kit (Qiagen) and sequenced in the ABI 3730xl sequencer using BigDye v3.1
Terminator/Buffer Ready Rxn Cycle Sequencing kit (Applied Biosystems). Data was
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analyzed

with

DNAstar

(SeqMan)

or

BioEdit

(http://www.mbio.ncsu.edu/bioedit/bioedit.html).

11. Quantitative reverse transcription real time PCR (qPCR)
qPCR primers were designed with Primer Express® Software v2.0 (Applied
Biosystems) and selected based on their specificity (checked with NCBI Primer-Blast,
http://www.ncbi.nlm.nih.gov/tools/primer-blast/) and whether they cross exon borders
(Table 2). Relative abundance of target genes to 18S rRNA transcripts in the cDNA
libraries was determined by qPCR with SYBR®Green in a GeneAmp 7500 Sequence
Detection System (Applied Biosystems) and calculated with the 2-∆∆CT method.
Statistical differences between treatments or time-points were determined on the
linearized 2-∆CT values. Each sample was measured in two separate reactions on the
same plate. Amplification efficiencies of the target genes and 18S rRNA primer pairs
were tested to ensure that they were not statistically different. In addition to melt curve
analyses, all the target gene qPCR products were confirmed by sequencing (either by
direct sequencing or cloning).

12. Whole mount in situ hybridization
The fragment of GNMT cDNA used as template for RNA probe synthesis was
generated by PCR amplification from Fundulus liver cDNA with designed primers (Table
2). The cDNA fragment was highly specific for GNMT according to a BLAST homology
search and spanned across the putative GNMT exons 2, 3 and 4 to avoid genomic DNA
binding. The PCR product was purified and inserted to pGEM-T® Easy Vector

61

(Promega). Sense and antisense digoxigenin ssRNA probes were synthesized by in
vitro transcription using T7 or SP6 RNA polymerase on GNMT plasmid linearized with
SpeI or ApaI (Appendix Protocol 8). Following hybridization with probes overnight at
64°C, embryos were washed with 2x saline sodium citrate buffer (SSC) and 0.2x SSC
twice for 30 min, respectively. After blocking with 2% blocking reagent, embryos were
incubated overnight with 4000x diluted anti-DIG antibody conjugated with alkaline
phosphatase at 4°C. The color reaction was carried out by incubation with BM-purple
substrate. Yolks were carefully removed by watchmaker’s forceps before imaging.
GNMT expression was recorded with a digital camera and dissecting microscope.
Stained regions were outlined as regions of interest (ROIs) and the mean intensity was
calculated with the use of KODAK 1D Image Analysis Software.

13. Paraffin embedding, sectioning and H&E staining
Adult Fundulus ovary and 14 dpf BaP-exposed Fundulus embryos were fixed in 4%
(w/v) PFA in PBS (pH 7.4) overnight, followed by dehydration in increasing gradients of
ethanol (70-100%). After cleared in ClearifyTM (American Master Tech Scientific, Inc.,
Lodi, CA), tissues were embedded in melted paraffin (Paraplast X-tra, Sigma-Aldrich)
and sectioned in 5 μM thickness with a microtome (Olympus American Inc., San Jose,
CA). For ovary, three adjacent sections were placed on three different slides with an “A”
set for hematoxilin and eosin (H&E) staining, a “B” set for GNMT sense section ISH and
a “C” set for GNMT anti-sense probe section ISH. For whole mount ISH processed
embryos, two adjacent sections were placed on two different slides with an “A” set for
eosin contrast staining, a “B” set for observation of the GNMT whole mount ISH signals
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only.
The sections were cleared with ClearifyTM and a gradient of ethanol (100–70%).
The slides were treated as indicated above and covered with cover-slips and observed
under a digital camera and light microscope.

14. Section in situ hybridization
The ovary sections were cleared in gradient of ethanol (100–70%) and hybridized
with the sense and antisense Fundulus GNMT probes as described above. Following
hybridization overnight at 50°C, sections were washed with 2x SSC and 0.2x SSC twice
for 20 min, respectively. After blocking with 2% blocking reagent, embryos were
incubated overnight with 4000x diluted anti-DIG antibody conjugated with alkaline
phosphatase at 4°C followed by coloration with BM-purple substrate. The slides were
covered with cover-slips and observed under a digital camera and light microscope.

15. Cytosol and nuclear protein extraction
For Fundulus, embryos (10 eggs/pool) or adult livers were homogenized in HEGD
buffer. Supernatants after centrifugation consisted of the embryo or liver cytosolic
preparations. Adult liver cytosol was prepared for method optimization and Fundulus
GNMT enzyme kinetics studies. Protein concentrations were measured by Bio-rad
Protein Assay using BSA as a standard.
For zebrafish, cytosolic and nuclear proteins from BaP (1, 10 and 100 μg/L BaP, 96
hpf exposure) treated larvae at 96 hpf were extracted with NE-PER® Nuclear and
Cytoplasmic Extraction Reagents (Thermo Fisher Scientific, Waltham, MA) and
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quantified with Bio-rad Protein Assay using BSA as a standard.

16. GNMT enzyme activity assay
The GNMT enzymatic activity was determined using the method of Cook and
Wagner (Cook and Wagner 1984) with some modifications, and performed in duplicate.
The GNMT assay mixture (100 μl) contained 0.1 M Tris HCl (pH 7.4), 5 mM DTT, 10 mM
glycine, 1 mM S-adenosyl-L-(methyl-3H) methionine (0.02 μCi/reaction) + cold SAM,
and 180-250 μg sample protein and was incubated at 25°C for 30-60 min. Unreacted
SAM was removed by the addition of activated charcoal and an aliquot of the
subsequent supernatant was subjected to liquid scintillation counting. Assay mixtures
without protein served as negative controls and the values obtained were subtracted to
give net counts. For method optimization, incubation time was set from 15-90 min and
protein amount was loaded from 50-600 μg. To study enzyme kinetic parameters (Vmax,
Km), 10 mM glycine was used while SAM concentrations varied from 0.02-3 mM or 1
mM SAM was used while glycine concentrations varied from 0.5-20 mM.

17. In vitro BaP effects on Fundulus GNMT enzyme activity
Samples of adult Fundulus liver cytosol were incubated with BaP to determine
BaP’s ability to inhibit GNMT in vitro. The protein samples (250 μg) were mixed with 1
μL of 1 mM, 5 mM or 10 mM BaP (in DMSO, final concentrations were 10 μM, 50 μM
and 100 μM, respectively), 1 μL DMSO or water and incubated at 4°C for 1 hr prior to
performing the GNMT activity assay as described above except pH was 9.0. Each
treatment group had five samples.
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18. Total DNMT enzyme activity
Total DNMT enzyme activities (de novo, maintenance) were measured with the
EpiQuik DNA Methyltransferase Activity/Inhibition Assay Kit (Epigentek Group,
Farmingdale, NY). In an assay with this kit, the cytosine-rich DNA substrate was stably
coated on the 96-strip well. DNMT enzymes transferred the methyl group from SAM to
methylate the DNA substrate. The amount of methylated DNA, which was proportional
to enzyme activity, was then colorimetrically quantified through an ELISA-like reaction.
The OD value was measured by HTS 7000 Bioassay Reader (Perkin Elmer, Waltham,
MA). Three biological samples were used per treatment and each sample was
measured in triplicate

19. Global DNA methylation
The MethylampTM Global DNA Methylation Quantification Kit (Epigentek Group)
was used to quantitate the methylated cytosine percentage in genomic DNA samples. In
an ELISA-like reaction, a 5-methylcytosine monoclonal antibody recognized methylated
DNA and then bound to a secondary antibody linked with a substrate enzyme. After the
colorimetric reaction, the methylated cytosine amount was in proportion to the OD
intensity at 450 nm measured by HTS 7000 Bioassay Reader. The cytosine methylation
percentage was calculated by using the formula: Cytosine methylation % = (OD
(sample-negative control)/36.5%)/(OD (positive control-negative control) X 10); 36.5% is
the GC content in zebrafish genome (Han and Zhao 2008). Each sample was measured
in duplicate.
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20. Exon, intron identification and gene homology
Exon and intron as well as splice variant information of specific genes were found
on Ensembl (http://useast.ensembl.org/index.html). Gene homologs or protein pairwise
alignments were done on NCBI HomoloGene (http://www.ncbi.nlm.nih.gov/homologene)
or SDSC Biology WorkBench.

21. CpG island identification and classification
CpG islands were found by using the Methyl Primer Express v1.0 (Applied
Biosystems). The criteria to determine CpG islands were set as follows: DNA region
length longer than 300 bp but shorter than 2000 bp; greater than 50% C+G content; and
observed CpG/expected CpG (aka CpG ratio) of 0.65 (Gardiner-Garden and Frommer
1987). The CpG ratio was calculated as the (number of CpGs X number of base pairs) /
(number of Cs X number of Gs). Promoters or regions were classified into 3 categories
to distinguish strong CpG islands, weak CpG islands and sequences with low
abundance of CpG sites (Takai and Jones 2002). High CpG promoters/regions contain
a 500 bp sequence with GC content above 55%, CpG ratio above 0.75, and a CpG
observed to expected ratio greater than 0.6. Intermediate CpG promoters/regions
contain a region below 500 bp and have moderate CpG richness (GC content less than
55%) with CpG ratio between 0.48 and 0.75 and have a CpG observed to expected
ratio between 0.4 and 0.6. Low CpG promoters/regions do not have a region of 500 bp
with a CpG ratio above 0.48 or CpG observed to expected ratio above 0.4 (Weber et al.
2007).
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22. Sodium bisulfite sequencing
Genomic DNA (1-1.5 μg) was heated at 95°C for 20 min and then further denatured
at 42°C for 20 min by the addition of 3 M NaOH. Freshly made bisulfite solution (2.5 M
sodium metabisulfite and 100 mM hydroquinone, pH 5.0, 200 μl/μg DNA) was added to
the denatured DNA and then incubated at 50°C water bath in the dark for 12-16 hrs.
Desulphonation, purification and recovery of DNA were done with EZ Bisulfite DNA
Clean-up Kit (ZYMO Research, Irvine, CA) (Appendix Protocol 3). Bisulfite specific
primers were designed by using Methyl Primer Express v1.0 (Table 2) or Methprimer
(http://www.urogene.org/methprimer/index1.html). Primer pairs close to the transcription
start site (TSS) were selected for use. Target genes were amplified from bisulfite
converted DNA by PCR with ZymoTaq™ PreMix (Hot start DNA taq polymerase, ZYMO
Research) following the programs: for RASSF1 CGI 1 and 2: 95°C 10 min, 1 cycle;
95°C 1 min, 45°C 2 min, 72°C 3 min, 5 cycles; 95°C 0.5 min, 45°C 2 min, 72°C 2 min,
35 cycles; 72°C 10 min, 1 cycle. For c-Jun and c-Myca: 95°C 10 min, 1 cycle; 95°C 1
min, 50°C 2 min, 72°C 3 min, 5 cycles; 95°C 0.5 min, 50°C 2 min, 72°C 2 min, 35 cycles;
72°C 10 min, 1 cycle. For vasa and TERT: 95°C 10 min, 1 cycle; 95°C 1 min, 54°C 2
min, 72°C 2 min, 40 cycles; 72°C 10 min, 1 cycle (Lindeman et al. 2010). PCR products
were ligated into pGEM® T Easy Vector System (Promega) and transformed into high
efficiency E.coli competent cells. Each treatment or time-point had 3 biological samples
and at least 8 white colonies from each sample were selected for sequencing. Plasmid
DNA was isolated in 96-well format by Qiagen Mini Prep Robots using the alkaline
extraction procedure with Qiagen reagents. Plasmid DNA was sequenced in the ABI
3730xl sequencer using BigDye v3.1 Terminator /Buffer Ready Rxn Cycle Sequencing
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kit (Applied Biosystems). Sequence data was analyzed with DNAstar (SeqMan). CpG
methylation percentage was calculated as (total number of methylated CpG)/(number of
CpG sites in each gene X number of colonies sequenced).

23. GC-MS analysis of ovary
Ovary was weighed and homogenized in CH2Cl2 with a Tissue Tearor (Biospec
Products, Bartlesville, OK) (Appendix Protocol 9). Surrogate internal standards (contain
napthalene d8, acenaphthalene d10, phenanthrene d10, chrysene d12 and perylene
d12; all compounds were at 0.2 mg/L in stock solution, use 20 μl per sample) were
added to measure the extraction recovery. The CH2Cl2 layer was collected after
centrifugation. The tissue layer was extracted two more times with CH2Cl2. All the
CH2Cl2 extracts were combined and passed through a Na2SO4 column and an alumina
column. After purification, CH2Cl2 extracts were blown down with nitrogen gas. The
residue was dissolved in hexane. BaP d12 and fluorene d10 (2 mg/L for each chemical
in stock solution, use 20 μl per sample) were added in the sample as internal standards.
Analysis was performed by GC-MS in selected ion monitoring mode. Standard curves
were constructed with 0.02, 0.08, 0.2, 1, and 2 μg/mL of all non-deuterated compounds
prepared in hexane.

24. UPLC-MS measurement of SAM, SAH and methionine
Embryos or liver tissues were homogenized in ice cold 0.4 M perchloride acid (PCA,
60 μl PCA/10 mg tissue) to precipitate protein. Supernatants were mixed with internal
standard solutions containing [2H3]-SAM (C/D/N Isotope, Quebec, Canada). The sample
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was adjusted to pH 5-7 with 2.5 M K3PO4 and left at 4°C for 15 min to complete
precipitation of potassium perchlorate.
Analyses were performed with Waters Acquity UPLC system coupled to a Waters
Micromass

Quattro

MicroTM triple-quadrupole

system

(Waters,

Milford,

MA).

Chromatographic separation was achieved by a Waters Acquity UPLCTM BEH C18
column (1.7 μm, 2.1 mm x 50 mm). The mobile phases were 0.1% formic acid in water
(elute A) and 0.1% formic acid in acetonitrile (elute B). UPLC and MS conditions still
need further optimization to improve sensitivity.

25. Statistical analysis
Results were analyzed by GraphPad Prism 5.0 (GraphPad Software, La Jolla, CA)
and presented as mean ± S.E. Statistical differences between treatment groups were
determined using student t-test (p < 0.05) or one-way ANOVA followed by Neuman–
Keulls post hoc test (p < 0.05). Data of the qPCR was calculated with the 2-∆∆CT method.
Statistical differences between treatments or time-points were determined on the
linearized 2-∆CT values. Data of the enzyme kinetic study was analyzed using nonlinear
regression analyses (Michaelis-Menten equation). The correlation of vasa promoter
methylation with gene expression was analyzed by nonparametric correlation
(Spearman).
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Table 2. Primers used in this study.
Gene
(Genbank
accession)

Species

Experiment

GNMT
(FJ607947)

Fundulus

5’ RACE

GNMT
(FJ607947)

Fundulus

5’ RACE

GNMT
(FJ607947)

Fundulus

GNMT
(FJ607947)

Primer (5’-3’)

Comments

-

5’ RACE first
PCR

R: ATCATGCTGGTGGAGGAGGGCTTCAG

-

5’ RACE nest
PCR

3’ RACE

F: CTGAAGACCCGATGGAACCGCAGGAA

-

3’ RACE first
PCR

Fundulus

3’ RACE

F: TTCGCCCACCTGCCGGACTTCAAAGG

-

3’ RACE nest
PCR

GNMT
(FJ607947)

Fundulus

cDNA
cloning

F: ACTAGCGGCAGCATGTC
R: CCCGGATCTCAGATAAATCAG

1745-1755

GNMT
(FJ607947)

Fundulus

3’UTR
cloning

F: CATGGAGCACACCGTCTAC
R: CCCGGATCTCAGATAAATCAG

794-804

GNMT
(FJ607947)

Fundulus

qPCR

F: CCTGCCGGACTTCAAAGGA
R: TACGGTGGTCGATGATGAGAAT

101

Span putative
exon 3 and 4.

18S rRNA
(AF021880)

Fundulus

qPCR

F: TGGTTAATTCCGATAACGAACGA
R: CGCCACTTGTCCCTCTAAGAA

95

Internal control.

GNMT
(FJ607947)

Fundulus

ISH probe

F: CTGAAGTACGCGCTGAAG
R: CAAAGGAGACCAGAGCGA

188

Span putative
exon 2, 3 and 4.

GNMT
(NM_212816.1)

Zebrafish

qPCR

F: TCATTGACCACCGCAACTATG
R: GTAGTCCAGTGTGATCATGTG

149

Span exon 4
and 5.

DNMT1
(NM_131189.1)

Zebrafish

qPCR

F: GGGCTACCAGTGCACCTTTG
R: GATGATAGCTCTGCGTCGAGTC

76

Span exon 26
and 27.

Vasa
(NM_131057)

Zebrafish

qPCR

F: CAGACAAGTTGGATCAAGAAGGAA
R: GGCGGCGGCACATAAAC

64

Span exon 15
and 16.

RASSF1
(NM_001004550.1)

Zebrafish

qPCR

F: TGTGCTGGACCCAATGAGAA
R: TTATCACGAGCCAGAGTGTATCG

176

Span exon 5
and 6.

TERT
(NM_001083866)

Zebrafish

qPCR

F: GAAAGCCGGTTCTGCTGGA
R: AGAGTGAACGCCAAGACCTC

142

Span exon 1
and 2.

c-Jun
(NM_199987.1)

Zebrafish

qPCR

F: CGCTTTCTCTCAGCATGACAGT
R: GATTGAGCGTCATGTTGTGTTTC

74

Do not span
exons.

c-Myca
(NM_131412.1)

Zebrafish

qPCR

F: GAAACAATTCTGGAACGGCATT
R: AGGTTGAGTCTGTCCTTGCTGAT

168

Span exon 1
and 2.

18S rRNA
(FJ915075.1)

Zebrafish

qPCR

F: TGGTTAATTCCGATAACGAACGA
R: CGCCACTTGTCCCTCTAAGAA

95

Internal control.

Vasa
(NM_131057)

Zebrafish

BS-seq

F: ATTGGGAATTTTAGTAGTATATTGATAGT
R:TTTAATTTAAAACCTCATTAATCTAAATCA

207

Contains 5
CpGs.

RASSF1
(NM_001004550.1)

Zebrafish

BS-seq

F: TTGTTTTTTTAAGAATGAGTTTAAT
R: AACAAAAAAATAAATTCCTCAAA

314

Contains 26
CpGs.

RASSF1
(NM_001004550.1)

Zebrafish

BS-seq

F: AGTGATTTATGTTTGTGGATATGTAA
R: CCACCTATCCAAAATAAACACCAC

278

Contains 9
CpGs.

RASSF1
(NM_001004550.1)

Zebrafish

BS-seq

F: AGTGATTTATGTTTGTGGATATGTAA
R: TATACAAACCCCAAATAAACTCTCC

438

Contains 17
CpGs.

TERT a
(NM_001083866)

Zebrafish

BS-seq

F: ATAGTAGGATAGGGTTTTGGTTTTG
R: CCTTCAATTCTTCAAAAATTAACTC

233

Contains 13
CpGs.

c-Jun
(NM_199987.1)

Zebrafish

BS-seq

F: TGAGGGTATTGGTTGAGTTGTA
R: AAAAATCCTCTCCAATTTCCTCT

425

Contains 36
CpGs.

c-Myca
(NM_131412.1)

Zebrafish

BS-seq

F: TAAGTGTTAAAATGTTGGTGAGTG
R:TACTATCAAACATCAATTCCTTCC

444

Contains 26
CpGs.

Vasa
(NM_131057)

Zebrafish

ISH probe

F: ATGGCTTGTGCTCAGACTG
R: AAAGCCCATGTCCAGCATTC

384

Span exon 17,
18, 19 and 20.

HSP90α
( AF068773.1)

Zebrafish

ISH probe

F: CCGCAGGTGGAGAAGAGGA
R: GACAGTGAACGATCCGCCA

578

Span exon 1, 2
and 3.

a

R: GTTGACGCCAGCGATAAAATGCTGAAG

Product
size (bp)

a

: Lindeman et al. 2010
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Length of 3’
UTR varied.
3 copies
identified.

CHAPTER 4. RESULTS
1. BaP effects on Fundulus GNMT expression and activity
1.1 Fundulus GNMT cDNA
The full length GNMT cDNA contained a 5’ UTR of 63-base pairs (bp) long, and an
open reading frame (ORF, Genbank Accession #FJ607947) of 888 bp (Figure 6) (Fang
et al. 2010a). Three copies of the 3’ UTR with length of 794, 797 or 804 bp were cloned
(Figure 7). Fundulus GNMT 3’ UTR was much longer compared to human (198 bp,
#NM_018960) and zebrafish UTRs (351 bp, #NM_212816.1) and, to date, only
Fundulus appears to have multiple copies (at least three) of GNMT 3’UTR. The
significance of the variation in this region and between species is unknown.
Fundulus GNMT cDNA encodes a deduced protein of 295 amino acids with 74%
identity with human GNMT (#Q14749) and 79% identity with zebrafish GNMT
(#AAH62527) (Figure 8). Six single nucleotide polymorphisms (SNP) were discovered in
the ORF region from two fish livers. SNPs in ORF positions 78 (C/T), 273 (A/G), 300
(A/C) did not change the amino acid translation, but SNPs in position 455 (A/T), 587
(A/G) and 841 (A/G) caused amino acid changes (Figure 6).

1.2 Constitutive GNMT mRNA expression during Fundulus development
Unfertilized eggs had the highest expression of GNMT mRNA, suggesting maternal
deposition into the egg and a possible important role of GNMT in early development.
Constitutive GNMT mRNA expression decreased on 2 and 3 dpf but was still
significantly higher than when expression leveled off between 4 and 14 dpf (Figure 9).
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Figure 6. Fundulus GNMT cDNA and protein sequences. The open reading frame and
deduced amino acid sequences of GNMT from Fundulus heteroclitus. Motifs highlighted
in grey are the conserved domains of the S-adenosylmethionine binding site (cd02440).
Gly140, Asn141 and Arg178 (in rectangles) form a hydrogen-bonding network for glycine
binding and orientation (Luka et al. 2007; Velichkova and Himo 2005). Nucleotides in
grey and amino acid residues underlined are changed by SNPs.
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Figure 7. Alignment of the three copies of Fundulus GNMT in 3’ UTR (beginning
immediately after the stop codon to the poly A tail).Three different copies of 3’ UTR in
Fundulus GNMT were detected following cloning and sequencing of genomic DNA (from
one fish). Identical sequence results were found from 8 E.coli colonies for copy #1 (804
bp), 7 colonies for copy #2 (797 bp) and 3 colonies for copy #3 (794 bp).
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Figure 8. GNMT protein sequence alignment among human, zebrafish and Fundulus.
Fundulus GNMT shares high identity with human and zebrafish GNMT. GNMT has
conserved glycine (arrows) and SAM binding domains (rectangles) in the 3 species.

Figure 9. Constitutive GNMT mRNA expression during Fundulus embryo development
measured by qPCR. Developmental stages corresponding to the time-points were
indicated on top of the bars. Bars with different letters are significantly different (p<0.05,
n=3 pools, 10 embryos/pool; one-way ANOVA and Neumann Keuls multiple comparison
tests, GraphPad Prism 5.0). Error bars represent standard error of the mean (SEM).
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1.3 Expression of GNMT mRNA in Fundulus oocytes
Developing oocytes were divided into stage I (previtellogenic up to 0.6 mm
diameter), stage II (vitellogenesis 0.6-1.3 mm), stage III (maturation 1.3-1.9 mm with
slight protein accumulation) and stage IV (maturation without protein accumulation) as
defined by (Wallace and Selman 1985). We have further divided the stage I follicles into
three size based categories: early stage I (stage Ia, 0-0.15 mm), mid stage I (stage Ib,
0.15-0.25 mm), and late stage I (stage Ic, 0.25-0.6 mm). Strongest expression of GNMT
mRNA was detected in the ooplasm of stage Ia oocytes (Figure 10C and F) (Fang et al.
2010b). The signal gradually declined in the ooplasm of stage Ib and Ic oocytes (Figure
8I and L) and became barely detectable in later stages (data not shown).

Figure 10. Expression of GNMT mRNA in adult oocytes. Adult ovaries were sectioned
and visualized by ISH using GNMT antisense probe (C, F, I and L) or H&E staining (A,
D, G and J). Strong expression of GNMT mRNA was detected in the ooplasm of stage Ia
oocytes (primary growth stage, C and F). Signal gradually decreased and became
barely detectable by stage Ib (previtellogenic follicle stage, I) and stage II oocytes
(vitellogenesis, L). Oocytes were characterized by the presence of yolk granules in
ooplasm (Wallace and Selman 1985).
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1.4 Effects of BaP on GNMT mRNA expression in Fundulus embryos
The qPCR results showed that BaP significantly induced GNMT mRNA expression
in whole embryo extracts over controls at 3, 10, and 14 dpf, but not at 2, 4 and 7 dpf
(Figure 11). The GNMT induction was sustained even when 10 day BaP-exposed
embryos were returned to clean water for another 4 days.

GNMT fold induction by BaP

6
5

Con (DMSO)
10 μg/L BaP
100 μg/L BaP

**

4
3
2

0

** **

*

1

2 dpf

3 dpf

4 dpf

7 dpf

10 dpf

14 dpf

14 dpfa

Figure 11. BaP waterborne exposure induced GNMT mRNA expression in Fundulus
embryos. Each bar represents n = 3-6 pools of 10 embryos. Each pool of samples was
measured by qPCR in duplicate. Bars ± SEM indicate fold change of GNMT expression
normalized to 18S rRNA expression and relative to individual time-point controls (* p <
0.05, ** p < 0.01, one-way ANOVA and Neumann Keuls multiple comparison tests). 14
dpfa = Embryos were exposed to BaP for 10 days and returned to clean water for
another 4 days.

At 7 dpf, strong GNMT expression was detected in the liver of Fundulus embryos
by whole mount ISH (Figure 12). In addition to liver, GNMT was also expressed in the
urinary bladder in 10 and 14 dpf embryos. The staining intensity in the liver area was
quantitated, and BaP increased GNMT mRNA transcription in the liver of 7, 10 and 14
dpf embryos (Figure 13). Compared to controls, BaP at 10 and 100 μg/L induced liver
GNMT mRNA expression by 20% and 43% in 7 dpf Fundulus embryos, and by 10% and
9% in 10 dpf embryos, and by 20% and 32% in 14 dpf embryos. Paraffin sectioning
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more clearly showed the distribution of GNMT expression in liver and urinary bladder in
14 dpf BaP-exposed embryos (Figure 14).

1.5 Fundulus GNMT enzyme kinetics
Fundulus liver cytosol displayed Michaelis-Menten kinetics for both SAM and
glycine substrates when one of the substrates was present in limited concentrations and
the other substrate was in excess. The extrapolated Km values for SAM and glycine
were 0.18 ± 0.03 and 3.24 ± 0.53 mM, respectively (Figure 15). Estimated Vmax for
SAM and glycine were 18.80 ± 0.78 and 22.29 ± 1.17 pmol/mg*min, respectively. As
indicated in Figure 15, the curves reached plateau activities with 1 mM SAM and 10 mM
glycine, suggesting the saturation concentrations for the enzyme. Therefore, these
concentrations were selected for GNMT activity analyses. GNMT activities were linear
with reaction time (15 – 90 min) and protein amount (50 – 600 μg) (data not shown).

1.6 BaP-initiated inhibition of GNMT enzyme activity
GNMT enzyme activity exists in unfertilized eggs. Constitutive GNMT activity was
significantly higher (about two fold) in 4 dpf embryos compared to all other time-points
tested (Figure 16). Waterborne BaP exposure decreased GNMT enzyme activity in 4, 10
and 14 dpf embryos. BaP exposure of 10 and 100 μg/L inhibited embryonic GNMT
enzyme activity by 33% and 36% in 4 dpf Fundulus embryos, by 33% and 55% in 10 dpf
embryos, and by 3% and 23% in 14 dpf embryos. However, in vitro incubation with BaP
(10-100 μM) had no effect on constitutive GNMT enzyme activity (Figure 17).

77

Figure 12. BaP induced GNMT mRNA expression in the liver of Fundulus embryos
measured by whole mount ISH. Embryos were exposed to DMSO, or BaP (10 or 100
μg/L) from 4.5 hpf to 7, 10 or 14 days. From 5 dpf to the end of exposure, PTU was
added to reduce pigmentation. Arrows show GNMT expression signals (in purple color)
in the livers of 7, 10 and 14 dpf Fundulus. Arrow heads show GNMT signals in the
urinary bladders of 10 and 14 dpf Fundulus. Panel A, E and I indicate nonspecific
binding in control (DMSO treated) embryos by using GNMT sense probe. Chorion and
yolk were removed from the embryo during the experimental procedure.

Figure 13. Intensity of GNMT expression in Fundulus embryonic livers by whole-mount
ISH. Expressed regions were analyzed by means of KODAK 1D Image Analysis
Software by creating regions of interest. * Indicates significant increase of GNMT
expression between the BaP treated and control group (* p<0.05, ** p<0.01, one-way
ANOVA and Neumann Keuls multiple comparison tests). For 7 and 14 dpf ISH, each bar
represents mean ± SEM of 9-17 embryos. For 10 dpf ISH, each bar represents mean ±
SEM of 21-28 embryos.
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Figure 14. Sections of 14 dpf BaP-exposed embryos stained by GNMT whole mount ISH
(purple). Fundulus embryos were exposed to 100 μg/L BaP from 4.5 hpf to 14 days. A is
the longitudinal section of the whole fish embryo; B is the eosin contrast staining (red) of
the adjacent slide of A; C and D show strong GNMT signals in the liver and urinary
bladder, respectively. E and F are higher magnification of the rectangular region of C
and D, respectively.
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Figure 15. Determination of GNMT kinetics with Fundulus liver cytosol. Liver cytosol
(250 μg) was used and reactions were performed at 25°C for 30 min. (A) Km (SAM) was
0.18 ± 0.03 mM (R2 = 0.92) and Vmax was 18.80 ± 0.78 pmol/mg*min. Reactions were
incubated with 10 mM glycine when the SAM concentration was varied from 0.02 - 3
mM. (B) Km (glycine) was 3.24 ± 0.53 mM (R2 is 0.91) and Vmax was 22.29 ± 1.17
pmol/mg*min. Reactions were incubated with 1 mM SAM when the glycine
concentration was varied from 0.5 - 20 mM.

Figure 16. BaP waterborne exposure inhibited GNMT enzyme activity in Fundulus
embryos. Embryo cytosolic protein (180 μg) was used and reactions were performed
with 1 mM SAM and 10 mM glycine at 25°C for 60 min. Each bar represents n = 5 pools,
10 embryos per pool, * p<0.05, ** p<0.01. Constitutive GNMT enzyme activity was
significantly higher at 4 dpf (b).
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Figure 17. In vitro effects of BaP on adult Fundulus liver cytosol GNMT enzyme activity.
There were no significant changes in enzyme activity when liver cytosols were
incubated with 1 μL of 1 mM, 5 mM or 10 mM BaP (in DMSO, final concentrations were
10 μM, 50 μM and 100 μM, respectively), DMSO solvent, or water before the GNMT
assay. Adult liver cytosolic protein (250 μg) was used and reactions were performed with
1 mM SAM and 10 mM glycine (pH 9.0) at 25°C for 30 min. Each reaction was
performed five times.
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2. BaP effects on zebrafish DNA methylation status
2.1 Constitutive zebrafish DNMT1 and GNMT mRNA expression during development
DNMT1 mRNA was maternally transferred into the eggs with high abundance
detected by qPCR in unfertilized zebrafish eggs (Figure 18A). DNMT1 expression
slightly decreased by 18.5% at 2 hpf relative to unfertilized eggs and then significantly
increased by 45.8% at 3.3 hpf compared to 2 hpf expression, suggesting embryonic
synthesis of mRNA began at the blastula stage. DNMT1 mRNA transcription dropped by
81.7% at 4 hpf compared to 3.3 hpf and then remained in low level except a small peak
in expression at 60 hpf.
Like DNMT, GNMT was also a maternally transferred mRNA with high abundance
detected by qPCR in unfertilized eggs (Figure 18B). After fertilization, GNMT expression
gradually went up by 54.0% at 1.25 hpf and 94.8% at 2 hpf when compared to
unfertilized eggs. After that, the GNMT transcription dropped by 56.0% at 4 hpf and 77%
at 12 hpf when compared to 2 hpf embryos. The turning point was at 24 hpf when
GNMT mRNA rose by 536.4% compared to 2 hpf. The mRNA expression went up by
95.4% at 60 hpf compared to 24 hpf expression and then went back down at 96 hpf
when only 62% of the 60 hpf expression was detected.
By comparing the relative expression between DNMT1 and GNMT, it was found
that DNMT1 was deposited about 7-fold more in unfertilized eggs compared to GNMT
(Figure 18C). Starting at 24 hpf, GNMT exceeded DNMT1 expression by 1.6-fold. At 96
hpf, GNMT was about 5.6-fold higher than DNMT1.
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A

B

C

Figure 18. Constitutive DNMT1 (A) and GNMT (B) expression during zebrafish embryo
development measured by qPCR. Each sample was measured in duplicate. Each bar
represents the mean ± SEM expression of each gene which was normalized to internal
control 18S rRNA and relative to expression level in unfertilized eggs. Developmental
stages corresponding to the time-points were indicated on top of the bars. Graph C
shows the ratio of DNMT1/GNMT mRNA expression. Dotted line in C indicates ratio=1
(equal expression of the two genes). Bars with different letters are significantly different
(p<0.05, n=3 pools, 20-30 embryos/pool; ANOVA and Neumann Keuls multiple
comparison tests).
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2.2 BaP effects on zebrafish DNMT1 and GNMT mRNA expression
There was a trend of DNMT1 induction by the 3 concentrations of BaP in 48 and 96
hpf zebrafish embryos/larvae (Figure 19). However, the modest inductions were not
statistically significant. DNMT1 expression was not affected in zebrafish embryos that
were exposed to 1, 10, and 100 μg/L BaP from 2.5 to 48, 60 or 96 hpf.
There was also a trend of GNMT induction by BaP in 48 and 96 hpf zebrafish
embryos/larvae (Figure 20). However, the modest inductions were not statistically
significant. BaP exposure at 1, 10, and 100 μg/L did not change the GNMT expression
in zebrafish embryos.

2.3 BaP effects on zebrafish total DNMT and GNMT enzyme activity
The total DNMT enzyme activity includes the activities from all DNMT iso-zymes in
zebrafish, namely DNMT 1, 3, 4, 5, 6, 7 and 8. The activity was measured in the nuclear
extracts from whole zebrafish larvae. BaP exposure at 1, 10, and 100 μg/L did not
change the total DNMT enzyme activity at 96 hpf (Figure 21).
The GNMT enzyme activity was measured in the cytosolic extracts from whole
zebrafish larvae. BaP at 1 μg/L increased GNMT activity by ~2-fold compared to the
activity in control zebrafish at 96 hpf (Figure 22). By using student T-test, this induction
was statistically significant (P=0.035). However, it was not statistically significant by
using one-way ANOVA among all the treatment groups. BaP exposure at 10 and 100
μg/L non-significantly induced GNMT enzyme activity by 51% and 75%, respectively.
The constitutive GNMT enzyme activity was about 6.3-fold higher in 96 hpf zebrafish
compared to the average activity in Fundulus embryos.
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DNMT1 fold induction by BaP
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Figure 19. BaP effects on DNMT1 mRNA expression in zebrafish embryos at 48, 60 and
96 hpf. Each sample was measured by qPCR in duplicate. Bars ± SEM indicate fold
change of GNMT expression normalized to 18S rRNA expression and relative to
individual time-point controls. No significant difference was noticed between control and
BaP-treated groups (n=3 pools, 20-30 embryos/pool; one-way ANOVA and Neumann
Keuls multiple comparison tests).

GNMT fold induction by BaP
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Figure 20. BaP effects on GNMT mRNA expression in zebrafish embryos at 48, 60 and
96 hpf. Each sample was measured by qPCR in duplicate. Bars ± SEM indicate fold
change of GNMT expression normalized to 18S rRNA expression and relative to
individual time-point controls. No significant difference was noticed between control and
BaP-treated groups (n=3 pools, 20-30 embryos/pool; one-way ANOVA and Neumann
Keuls multiple comparison tests).
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Figure 21. BaP effects on total DNMT activity in zebrafish embryos at 96 hpf. BaP (0100 μg/L) waterborne exposure from 2.5 to 96 hpf did not alter total nuclear DNMT (de
novo and maintenance) activity in zebrafish. Each sample was measured in triplicate.
Each bar ± SEM represents n = 3 pools, 20 embryos per pool (one-way ANOVA and
Neumann Keuls multiple comparison tests).

*

200
150
100
50
0

Con

1BaP

10 BaP 100 BaP

Figure 22. BaP effects on GNMT activity in zebrafish embryos at 96 hpf. BaP at 1 μg/L
waterborne exposure from 2.5 to 96 hpf significantly increased GNMT enzyme activity (n
= 3 pools, 20 embryos per pool; * P<0.05, student T-test). However, BaP at 10 and
100 μg/L did not alter total nuclear GNMT activity in zebrafish. Each bar ± SEM
represents n = 3 pools, 20 embryos per pool (one-way ANOVA and Neumann Keuls
multiple comparison tests). Enzyme activity assay was tested in 3 times for each
biological sample.
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2.4 BaP effects on global DNA methylation status
Constitutively, 5.2% of cytosines in zebrafish were methylated at 96 hpf. BaP
exposure at 10 μg/L for 96 hours reduced 5-methylcytosine content by 25.0% compared
to control methylation (Figure 23). By using student T-test, this reduction was
statistically significant (P=0.04). However, it was not statistically significant by using
one-way ANOVA. BaP at 100 μg/L significantly reduced 5-methylcytosine content by
44.8% compared to the control group and by 36.6% compared to 1 μg/L BaP treated

% cytosine methylation

group (P=0.02, one-way ANOVA and Neumann Keuls multiple comparison tests).
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Figure 23. BaP effects on global DNA methylation in zebrafish embryos measured by
using MethylampTM Global DNA Methylation Quantification Kit (Epigentek Group).
Embryos were exposed to waterborne BaP (0-100 μg/L) from ~2.5 to 96 hpf. BaP at 100
μg/L significantly reduced 5-methylcytosine content by 44.8% compare to control and
36.6% compare to 1 μg/L BaP. * p<0.05, one-way ANOVA and Neumann Keuls multiple
comparison tests for n=3 pools with 20 embryos per pool.
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2.5 Sequence homology of human, mouse, rat and zebrafish vasa
The Genbank accession numbers and vasa homology between species are shown
in Table 3. VASA DNA contains 22, 21, 21 or 27 exons in human, mouse, rat and
zebrafish, respectively (Figure 24). Human vasa has 2 CGIs, one is located in the
proximal promoter and the second one spans the proximal promoter, first exon, first
intron, and the second exon. Mouse and rat vasa have a CGI crossing the proximal
promoter, first exon and first intron. In rat, there is another CGI in the third intron within
the gene body. Zebrafish vasa does not have promoter CGIs. However, there are two
CGIs in the third and twenty-sixth introns.

Figure 24. Sequence comparison of vasa. Locations of exons and introns in vasa DNA
sequences were compared using Ensembl (http://useast.ensembl.org/index.html).
Ensembl ranscript name and ID were listed on top of each schematic sequence. CGIs
were found by Methyl Primer Express v1.0 and positioned on the figure manually. Vasa
DNA has 22, 21, 21 or 27 exons in human, mouse, rat, and zebrafish respectively. All
except zebrafish have 1 or 2 CpG islands crossing the proximal promoter and first exon.
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Table 3. Homology of vasa, RASSF1, TERT, c-Jun and c-Myc between different species.

vasa

H. sapiens
M. musculus
R. norvegicus
D. rerio

Splice
variants
14
2
2
4

Genbank
accession
NP_077726.1
NP_034159.1
XP_001067709.1
NP_571132.1

Amino
acid (aa)
724
702
811
716

Identity with
D.rerio
70%
73%
73%
-

RASSF1

H. sapiens
M. musculus
R. norvegicus
D. rerio

9
9
2
5

NP_733832.1
NP_062687.1
NP_001032644.1
NP_001004550.1

344
270
340
363

53%
50%
52%
-

TERT

H. sapiens
M. musculus
R. norvegicus
D. rerio

8
3
2
2

NP_937983.2
NP_033380.1
NP_445875.1
NP_001077335.1

1132
1122
1125
1098

39%
32%
38%
-

c-Jun

H. sapiens
M. musculus
R. norvegicus
D. rerio

1
2
1
1

NP_002219.1
NP_034721.1
NP_068607.1
NP_956281.1

331
334
334
308

71%
71%
72%
-

c-Myc

H. sapiens
M. musculus
R. norvegicus
D. rerio (c-Myc a)
D. rerio (c-Myc b)

6
6
1
1
2

454
454
453
419
396

68a/66b%
70a/66 b%
70a/66b%
66%c
-

Species

NP_002458.2
NP_034979.3
NP_036735.2
NP_571487.2
NP_956466.1

a

Identities with D. rerio c-Myc a
D. rerio c-Myc b
c
Identities between D. rerio c-Myc a and c-Myc b
b
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2.6 De novo DNA methylation in vasa promoter during zebrafish development
The zebrafish vasa target region is illustrated on Figure 25 and Table 4. The 5 CpG
sites in the vasa promoter were about 6% methylated at 3.3, 5, 6, and 8 hpf zebrafish
(Figure 26 and 27A). At 11 hpf, CpGs methylation increased to 20%. By 12 hpf, the CpG
methylation percentage increased significantly to 37.5%. Methylation increased with
development to 68.3% at 48 hpf and 79.8% at 96 hpf. The promoter was also highly
methylated in the 1.5-year old female livers (76.8%).
The time frame of de novo methylation was different in the 5 CpG sites (Figure 28).
In vasa CpG #1 and #3 (Figure 28A and C), the methylation percentage increased
significantly between 24-48 hpf. In vasa CpG #2, de novo methylation occurred from 2496 hpf (Figure 28B). In CpG #4, the methylation percentage increased between 11-48
hpf for CpG #4 (Figure 28D). In CpG #5, the initiation of methylation began at 8 hpf and
lasted until 48 hpf (Figure 28E). When the maximal percentage of overall methylation in
the 5 CpG sites was achieved at 96 hpf, the maximal methylation percentage of each
individual CpG site was different (Figure 29C). CpG #4 and #5 were more significantly
methylated (94.7 and 100%, respectively) compared to CpG #1, #2 and #3 (64.1, 76.3
and 63.8% respectively).

2.7 Constitutively vasa mRNA expression during zebrafish development
Vasa mRNA was a maternally deposited into the oocyte with high abundance
detected by qPCR in unfertilized eggs (Figure 27B). After fertilization, vasa expression
significantly increased by 29.0% at 3.3 hpf, suggesting embryonic transcription of vasa
mRNA. The mRNA dropped by 49.2% at 4 hpf and by 59.6% at 6 hpf compared to 3.3
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hpf embryos. The highest degree of vasa mRNA reduction occurred at 12 hpf when the
abundance dropped by 89.7% compared to 6 hpf. The vasa expression at 12 hpf was
equivalent to 4.2% of the vasa expression at 3.3 hpf. The decreased expression
continued as vasa abundance at 24 hpf dropped by 66.7% compared to 12 hpf and the
abundance at 60 hpf dropped by 40.8% compared to 24 hpf. The lowest expression was
detected at 96 hpf, which was only 0.2% of the vasa transcription in the 3.3 hpf embryos.
The trends of vasa DNA methylation and mRNA expression during embryogenesis
were opposite from each other (Figure 27C). As the DNA methylation increased, vasa
expression decreased significantly.
2.8 BaP effects on vasa promoter CpG methylation and gene expression
BaP at 100 μg/L waterborne exposure from 2.5 to 96 hpf significantly decreased the
overall methylation percentage by 17.2% in the 5 CpG sites measured in vasa promoter
(Figure 29A and B). However, the reduction of methylation was not specific to any single
CpG site (Figure 29C).
Consistent with promoter DNA demethylation, BaP waterborne exposure at 100
μg/L from 2.5 to 96 hpf significantly increased the vasa mRNA expression by 33.0%
(Figure 30). The nonparametric Spearman correlation coefficient of vasa promoter
methylation with gene expression was -0.975 (P=0.017).
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Figure 25. Schematic figures of the sodium bisulfite sequencing regions for the five
target genes.

Table 4. Candidate genes in the bisulfite sequencing study.
Gene

Chromosome

Region of interest

Within CpG
island?

CpG
sites

Gene category

RASSF1

22

-179 to +135 cross the first
promoter

Yes

26

Tumor
suppressor gene

RASSF1

22

-123 to +155 or +315
cross the second promoter

Yes

9 or 17

Tumor
suppressor gene

Vasa

10

-369 to -163 in 5’ promoter

No

5

PGC marker

TERT

19

-1136 to -904 in 5’ promoter

Yes

13

Potential protooncogene

c-Jun

20

+970 to +1394 in exon 1

Yes

36

Proto-oncogene

c-Myca

24

+517 to +960 in exon 2

Yes

26

Proto-oncogene
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Figure 26. Constitutive CpG methylation pattern in zebrafish vasa promoter. Each CpG
in the DNA sequence is represented by either closed circle (methylated cyosine) or open
circle (unmethylated cytosines) (n=3 for each time-point, represented by a, b, and c).
Each row of CpGs represents one colony sequenced.
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Figure 27. Constitutive zebrafish vasa promoter methylation percentage (A) and mRNA
expression (B). The 5 CpGs measured by sodium bisulfite sequencing had a very low
percentage of methylation at 3.3, 5, 6, 8, and 11 hpf. De novo methylation initiated at
between 11-12 hpf and continued until 48 hpf. The maximal percentage methylation was
about 80% and remained constant from 48 hpf to adulthood in 1.5-year old female liver.
Vasa transcription was measured by qPCR and normalized to internal control 18S rRNA
and relative to 96 hpf expression level (2-∆∆CT method). Vasa expression was high in
unfertilized eggs and became significantly higher at 3.3 hpf indicating embryonic
transcription. The most significant drop of mRNA expression occurred between the 6
and12 hpf data points (89.7% decrease). Each bar ± SEM represents n = 3 pools. Bars
with different letters are significantly different (one-way ANOVA and Neumann Keuls
multiple comparison tests). Panel (C) is the maximal response curves for vasa De novo
methylation and mRNA expression during zebrafish embryogenesis. The correlation
coefficient of vasa promoter methylation with gene expression was -0.975 (P=0.017,
Nonparametric correlation Spearman).
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Figure 28. De novo methylation of each CpG site in the vasa promoter. The time frame
of de novo methylation was between 12-48 hpf in CpG #1 (A) and #3 (C), 12-96 hpf for
CpG #2 (B), 11-48 hpf for CpG #4 (D), and 8-48 hpf for CpG #5 (E). Each point ± SEM
represents n = 3 pools. Error bars with different letters are significantly different (P<0.05,
one-way ANOVA and Neumann Keuls multiple comparison tests).
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Figure 29. BaP effects on vasa promoter methylation pattern (A) and percentage (B and
C). BaP at 100 μg/L waterborne exposure from 2.5 to 96 hpf significantly decreased the
overall methylation percentage in the 5 CpG sites measured (* P<0.05, Student T-test).
However, the reduction of methylation was not specific to any single CpG site (C). In
controls, CpG #4 and #5 were methylated at a higher percentage compared to CpG #1,
#2 and #3. Each bar ± SEM represents n = 3 pools. White bars with different letters are
significantly different from the other white bar controls (* P<0.05, one-way ANOVA
followed by Neumann Keuls multiple comparison tests).
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Figure 30. BaP effects on vasa mRNA expression in zebrafish embryos. Each sample
was measured by qPCR in duplicate. Bars ± SEM indicate fold change of GNMT
expression normalized to 18S rRNA expression and relative to controls. BaP at 100 μg/L
significantly increased vasa expression (n=6 pools, 20-30 embryos/pool; * P<0.05, oneway ANOVA and Neumann Keuls multiple comparison tests).
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2.9 Sequence homology of human, mouse, rat and zebrafish RASSF1
The Genbank accession numbers and RASSF1 homology between species are
shown in Table 3. RASSF1 in all 4 species contains 6 exons (Figure 31). They all have
at least two promoters with CGIs crossing the proximal promoter and first/second exon.
Mouse and rat have a third CGI crossing the fourth and fifth exons. Zebrafish has a third
CGI located within the second intron, which might serve as a third promoter (Figure 32).

Figure 31. Sequence comparison of RASSF1. Locations of exons and introns in
RASSF1 DNA sequence were compared among human, mouse, rat and zebrafish using
Ensembl (http://useast.ensembl.org/index.html). Ensembl ranscript name and ID were
listed on top of each schematic sequence. CGIs were found by Methyl Primer Express
v1.0 and positioned on the figure manually. RASSF1 in the 4 species all contains 6
exons and has at least 2 CGI promoters.

Figure 32. Zebrafish RASSF1 splice variants (modified from Ensembl figure,
http://useast.ensembl.org/Danio_rerio/Gene/Splice?g=ENSDARG00000004840;r=22:10
755238-10768670).
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2.10 Sequence homology of human, mouse, rat and zebrafish TERT
The Genbank accession numbers and TERT homology between species are shown
in Table 3. All of the 4 species have 16 exons in TERT (Figure 33). TERT in human,
mouse and rat has one CGI crossing the proximal promoter, first exon, first intron, and
second exon. In zebrafish, there is one CGI in the proximal promoter and another one
crossing the end of proximal promoter, first exon and first intron. Human TERT has 17
CGIs within the gene body. However, there is no CGI within the gene body of mouse
TERT and only one CGI in the second exon of rat. Zebrafish TERT has four CGIs
located inside of the gene body.

Figure 33. Sequence comparison of TERT. Locations of exons and introns in TERT DNA
sequence were compared among human, mouse, rat and zebrafish using Ensembl
(http://useast.ensembl.org/index.html). Ensembl ranscript name and ID were listed on
top of each schematic sequence. CGIs were found by Methyl Primer Express v1.0 and
positioned on the figure manually. TERT in the 4 species all contains 16 exons and has
1 or 2 CpG islands crossing the proximal promoter and first exon. Notably, human TERT
DNA contains more CpG islands within the gene body.
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2.11 Sequence homology of human, mouse, rat and zebrafish c-Jun
The Genbank accession numbers and c-Jun homology between species are shown
in Table 3. All of the 4 species have only one exon and no introns in c-Jun (Figure 34).
Interestingly, there are no 5’ and 3’ UTRs in rat c-Jun. In human and mouse, the first
CGI spans across the proximal promoter, 5’ UTR and the beginning of the coding region.
The second CGI covers most of the coding region. In rat c-Jun, one CGI is located
solely in the proximal promoter and the other CGI almost covers the entire exon.
Zebrafish c-Jun has a single CGI spanning a short region of the proximal promoter and
almost the whole 5’ UTR and coding region.

Figure 34. Sequence comparison of c-Jun. Locations of exons and introns in c-Jun DNA
sequence were compared among human, mouse, rat and zebrafish using Ensembl
(http://useast.ensembl.org/index.html). Ensembl ranscript name and ID were listed on
top of each schematic sequence. CGIs were found by Methyl Primer Express v1.0 and
positioned on the figure manually. c-Jun is intronless in the 4 species. All species
contain 1 or 2 CpG islands crossing the proximal promoter and first exon. Notably, the 5’
UTR and coding region have high density of CpG sites. In contrast, no CpG island is
detected in the 3’ UTR.
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2.12 Sequence homology of human, mouse, rat and zebrafish c-Myc
The Genbank accession numbers and c-Myca homology between species are
shown in Table 3. All of the 4 species have 3 exons in c-Myca (Figure 35). c-Myca in
human, mouse and rat has 5, 3, or 4 CGIs covering the proximal promote, first exon,
first intron, second exon and the coding region of the third exon. Zebrafish c-Myca has a
single CGI spanning the second exon, second intron and the coding region of the third
exon.

Figure 35. Sequence comparison of c-Myc. Locations of exons and introns in c-Myc
DNA sequence were compared among human, mouse, rat and zebrafish using Ensembl
(http://useast.ensembl.org/index.html). Ensembl ranscript name and ID were listed on
top of each schematic sequence. CGIs were found by Methyl Primer Express v1.0 and
positioned on the figure manually. c-Myc in the 4 species all contains 3 exons. All except
zebrafish have 1 or 2 CpG islands crossing the proximal promoter and first exon.
Notably, the entire second exon and almost the whole coding region of the third exon in
c-Myc are within CpG islands in the 4 species. No CpG island exists in the 3’ UTR.
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2.13 Efficiency of sodium bisulfite treatment
The rate of conversion of non-CpG cytosine was examined to evaluate the
efficiency of bisulfite conversion. Three PCR products (eight colonies chosen from each
product) derived from vasa (207 bp), RASSF1 CGI 1 (314 bp), CGI 2 (438 bp), TERT
(233 bp), c-Jun (425 bp) and c-Myca (444 bp) were sequenced. The amplified regions
have 43, 94, 51, 101 and 91 non CpG cytosines respectively. The efficiencies of bisulfite
conversion were all above 99.8% (Table 5). This demonstrates that the sodium bisulfite
conversion of cytosines was very efficient and should not generate artifacts due to
incomplete conversion.
Table 5. Efficiency of sodium bisulfite treatment.
Gene
RASSF1 CpG island 1
RASSF1 CpG island 2
TERT
c-Jun
c-Myca
vasa

# of non-CpG Cs
43
94
51
101
91
29

Bisulfite conversion efficiency
99.77±0.23%
100.00±0%
99.83±0.09%
99.83±0.03%
99.87±0.09%
99.90±0.10%

2.14 Single and dinucleotide polymorphism
When performing the alignments between converted Genbank sequences (nonCpG C was converted to T) and our data in DNAstar, polymorphisms were discovered in
RASSF1, TERT and c-Myca. Dinucleotide polymorphism occurred in high prevalence in
certain CGs and cause CG loss in our fish. In RASSF1 CGI 2, 37.9% of the CpG #16
sequenced was mutated to TT (Table 6). In TERT, CpG #7 was completely changed to
TA. In c-Myca, 82.1% of CpG #26 was changed to TT. Notably, due to the sodium
bisulfite treatment, a T can be a C or T in the original sequences, therefore, the actual
TT can be CC, CT, TC or TT mutation and TA can be CA or TA in the untreated DNA.
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Table 6. Single and dinucleotide polymorphisms detected in our zebrafish.
Gene
SNPs
Prevalence
RASSF1 CGI 1
G/T
17.8/82.2%
RASSF1 CGI 2
CG/TT
62.1/37.9%
TERT
CG/TA
0/100%
c-Myca
CG/TT
18.9/82.1%
Locations numbered forward or back from transcription start site (+1).

Locations
-54
+2060, +2061
-1017, -1016
+931, +932

2.15 Constitutive DNA methylation in RASSF1 during development
The RASSF1 target regions are illustrated on Figure 25 and Table 4. The 26 CpG
sites located in the first promoter (CGI-1) were nearly 0% methylated at 3.3 hpf in midblastula embryos, 96 hpf early larvae, and 1.5 year old female liver (Figure 36A). The
methylation percentages were not significantly different in the 3 life stages (Figure 36B).
In contrast, the CpG sites in the second promoter (CGI-2) were highly methylated
(Figure 37A). For the 3.3 hpf embryos, 7 CpG sites were measured in one biological
sample. Four colonies out of 12 were totally unmethylated which suggests the CpGs
were in the process of rapid demethylation or remethylation. CpG sites (17) were
measured for 5, 6, 96 hpf embryos and adult liver tissues. The percentage of CpG
methylation reached 96.5% at 5 hpf and remained highly methylated at 6 hpf (98.5%)
and 96 hpf (92.5%) (Figure 37B). In adult female livers, the methylation percentage
dropped significantly to 73.3%.

2.16 Constitutive RASSF1 mRNA expression during zebrafish development
RASSF1 expression was low at 3.3 and 4 hpf and then increased rapidly by 8.7fold at 6 hpf and by 15.3-fold at 96 hpf (Figure 38). The RASSF1 mRNA concentration in
adult female liver was 73.7% lower than the mRNA in 96 hpf larvae but still about 4-fold
higher than that in 3.3 hpf embryos.
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Figure 36. Constitutive CpG methylation pattern (A) and percentage (B) in zebrafish
RASSF1 CGI-1 (first promoter). Each CpG in the DNA sequence is represented by
either closed circle (methylated cyosine) or open circle (unmethylated cytosines). Each
row of CpGs represents one colony sequenced. The 26 CpGs measured by sodium
bisulfite sequencing had very low or zero methylation at 3.3 hpf, 96 hpf and adult female
(1.5-year old) liver. No significant changes in CpG methylation pattern or percentage
were observed in this gene region at the 3 time-points tested (n=3 pools; one-way
ANOVA and Neumann Keuls multiple comparison tests).
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Figure 37. Constitutive CpG methylation pattern (A) and percentage (B) in in zebrafish
RASSF1 CGI-2 (second promoter). Each CpG in the DNA sequence is represented by
either closed circle (methylated cyosine) or open circle (unmethylated cytosines). The
dash in panel (A) indicates CG is replaced by dinucleotide TT, which suggests that
evolutionary CG loss is affecting the 16th CpG site of some DNA molecules. Each row of
CpGs represents one colony sequenced. The 16 CpGs measured by sodium bisulfite
sequencing had very high percentage of methylation at 3.3, 5, 6, 96 hpf and adult
female liver (1.5-year old). Significant reduction of CpG methylation percentage was
observed in adult female liver compared to 5, 6 and 96 hpf (n=3 pools; ** p<0.005, oneway ANOVA and Neumann Keuls multiple comparison tests).
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Figure 38. Constitutive zebrafish RASSF1 mRNA expression. Each sample was
measured by qPCR in duplicate. Each bar represents the mean ± SEM expression of
each gene which was normalized to internal control 18S rRNA and relative to 3.3 hpf
expression level (2-∆∆CT method). The data were analyzed by one-way ANOVA followed
by Newman-Keuls multiple comparison test using GraphPad Prism 5.0, different letters
labled on the bars indicate statistically significant; n= 3.

2.17 Constitutive TERT DNA methylation and gene expression during zebrafish
development
The TERT target region is illustrated on Figure 25 and Table 4. The 12 CpG sites
located in the CGI in the TERT promoter were measured by sodium bisulfite sequencing.
CpG #1 was completely unmethylated in all the time-points tested (Figure 39A).
However, all of the other CpGs were highly methylated. As a result, the methylation
percentage in TERT was 84.6% in 3.3 hpf embryos, 88.6% in 96 hpf larvae, and 86.5%
in adult female liver (Figure 39B). Neither the methylation pattern nor the percentage
was statistically different between the 3 time-points. However, TERT gene expression
was significantly different (Figure 39C). TERT expression at 96 hpf was 3.5-fold higher
than that at 3.3 hpf. TERT transcription in adult liver was extremely low, and was only
5.3% and 1.5% of the expression in 3.3 hpf embryos and 96 hpf larvae, respectively.
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Figure 39. Constitutive zebrafish TERT methylation pattern (A), percentage (B), and
mRNA expression (C). Each CpG in the DNA sequence is represented by either closed
circle (methylated cyosine) or open circle (unmethylated cytosines). Each row of CpGs
represents one colony sequenced. The dash in panel (A) indicates CG is replaced by
dinucleotide TA, which suggests that evolutionary CG loss is affecting CpG #7 of all the
DNA molecules sequenced. The other 12 CpGs except CpG #1 measured by sodium
bisulfite sequencing had very high percentage of methylation at 3.3 hpf, 96 hpf and adult
female (1.5-year old) liver. No significant changes of CpG methylation pattern or
percentage were observed at the 3 time-points tested. TERT transcription was
measured by qPCR and normalized to internal control 18S rRNA and relative to 3.3 hpf
expression level (2-∆∆CT method). Even though DNA methylation was not changed, TERT
mRNA expression was dramatically different among the fish at the 3 life stages (n=3
pools; * p<0.05, *** p<0.0001, one-way ANOVA and Neumann Keuls multiple
comparison tests). Each bar represents the mean ± SEM.
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2.18 Constitutive c-Jun DNA methylation and gene expression during zebrafish
development
The c-Jun target region is illustrated on Figure 25 and Table 4. The 36 CpG sites
located in the CGI in the c-Jun first exon were hypomethylated (Figure 40A). The
methylation percentage in c-Jun was 0.3% in 3.3 hpf embryos, 0.2% in 96 hpf larvae,
and 0% in adult female liver (Figure 40B). Neither the methylation pattern nor the
percentage was statistically different between the 3 time-points. However, the gene
expression was significantly different (Figure 40C). c-Jun expression at 96 hpf was 379fold higher compared to expression at 3.3 hpf. c-Jun transcription in adult liver was
lower than 96 hpf larvae, but still 39-fold higher than the expression in 3.3 hpf embryos.

2.19 Constitutive c-Myca DNA methylation and gene expression during zebrafish
development
The c-Myc target region is illustrated on Figure 25 and Table 4. The 26 CpG sites
located in the CGI in the c-Myca second exon were also hypomethylated (Figure 41A).
The methylation percentage in c-Myca was 24.1% in 3.3 hpf embryos, 7.1% in 96 hpf
larvae, and 2.6% in adult female liver (Figure 41B). Neither the methylation pattern nor
the percentage was statistically different between the 3 time-points. The methylation
percentage was significantly higher in CpG #21-26 than in CpG #1-20 (Figure 41D).
However, the gene expression was significantly different (Figure 41C). c-Myca
expression at 96 hpf was the highest, 5.8-fold higher than the expression at 3.3 hpf and
7.4-fold higher than that in adult liver. There was no significant difference between cMyca expression between 3.3 hpf embryos and adult female livers.
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Figure 40. Constitutive zebrafish c-Jun methylation pattern (A), percentage (B), and
mRNA expression. Each CpG in the DNA sequence is represented by either closed
circle (methylated cyosine) or open circle (unmethylated cytosines). Each row of CpGs
represents one colony sequenced. The 36 CpGs measured by sodium bisulfite
sequencing had very low or zero percentage of methylation at 3.3 hpf, 96 hpf and adult
female (1.5-year old) liver. No significant changes of CpG methylation pattern or
percentage were observed at the 3 time-points tested. c-Jun transcription was measured
by qPCR and normalized to internal control 18S rRNA and relative to 3.3 hpf expression
level (2-∆∆CT method). Even though DNA methylation was not changed, c-Jun mRNA
expression was dramatically different among the fish at the 3 life stages (n=3 pools; *
p<0.05, *** p<0.0001, one-way ANOVA and Neumann Keuls multiple comparison tests).
Each bar represents the mean ± SEM.
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Figure 41. Constitutive zebrafish c-Myca methylation pattern (A), percentage (B), and
mRNA expression. Each CpG in the DNA sequence is represented by either closed
circle (methylated cyosine) or open circle (unmethylated cytosines). The dash in panel
(A) indicates CG is replaced by dinucleotide TT, which suggests that evolutionary CG
loss is occurring in the CpG #26 in some DNA molecules. Each row of CpGs represents
one colony sequenced. The 26 CpGs measured by sodium bisulfite sequencing had a
very low percentage of methylation at 3.3 hpf, 96 hpf and adult female (1.5-year old)
liver. However, CpG #21-26 had higher methylation compared to CpG #1-20 (panel C, *
P<0.05, Student T-Test). No significant changes of CpG methylation pattern or
percentage were observed at the 3 time-points tested. c-Myca transcription (D) was
measured by qPCR and normalized to internal control 18S rRNA and relative to 3.3 hpf
expression level (2-∆∆CT method). Even though DNA methylation was not changed, cMyca mRNA expression was significantly higher at 96 hpf compared to 3.3 hpf and adult
liver (n=3 pools; *** p<0.0001, one-way ANOVA and Neumann Keuls multiple
comparison tests). Each bar represents the mean ± SEM.
109

2.20 BaP effects on RASSF1, TERT, c-Jun and c-Myca methylation and gene
expression
BaP treatment at 100 μg/L from 2.5 to 96 hpf in zebrafish embryos did not change
CpG methylation pattern or percentage in RASSF1 CGI-1 (Figure 42A and C), RASSF1
CGI-2 (Figure 42B and D), TERT (Figure 44A and B), c-Jun (Figure 45A and B) and cMyca (Figure 46A and B). Gene expression of RASSF1 (Figure 43), TERT (Figure 44C),
c-Jun (Figure 45C) and c-Myca (Figure 46C) was not changed in the zebrafish that were
exposed to BaP at 1, 10, 100 μg/L from 2.5 to 48, 60 or 96 hpf.
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Continue to the next page.
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Figure 42. BaP effects on RASSF1 DNA methylation pattern and percentage. BaP
effects on RASSF1 DNA methylation pattern (A for CGI 1 in first promoter, B for CGI 2 in
second promoter) and percentage (C for CGI 1 in first promoter, D for CGI 2 in second
promoter). BaP at 100 μg/L waterborne exposure from 2.5 to 96 hpf did not significantly
change CGI methylation pattern or percentage at the 2 regions of RASSF1 in zebrafish
(n=3 pools, 20 larvae/pool; Student T-test).
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Figure 43. BaP effects on RASSF1 mRNA expression in 96 hpf zebrafish embryos. Each
sample was measured by qPCR in duplicate. Bars ± SEM indicate fold change of
expression normalized to 18S rRNA expression and relative to control gene expression.
No significant differential gene expression between the control and BaP-treated groups
was noticed. (n=3 pools, 20 larvae/pool; one-way ANOVA and Neumann Keuls multiple
comparison tests).
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Figure 44. BaP effects on TERT methylation pattern, percentage and gene expression.
BaP effects on TERT DNA methylation pattern (A), percentage (B), and gene expression
(C). BaP at 100 μg/L waterborne exposure from 2.5 to 96 hpf did not significantly
change TERT CGI methylation pattern or percentage in zebrafish. No significant
differential TERT transcription between the control and BaP-treated groups was noticed
either. Gene expression was normalized to 18S rRNA expression and relative to control
gene expression. (n=3 pools, 20 larvae/pool; Student T-test or one-way ANOVA followed
by Neumann Keuls multiple comparison tests).
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Figure 45. BaP effects on c-Jun methylation pattern, percentage, and gene expression.
BaP effects on c-Jun DNA methylation pattern (A), percentage (B), and gene expression
(C). BaP at 100 μg/L waterborne exposure from 2.5 to 96 hpf did not significantly
change c-Jun CGI methylation pattern or percentage in zebrafish. No significant
differential c-Jun transcription between the control and BaP-treated groups was noticed
either. Gene expression was normalized to 18S rRNA expression and relative to control
gene expression. (n=3 pools, 20 larvae/pool; Student T-test or one-way ANOVA followed
by Neumann Keuls multiple comparison tests).

113

A

c-Myca
100
80
60
40
20
0

Control

c-Myca

C

Fold changes

% CpG methylation

B

1.5

1.0

0.5

0.0

100 BaP

Con

1 BaP

10 BaP

100 BaP

Figure 46. BaP effects on c-Myca methylation pattern, percentage and gene expression.
BaP effects on c-Myca DNA methylation pattern (A), percentage (B), and gene
expression (C). BaP at 100 μg/L waterborne exposure from 2.5 to 96 hpf did not
significantly change c-Myca CGI methylation pattern or percentage in zebrafish. No
significant differential c-Myca transcription between the control and BaP-treated groups
was noticed either. Gene expression was normalized to 18S rRNA expression and
relative to control gene expression. (n=3 pools, 20 larvae/pool; Student T-test or oneway ANOVA followed by Neumann Keuls multiple comparison tests).
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3. BaP effects on zebrafish reproduction and development
3.1 BaP effects on embryo survival, hatching and deformity by developmental BaP
exposure
When BaP exposure started at 2.5 hpf during embryogenesis, the survival rate was
significantly decreased by 38.5% compared to controls in the 10 μg/L BaP treated group
(Figure 47A). The control survival was 59.2%. In 1 and 100 μg/L BaP treated groups,
the average survival rates were slightly reduced by 25.0% but they were not statistically
significant compared to control group. The majority of death occurred within the first 24
hpf. After that, the survival rate was very stable at 48, 60 and 72 hpf.
Zebrafish embryos began to hatch between 24-48 hpf (Figure 47 B). About 59.0% of
control embryos hatched at 48 hpf. For BaP treatment groups, only 12.8 to 23.9% of
embryos hatched by the same time. By 60 hpf, 88.3% of control embryos hatched but
only 64.5% hatched in 1 μg/L BaP treated group and 74.5% hatched in 100 μg/L BaP
group. By 72 hpf, there were no differences in the hatching percentages between all
groups. Therefore, although BaP delayed zebrafish hatching, the overall hatching
percentage was not affected.
The background deformity incidence (number of deformed larvae/total number of
viable larvae in the same vial at 72 hpf) was about 6.9% in our fish (Figure 47C). BaP at
1, 10 and 100 μg/L non-significantly increased the deformity incidence. The deformities
observed included pericardial edema, scoliosis and missing eyes.
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Figure 47. BaP effects on the embryo survival rate (A), hatching efficiency (B), and
deformity incidence (deformities including pericardial edema, tube heart, head or tail
abnormalities; deformity incidence=(number of deformed fish/total viable fish in the
same vial at 72 hpf)X100%) (C) during embryogenesis (from 2.5 to 72 hpf). BaP at 10
μg/L significantly reduced the survival rate by 38.3% at 24 hpf, 39.6% at 48 hpf, 40.9%
at 60 hpf, and 42.2% at 96 hpf compared to controls. The majority of death occurred
before 24 hpf. BaP decreased the hatching percentage at 48 and 60 hpf. However, the
hatching percentage was not different at 72 hpf. The exposure did not significantly
change the deformity percentage (n=4 pools, 30 embryos/pool; *, P<0.05, *, P<0.005,
one-way ANOVA and Neumann Keuls multiple comparison tests).
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3.2 BaP concentrations in zebrafish ovary
Adult zebrafish (2 males and 4 females per tank, 3 tanks per treatment) were
exposed to control ethanol, 22.5 ± 2.3, and 42.0 ± 1.9 μg/L of BaP. All the BaP
concentrations in the exposed water were confirmed by GC-MS analysis (Table 7). BaP
was extracted from ovaries (n=3, taken from one female from each tank) and analyzed
by GC-MS. The recoveries for the surrogate compounds were between 43-106%,
indicating efficient extraction for PAHs (Table 8). A BaP peak was found in all BaP
treated ovaries. No BaP peak was found in the control treated ovaries. However, BaP
concentrations were below the lowest point on the standard curve (0.02 ng/μL), which
indicated that the BaP amount in each treated ovary was less than 4 ng (data not
shown).
Table 7. Actual BaP concentrations in adult zebrafish exposure water

Tank A
Tank B
Tank C
Average

Exposure 1 (μg/L)
43.5
43.5
36.0
41.0 ± 2.5

Exposure 2 (μg/L)
36.8
47.3
45.0
43.0 ± 3.2

Exposure 3 (μg/L)
26.6
22.1
18.8
22.5 ± 2.3

Table 8. Recovery of surrogate standards from zebrafish ovary.
Compound
Napthalene d8
Acenaphthalene d10
Phenanthrene d10
Chrysene d12
Perylene d12

Recovery
43.3 ± 9.5%
81.7 ± 5.4%
106.7 ± 3.6%
100.0 ± 4.7%
98.3 ± 2.8%

3.3 BaP effects on egg production
Before exposure began, the average egg production for zebrafish (2 males and 4
females per tank) was approximately 96 eggs/day and 131 eggs/spawn (Figure 48A and
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B). During the exposure, the average egg number collected was 135 eggs/day or 187
eggs/spawn from control tanks, 69 eggs/day or 92 eggs/spawn from the 22.5 ± 2.3 μg/L
BaP tanks, and 68 eggs/day or 128 eggs/spawn from the 42.0 ± 1.9 μg/L BaP tanks.
Therefore, BaP at 22.5 ± 2.3 μg/L non-significantly reduced the egg production by
48.9% per day and 50.8% per spawn; BaP at 42.0 ± 1.9 μg/L non-significantly
decreased the egg number by 49.6% per day and 31.6% per spawn.
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Figure 48. BaP effects on the egg production by parental zebrafish. Eggs were collected
before and after BaP waterborne exposure to adult zebrafish for 7 days. The average
number of eggs collected per day (A) or per spawn (B) was non-significantly decreased
in BaP-treated zebrafish compared to control treated zebrafish (sample sizes are
indicated below the bars, one-way ANOVA and Neumann Keuls multiple comparison
tests).

3.4 BaP effects on embryo survival and deformity
Before exposure, the survival rate (at 96 hpf) and deformity incidence (number of
deformed larvae/total number of survived larvae in the same vial at 96 hpf) of zebrafish
embryos were 97.2% and 2.6%, respectively (Figure 49A). When parents and their
embryos were continually exposed to 42.0 ± 1.9 μg/L BaP, the survival rate severely
dropped from 86.4% in controls to 27.2%, which is a 68.5% decrease. The majority of
death occurred within the first 24 hpf. After that, the survival rate remained stable at 48,
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72 and 96 hpf. The background deformity incidence was about 1.3% in the control fish
(Figure 49B). Parental and developmental BaP exposure at 42.0 ± 1.9 μg/L nonsignificantly increased the deformity incidence to an average of 8.1%. The teratogenic
effects observed included pericardial edema, tube heart, scoliosis and missing eyes
(Figure 50).
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Figure 49. BaP effects on cumulative survival and deformity (deformities including
pericardial edema, tube heart, head or tail abnormalities; deformity incidence=(number
of deformed fish/total viable fish in the same vial at 96 hpf)X100%) of the offspring from
BaP exposed parents. Eggs were collected before and after BaP (42.0 ± 1.9 μg/L)
exposure to the parental zebrafish for 7-11 days. BaP significantly decreased the total
survival rate from 86.4% to 27.2% (A, sample sizes are indicated on top of the bars, 1030 embryos/pool; *** P<0.0001, one-way ANOVA and Neumann Keuls multiple
comparison tests). The majority of death happened before 24 hpf. BaP exposure at
(42.0 ± 1.9 μg/L) increased the deformity incidence but it was not statistically significant
(B).
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Figure 50. Representative deformed BaP-treated zebrafish offspring from BaP exposed
parents. Panel A shows a control zebrafish hatchling at 96 hpf. Panel C, E, G, I and K
show BaP-exposed (42.0 ± 1.9 μg/L) zebrafish hatchling with mild pericardial edema,
severe pericariac edema with a normal heart, severe pericardial edema with tube heart,
curly tail, and deformed body without eyes, respectively (in arrows). Panel B, D, F, H
and J are higher magnification images in the region of deformity of panel A, C, E, G and
I, respectively.
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3.5 BaP effects on the global DNA methylation status of offspring.
In control conditions, the cytosine methylation percentage in 3.3 hpf embryos was
5.1-fold higher compared to the level in 96 hpf larvae (Figure 51). Replicate
measurements of global DNA methylation were done, and the 3 methods used to
extract 3.3 hpf zebrafish DNA did not impact the DNA methylation results (data not
shown). At 3.3 hpf, BaP at 42.0 ± 1.9 μg/L non-significantly reduced the total DNA
methylation, but by 96 hpf, BaP at 42.0 ± 1.9 μg/L significantly reduced DNA methylation
by 49.0%.
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Figure 51. BaP effects on global DNA methylation in the offspring from BaP exposed
parents. Constitutively, cytosine methylation percentage in zebrafish was 5.1 times
higher at 3.3 hpf than the percentage at 96 hpf. BaP at 42.0 ± 1.9 μg/L significantly
reduced 5-methylcytosine percentage by 49.0% at 96 hpf (* p<0.05, *** P<0.005,
Student T-test for n=3 pools and each pool had 200 embryos at 3.3 hpf or 30 larvae at
96 hpf).
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CHAPTER 5. DISCUSSION
1. BaP effects on Fundulus GNMT expression and activity
Fundulus is a estuarine teleost found in contaminated environments along the
Atlantic coast of the US with relevant human diseases including cancer and
reproductive/developmental deficits. Because of its small size, external development,
and transparent chorion, it is suitable to study developmental toxicities. The Fundulus
GNMT deduced protein has 295 amino acids and 74% similarity with human GNMT
(Figure 6 and 8). As shown in Table 9, the Fundulus liver GNMT Kms compared
similarly with previously reported mammalian kinetic values. Therefore, Fundulus is a
relevant and useful model organism to further investigate GNMT functions in
embryogenesis and BaP-mediated developmental toxicity.

Table 9. Kinetic parameters of glycine N-methyltransferase of liver cytosol from different species.
Km (SAM a)
mM
0.28
Homo sapiens
0.27
Homo sapiens
0.18
Mus musculus
0.11
Rattus norvegicus
0.05
Rattus norvegicus
0.32
Oryctolagus cuniculus
0.2
Oryctolagus cuniculus
0.1
Oryctolagus cuniculus
0.25
Sus scrofa
0.18
Fundulus heteroclitus
a
SAM: S-adenosylmethionine.
Species

Km (glycine)
mM
12.2
6.3
3.6
2.0
0.29
2.9
1.0
2.2
11.1
3.24

Assay
temperature
25°C
30°C
25°C
25°C
30°C
30°C
Unspecified
37°C
30°C
25°C

Reference
Pakhomova et al. 2004
Ogawa et al. 1993
Pakhomova et al. 2004
Pakhomova et al. 2004
Ogawa et al. 1993
Ogawa et al. 1993
Kloor et al. 2004
Heady and Kerr 1973
Ogawa et al. 1993
This study

GNMT protein was first discovered in guinea pig livers (Blumenstein and Williams
1963) and then purified ten years later (Heady and Kerr 1973). Sequences for GNMT
have been identified in many other species including human, mouse, rat, rabbit, cow,
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dog, chicken, zebrafish, medaka and fruitfly, etc. In mammals, GNMT mRNA and protein
expression is highest in the liver, pancreas, prostate and kidney (proximal kidney
tubules) (Yeo and Wagner 1994). But to date, GNMT expression during oogenesis,
embryogenesis and its developmental significance have not been reported in any other
organisms. In this study, we found that GNMT mRNA was in developing oocytes,
expressed throughout embryogenesis, and was mainly localized in the Fundulus
embryonic liver and urinary bladder. GNMT enzyme activity was also detected in
unfertilized eggs and developing embryos suggesting its critical role during early
development.
By using qPCR, we found that unfertilized Fundulus eggs had the highest
expression of GNMT mRNA, about 19-fold higher than 4 dpf embryo expression (Figure
9), implying that GNMT was possibly a maternally deposited mRNA. By using whole
mount ISH, we confirmed that GNMT was actively transcribed and accumulated in
growing oocytes. We also detected GNMT activities in unfertilized eggs. However, the
GNMT activity did not peak in unfertilized eggs (as could be predicted based on mRNA
levels) but rather later during development. This suggests a large portion of the
maternally deposited GNMT mRNA was not translated to GNMT protein before
fertilization. Generally, as discussed in (Alizadeh et al. 2005), during meiotic maturation
and in embryos shortly after fertilization accumulated maternal mRNA species degrade
rapidly for protein synthesis if they encode essential proteins for these specific events.
This could account for our results that while constitutive whole embryo GNMT mRNA
expression dropped dramatically post fertilization, in 2 and 3 dpf Fundulus embryos it
was still significantly higher than when expression leveled off between 4 and 14 dpf.
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GNMT activity was also higher in early development (4 dpf) than later time-points
suggesting GNMT activity is critical to Fundulus embryogenesis at early stages
corresponding to periods of rapid organogenesis (Armstrong and Child 1965).
Interestingly, the temporal expression pattern of Fundulus embryonic GNMT is very
similar to zebrafish DNMT1 (Figures 9 and 18). Maternal transcripts of the zebrafish
DNMT1 are present at high levels in early embryos and then the mRNA abundance
decreases after the blastula stage.
In this study, we found by qPCR that the developmental toxicant, BaP, induced
GNMT mRNA expression at 3, 10, and 14 dpf using homogenized whole Fundulus
embryo pools (Figure 12). Similarly, whole mount ISH results also indicated that GNMT
mRNA expression was induced modestly by BaP in the embryo liver region at 7, 10, 14
dpf. We also did ISH on 4 dpf embryos, but embryos are then undergoing
organogenesis and organs like liver and urinary bladder are not easily visualized. It was
difficult to distinguish and quantitate the tissue specific expression by ISH at this timepoint. While studies of BaP effects on GNMT are very limited, BaP exposure also
induced GNMT mRNA expression in HepG2 cells in vitro (Lee et al. 2006). Induction of
GNMT expression is consistent with the recent recognition that the 5’-regulatory region
of the human GNMT contains a BaP inducible XRE (Lee et al. 2009).

While the

Fundulus GNMT promoter is not available, our bioinformatics analysis using the
Transcription Element Search System (TESS, combined search) on the GNMT
promoter of zebrafish, a more genetically established teleost model, revealed five
putative AhR or AhR/ARNT binding sites between -2000 nt and the transcription start
site (Table 10). Collectively, this new data suggests that the AhR may have a role in
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GNMT expression and may explain the BaP-induced mRNA expression that we found in
Fundulus embryos. The AhR-GNMT relationship is further suggested in AhR null mice
where liver constitutive GNMT expression is significantly lower than in wild-type mice
(Boutros et al. 2009). Therefore, the transcription induction by BaP was possibly
mediated through the interaction between AhR and XRE in the upstream region of the
GNMT gene.

Table 10. Putative xenobiotic response elements in the GNMT (zebrafish) promoter.
Xenobiotic response elements
AhR a
AhR
ARNT b -AhR
AhR
AhR

Locations
-1574 to -1558
-1535 to -1524
-1185 to -1174
-765 to -760
-738 to -727

Locations numbered back from transcription start site (+1). GenBank
Accession No. NW_001880090.1.
a
AhR: Aryl hydrocarbon receptor;
b
ARNT: Ah receptor nuclear translocator.

In contrast to mRNA induction, BaP exposure significantly reduced GNMT enzyme
activity. To determine if BaP was a direct inhibitor of GNMT, BaP was added to the
enzyme reaction system but did not alter the GNMT enzyme activity by Fundulus liver
cytosol (Figure 17). Our results contrasted to a similar in vitro study (Chen et al. 2004)
showing that when BaP was incorporated into a recombinant human GNMT assay
system, GNMT activity was reduced by 50% when compared to control DMSO. In either
case, the in vitro studies do not represent the in vivo system where BaP metabolites
may also be acting as GNMT inhibitors.
Another possible mechanism to explain enzyme inhibition is that the BaP-mediated
mRNA increase is reflected in more post translational assembly of the homodimeric
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BaP-binding form. As a result, the assembly of the enzymatically active homotetrameric
form of GNMT could be decreased. In fact, Bhat and coworkers found that BaP altered
the post-translational modification of GNMT and resulted in formation of GNMT
homodimer, which is the PAH binding but nonenzymatic form (Bhat et al. 1997). In our
case, BaP may shift the GNMT translation from tetramer to dimer, and thus, reduce the
GNMT enzyme activity. To specifically address this latter hypothesis, a fish-specific
GNMT antibody to measure relative homodimer vs. tetramer protein abundances
following BaP exposure is necessary. Unfortunately, the commercially available human
GNMT antibody does not cross-react with the Fundulus protein (data not shown).
To date, studies suggest GNMT is involved in cellular defense mechanisms in
response to environmental stressors and disease states. After BaP exposure, GNMT
transfected cells have reduced BPDE formation (Chen et al. 2004), and cell lines
expressing constitutively higher GNMT expression have less cytotoxicity than low
GNMT expressing cell lines (Lee et al. 2006). Carcinogenic effects of aflatoxin B1 were
reduced in GNMT knockout mice (Yen et al. 2009). GNMT enzyme activity and protein
expression were induced after exposure to various xenobiotics, such as ethanol
(Villanueva and Halsted 2004), retinoid compounds (Rowling and Schalinske 2001),
glucocorticoids (Rowling and Schalinske 2003), excess dietary methionine (Rowling et
al. 2002a) and streptozotocin (used to establish diabetic animal models) (Nieman et al.
2006). Thus, GNMT induction is responsive to various environmental stressors and is
possibly involved in protective mechanisms. On the other hand, diminished GNMT
expression is commonly seen in various cancer states including HCC, prostate cancer
and cholangiocarcinoma (Tseng et al. 2003; Huang et al. 2007; Huang et al. 2008).
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Clearly, there remains much to resolve with respect to the roles of GNMT in disease and
the relative utility of mRNA expression versus enzyme activity as a biomarker of effect.
Another concern about the diminished developmental GNMT activities in vivo after
BaP exposure is the potential effect on SAM/SAH homeostasis and DNA methylation
status. A number of more recent studies have established a relationship between altered
GNMT expression and DNA methylation (Lu et al. 2000; Mato et al. 1997; Rowling et al.
2002b). Altered GNMT activity will change the ratio of SAM/SAH and affect the
methylation capacity in the body. Compared to control wild-type animals, GNMT
knockout mice had 7-fold more methionine, 35-fold more SAM and a 100-fold increase
in the SAM:SAH ratio (Luka et al. 2006) and changes in global or chromosome specific
DNA methylation patterns (Martinez-Chantar et al. 2008). These studies highlight the
ability for altered GNMT, SAM and SAH homeostasis to affect critical cellular pathways
epigenetically. Future studies should measure global or gene specific methylation
changes and SAM /SAH concentrations (Figure 52) after BaP exposure.

Figure 52. Ultra performance liquid chromatography-mass spectrometry (UPLC-MS)
detection of SAM, SAH and methionine (75 nM). [2H3]SAM was used as internal control.
The method showed complete separation of the three chemicals of interest within 3 min.
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2. BaP effects on zebrafish DNA methylation
Although Fundulus is a great environmentally relevant model for toxicology studies,
its limited genome resources make it difficult to do DNA methylation analysis. The
sequence information for promoters, introns, exons and even full length cDNAs of
Fundulus genes is not readily available without intensive cloning and sequencing.
Therefore, the genetically better defined zebrafish model was used in the rest of this
study to further investigate the epigenetic mechanisms of BaP toxicity. Compared to
Fundulus, zebrafish development is more rapid (Table 11) (Armstrong and Child, 1965;
Kimmel et al. 1995). Zebrafish organogenesis is very fast, and most organ primordia
have formed by 24 hpf. The 24 hpf zebrafish embryos have a full set of 30 pairs of
somites and a beating heart. Between 48-72 hpf, the embryos hatch. However, the
hatchling’s mouth does not open and swim bladder does not inflate until after 72 hpf.
The newly hatched zebrafish still live on the yolk nutrients until 96 hpf. Before 96 hpf,
zebrafish hatchlings’ mobility and swimming ability are very limited. In contrast, although
the embryonic development takes ~17 days, Fundulus hatches with an open-mouth and
an inflated swim bladder, which allow the fish to eat and swim immediately after hatch.
Therefore, when zebrafish hatch they are still comparably immature with poorlydeveloped digestive and central nervous systems. In my study, 96 hpf was selected as
one of the time-points of interest because it is the time when the development is more
complete and abnormal morphology becomes apparent. Another early development
time-point selected was 3.3 hpf, the middle of blastula stage, when global DNA
demethylation and remethylation occurs (Mhanni and McGowan, 2004). In addition,
livers of 1.5 year-old female zebrafish were used for comparative analysis of age and
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tissue effects on DNA methylation.
Table 11. Comparison of Fundulus and zebrafish development.
Stages
Zygote
Cleavage
Blastula
Gastrula
Segmentation
Pharynugula
Hatching
a
(Armstrong and Child, 1965)
b
(Kimmel et al. 1995)

Fundulus a
0-1.75 h
1.75-7.5 h
11-27 h
27-40 h
40-74 h
74-384 h
384-408 h

Zebrafish b
0-0.75 h
0.75-2.25 h
2.25-5.25 h
5.25-10 h
10-24 h
24-48 h
48-72 h

Our data showed that approximately 1.9-5.2% of the cytosines were methylated in
the genome of 96 hpf zebrafish (Figure 23), which was comparable to the level of
general DNA methylation in mammals. Unexpectedly, we found that the cytosine
methylation percentage (~10%) in 3.3 hpf embryos was 2-5 times higher than the level
in 96 hpf zebrafish larvae (Figure 51). We are aware that some of the DNA extraction
methods (e.g. without proteinase K or RNase treatment) may affect the integrity of
methylated cytosines (Warnecke et al. 2002) or the low dose of vehicle solvent ethanol
(100 ppm) might affect the DNA methylation differently at different developmental timepoints. However, the cytosine methylation percentages were the same in the DNA that
was extracted from untreated 3.3 hpf embryos by using three different methods
(traditional phenol/chloroform, DNAzol, and Qiagen DNeasy Blood & Tissue Easy Kit; all
treated with proteinase K and RNase) (data not shown). This suggests that at 3.3 hpf,
zebrafish might have completed or nearly completed the first wave of DNA
demethylation and remethylation that occur in early embryos. We also found a second
wave of DNA demethylation occurring in zebrafish between 3.3 and 96 hpf. This wave of
demethylation is perhaps not affecting the entire genome because 1.9-5.2% of
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cytosines are still methylated at 96 hpf. Although it is well accepted that DNA
demethylation is common in the aging process, until recently very few studies have
investigated the DNA methylation changes during early postnatal development. For
example, in the human cerebral cortex during the course of development, maturation
and aging, a sharp rise in methylation was detected in 18 out of 50 loci within the first
months or years after birth (Siegmund et al. 2007). They also observed significant
decrease in DNA methylation in the repetitive elements during the first decade of life.
Another study found 31 genes that gained methylation and 111 that lost methylation in
early postnatal liver development in mice (Waterland et al. 2009). The group also
noticed that all the methylation changes were linked to changes of gene expression.
Therefore, developmental epigenetic establishment extends well beyond early
embryonic development. Further studies will be needed to trace more precisely the
timing of demethylation and identify the affected genome loci.
We found that BaP was able to modify DNA methylation and result in global loss of
DNA methylation (Figure 23). The demethylation effects were seen in zebrafish larvae
that were exposed to 100 μg/L waterborne BaP from 2.5-96 hpf and in zebrafish
offspring that were born from BaP (42.0 ± 1.9 μg/L) exposed parents and were
subsequently exposed to BaP until 96 hpf (Figure 51). The demethylation effect caused
by BaP may play a role in the reported DNA hypomethylation triggered by air pollution
or cigarette smoke (both of which contain BaP as one of their major toxic constituents)
(Baccarelli and Bollati, 2009; Ma et al. 2011). DNA hypomethylation may increase the
vulnerability to many diseases by altering gene expression, elevating mutation rates,
increasing genome instability or triggering apoptosis (Kisseljova and Kisseljov 2005).
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In order to identify the mechanism of BaP induced hypomethylation, we measured
the gene expression and enzyme activity of two important methyltransferases, namely
DNMT and GNMT. In zebrafish, 8 isozymes of DNMT are known. All the isozymes are
involved in DNA methylation except DNMT2. DNMT1 is the most studied DNMT
isozyme in zebrafish, but little is known for the rest of DNMTs. Therefore, we have only
tested the gene expression of DNMT1. Constitutively, we found that both DNMT1 and
GNMT were maternally transferred mRNAs and expressed throughout development
(Figure 18). However, their expression profiles were distinct. DNMT1 mRNA dropped
significantly at 2 hpf and then increased at 3.3 hpf, indicating zygotic DNMT1 mRNA
synthesis was initiated in the early embryos. The average DNMT mRNA expression
from 8-cell (1.25 hpf) to mid-blastula (3.3 hpf) was approximately 5-fold higher than the
average expression from sphere (4 hpf) to early larvae (96 hpf) stage, suggesting
significant importance of DNMT1 for early embryogenesis. The developmental DNMT1
expression profile was similar to previous findings using whole mount ISH (Martin et al.
1999). Martin et al. observed that DNMT1 mRNA was distributed at ubiquitously high
level in all cells even though DNA was hypomethylated at the blastula and gastrula
stages compared to sperm or older embryos. The possible explanation is that the
maintenance DNMT1 was initially retained in the cytoplasm and the lack of access to
the nucleus lead to global loss of DNA methylation. After the global demethylation,
DNMT1 entered the nucleus and facilitated the de novo methylation along with DNMT3a
and DNMT3b. On the other hand, GNMT expression increased from fertilization to 2 hpf,
possibly involving the degradation of the cellular SAM, and thus, facilitating the DNA
demethylation. After 2 hpf, the decreased GNMT expression may be related to a higher
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SAM supply needed for the DNA remethylation process. However, SAM concentrations
at early age zebrafish have not been reported in the literature. Starting at 24 hpf, GNMT
transcription increased significantly. By comparing the relative expression between the
two genes, we found that maternal DNMT1 mRNA deposition was 7-fold higher than
GNMT, suggesting the more important role of DNMT1. DNMT1 abundance was higher
than GNMT until 12 hpf when GNMT expression began to exceed DNMT1. At 96 hpf,
GNMT was about 5.6-fold higher than DNMT1, which is reasonable because GNMT is
one of the most abundant cytosolic proteins (Luka et al. 2009), but DNMT1 is usually
not highly expressed.
In embryos/larvae exposed to BaP from 2.5 hpf to 48, 60 or 96 hpf, alteration of
DNMT1 mRNA expression was not seen (Figure 19). Similarly, total DNMT activities
(including the 7 DNMT isozymes) in the nucleus were not affected (Figure 21). This is
contradictory to the previous findings that BPDE, the metabolite of BaP, was capable of
inhibiting DNMT activity in vitro (Pfeifer et al. 1984; Wilson and Jones 1983; Wilson and
Jones 1984; Wojciechowski and Meehan 1984). One possible explanation for the
discrepancy is that high doses of BPDE (1251.5 or 1650 μg/L) were used in the cell
experiments. Not only were our initial BaP doses lower (1-100 μg/L), the majority of BaP
would be metabolically deactivated, and the expected BPDE concentration in embryos
would be very low. Another possible reason that BaP did not affect DNMT activity is that
we were using whole embryo extracts for the DNMT assay. Although BaP did not affect
the overall DNMT activity by protein degradation or inhibitory binding, it may change the
DNMT enzyme activity locally by interfering with the interaction between DNMT and
DNA, leading to DNA demethylation (Wojciechowski and Meehan 1984).
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Similarly, zebrafish GNMT mRNA expression was not changed by the same BaP
waterborne exposure up to 96 hpf (Figure 20). However, there was a trend of BaP
induced upregulation in the GNMT enzyme activity, which is statistically significant only
by Student T-test (P=0.035) but not by ANOVA (Figure 22). If GNMT activity was
induced by BaP, it would be expected that the SAM supply would be decreased in the
embryos and lead to hypomethylation. Here we note that the GNMT results from
zebrafish were different from what we found in Fundulus where GNMT mRNA was
increased and enzyme activity was decreased by BaP. Therefore, these two fish species
may respond to BaP exposure differently in terms of GNMT expression. Furthermore,
the constitutive GNMT enzyme activity was about 7.7-fold higher in 96 hpf zebrafish
compared to the activity in 14 dpf Fundulus, implying that the two fish have differences
in the GNMT related pathways. Because Fundulus are able to develop tolerance to PAH
exposure, it would be interesting to test whether the decreased GNMT activity and
potentially increased SAM concentrations in Fundulus can protect the fish against BaP’s
demethylating effects.
Although the overall DNMT and GNMT expression were not affected by BaP, other
DNA methylation mechanisms could be adversely impacted and contribute to the
demethylation caused by BaP. For instance, BaP induced oxidative stress and DNA
damage might affect the recognition of DNA to the methyl-CpG binding protein and then
cause aberrant methylation. DNA demethylation might occur when BPDE-DNA adducts
are repaired by the nucleotide excision repair mechanism, which is well known to cause
hypomethylation by repairing DNA with unmethylated cytosines (Jost and Jost 1994).
Because histone modification and DNA methylation are interrelated, BaP might change
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the histone acetylation in gene promoters as it did in the breast cancer cell lines
(Sadikovic et al. 2008) and the hyperactylation regions may be demethylated (Cervoni
and Szyf 2001; Vaissiere et al. 2008).
To further study the BaP demethylation effects, 5 specific genes, i.e. vasa, RASSF1,
TERT, c-jun and c-Myca, were selected for sodium bisulfite sequencing analysis, which
is able to generate single nucleotide resolution of individual CpG methylation status.
Vasa is a germ cell specific gene that is regulated by hormone changes and is
deregulated by PAH exposure. Vasa is used as a germline marker to distinguish the
germ cell (including PGCs) population. Therefore, it is important to test whether
embryonic vasa methylation and expression as well as PGC migration patterns are
affected by BaP, which is known to compromise development and offspring fertility.
Because BaP is a potent carcinogen, it is also critical to see whether early life BaP
exposure will leave aberrant DNA methylation marks in cancer-related genes and cause
persistent gene expression changes and carcinogenesis in later life (Lu et al. 2010).
The tumor suppressor gene RASSF1 was selected because it is one of the most
frequently silenced genes by promoter hypermethylation in many cancer types. TERT is
a proto-oncogene that contributes to the immortality of tumor cells. c-Jun and c-Myca
are well validated proto-oncogenes and their gene expression is affected by BaP or
BPDE exposures (Qin and Meng 2006; Lu et al. 2010; Zhang and Shiverick 1997;
Fields et al. 2004). In addition, altered DNA methylation and subsequent gene
expression of c-Jun and c-Myca have been detected in chemically-induced tumors.
Furthermore, the target regions of the 5 genes represent sequences with different CpG
richness, and they are located in 5 different chromosomes (Figure 25, Table 4 and 12).
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Importantly, the CGI distribution, splicing and protein homology of the 5 genes are well
conserved between zebrafish and mammals (Figures 24, 31, 33, 34 and 35).
Table 12. Analysis of target CpG islands investigated in this study.
Gene
Length (bp)
C+G% CpG%
CpG ratio a
Type of CGI b
RASSF1 CGI 1
552
48.37
7.44
1.28
ICP
RASSF1 CGI 2
438
50.91
3.89
0.60
ICP
TERT
970
46.49
3.51
0.65
ICP
c-Jun
1610
55.47
7.02
0.92
HCP
c-Myca
920
51.63
4.68
0.70
ICP
vasa
212
32.08
2.36
0.92
LCP
a
See section: CpG island identification and classification (Chapter 3, Methods 21)
b
As assigned based on (Weber et al. 2007)

The vasa promoter is a LCP (Table 12) and would be predicted to be highly
methylated, which was supported by our results. The de novo DNA methylation in the
vasa promoter did not occur in the blastula stage (3.3 hpf) when the majority of the
methylation patterns are typically established (Figures 26 and 27). In fact, vasa
promoter did not begin to be methylated until 11 hpf and became fully methylated by 48
hpf. The DNA methylation pattern was thereafter consistent with the liver of adult
zebrafish. Therefore, vasa promoter de novo methylation occurred slowly during late
embryonic and early postnatal development instead of rapid remethylation in early
embryogenesis like most of the other genes do. Consistent with the increasing promoter
methylation during development, vasa mRNA expression was decreasing continuously
over the same period (Figure 27). The most dramatic decline of vasa mRNA occurred at
12 hpf, the same time-point when the promoter methylation percentage first became
significantly higher than the previous status. The opposite trends of DNA methylation
and gene expression suggest that vasa promoter methylation status was associated
with the zygotic vasa expression that was initiated at 3.3 hpf. However, it is possible that
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the decline of the mRNA transcripts is due to the slow degradation of the maternally
transferred mRNA. However, this assumption is unlikely to be true because the average
half-life of mRNAs are typically very short, for example, mRNA half-life was only 6.8 min
in E. coli (Selinger et al. 2003); globin mRNA was rather stable and had a half-life of a
few hours in mammalian cells (Shyu et al. 1989). Another concern is that the genomic
DNA was extracted from all embryo tissues whereas the vasa mRNA was predominately
being synthesized by the PGCs and only a small fraction of them originate from somatic
tissues. Therefore, it is necessary to isolate genomic DNA from isolated PGCs to
correlate the methylation with gene expression or do promoter reporter gene assay to
further support the inverse relationship between vasa promoter methylation and gene
expression.
We also found that BaP exposure significantly reduced vasa promoter methylation
and increased vasa mRNA expression in 96 hpf zebrafish larvae (Figure 29 and 30).
This suggests that demethylation of the LCP in vasa is permissive to gene activation,
further supporting the inverse relationship of vasa promoter methylation and gene
expression. Because vasa is required for PGC migration, our future study will measure
the PGC numbers, distribution (e.g. ectopic expression and final localization) and
migration pattern by doing whole mount two-probe ISH with our newly developed vasa
and heat shock protein 90α (HSP90α) DIG-cRNA probes. HSP90α is a somite specific
gene used to visualize the somites (Willey and Krone 2001), which serve as markers of
the fish body in order to localize PGC migration.
It is well conserved among human, rat, mice and zebrafish that the single copy of
RASSF1 can generate multiple transcript variants by using two different CGI promoters
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(Figure 31). Zebrafish RASSF1 has 5 transcripts and possibly 3 CpG rich promoters
crossing each TSS (Figure 32). Based on the cDNA alignment with the genomic DNA,
we found that RASSF1-001 is possibly controlled by the first promoter, RASSF1-201
and RASSF1-203 are controlled by the second promoter and RASSF1-002 and
RASSF1-202 are regulated by the third promoter. Because the first and second
promoters regulate the transcripts that are most similar to human RASSF1A and
RASSF1C, we selected them for DNA methylation analysis. Notably, the first promoter is
frequently reported to be hypermethylated in cancers and is responsible for the
RASSF1A silencing (Dammann et al. 2000). On the contrary, the methylation of the
second promoter is not affected in cancer, and thus, RASSF1C is usually not
deactivated (Vos et al. 2000; Li et al. 2004). Because the high identity between the 5
transcripts, it is a challenge to design specific qPCR primers to target each RASSF1
isoform. Instead, we measured all the isoforms of RASSF1 transcripts simultaneously
using the primer pairs located at exon 5 or 6 (Table 2). Our results showed that RASSF1
CGI-1 was almost 100% unmethylated in blastula embryos, early larvae and adult liver
(Figure 36), which is similar to the normal methylation pattern in the first promoter of
human RASSF1. In contrast, RASSF1 CGI-2 was heavily methylated (>92%) in 5-6 hpf
embryos and early larvae (Figure 37). In contrast to vasa, the methylation pattern for
RASSF1

CGI-2

was

established

during

early

embryogenesis

because

both

unmethylated and heavily methylated RASSF1 CGI-2 co-existed in 3.3 hpf blastula
embryos (Figure 37A). The methylation of RASSF1 CGI-2 was decreased in the aging
fish, which is similar to the trend of global DNA hypomethylation detected in aging
animal tissues. There was no apparent correlation between promoter methylation
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patterns and RASSF1 mRNA expression because the amplified mRNA was not specific
to reflect the transcripts that are regulated by CGI-1 or CGI-2. The mRNA expression
that was measured represented the total RASSF1 transcripts, which made it difficult to
relate each transcript to the individual promoter methylation. However, it was still highly
relevant to find differential RASSF1 expression in different stages of development
(Figure 38). The RASSF1 expression seems to correlate well with the growth pace of
the embryo because the mRNA was continuously increasing from 6 to 96 hpf when the
embryos experienced increased growth. This implicates that although RASSF1 is not
essential for development (Van der et al. 2005), it may be important to inhibit mitosis in
transformed cells and prevent the propagation of mutations or adverse epigenetic marks
that contribute to the tumorigenesis later in life (Donninger et al. 2007; Tommasi et al.
2005). BaP did not change the methylation patterns of the two RASSF1 promoters or
gene expression; however, it does not rule out the possibility that RASSF1 may be
affected under other the exposure conditions (e.g. a higher cancer-inducing dose of
BaP).
The proximal promoter of TERT was highly methylated (except in CpG #1) and
resistant to the global DNA methylation reprogramming process in early embryogenesis
(Figure 39). Although the methylation patterns were unchanged in blastula embryos,
early larvae and adult female livers, TERT mRNA abundances were significantly
different at these 3 developmental time-points. TERT expression was the highest in 96
hpf larvae when extensive cellular proliferation was occurring and requiring TERT to add
telomere ends to the newly-replicated DNA in the young animals. On the contrary, TERT
expression was the lowest in adult female liver because the aging animals were losing
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telomerase activity and capacity to repair their telomeres. BaP exposure at our
conditions did not change the TERT promoter methylation or gene expression (Figure
44).
c-Jun is an intronless gene with many CpGs within its gene body. It is rare for a
gene body to have dense CGIs because the majority of genes have a low-density of
CpG sites that are extensively methylated. Our study focused on the CGI in the coding
region of c-Jun. We found that the CpG sites were nearly 100% unmethylated, and the
methylation patterns were maintained from 3.3 hpf to 1.5 year-old zebrafish (Figure 40).
However, the c-Jun mRNA expression was significantly different throughout life. In
responding to the massive proliferation cues in the rapidly growing 96 hpf early larvae,
c-Jun mRNA signals increased by almost 380-fold compared to 3.3 hpf embryos. In the
liver of adult females, c-Jun expression decreased significantly, but were still about 39fold higher than the expression in 3.3 hpf embryos. This indicates that the low
methylation in the c-Jun gene body is permissive to gene expression but the actual
magnitude is determined by other factors such as transcriptional activators or
repressors. Although alteration of c-Jun expression by higher doses of BaP or BPDE
was reported in several publications (Sparfel et al. 2010; Qin and Meng 2006; Dreij et al.
2010; Lu et al. 2010), in vivo BaP exposure at 100 μg/L was unable to change the c-Jun
expression or gene body methylation (Figure 44).
Due to the genome duplication, zebrafish has two copies of c-Myc. Similar to
mammalian c-Myc, both zebrafish c-Myc genes have a non-coding first exon and two
coding exons. The two coding exons and the intron in-between contain a high density of
CpG sites. Zebrafish c-Myca is phylogenetically closer to mammalian c-Myc (Table 3),
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thus we analyzed c-Myca methylation and expression in this study. The target region
was in the second exon, which is within the coding region. The data showed that these
CpG sites had low methylation percentage through life (Figure 41). Interestingly, the first
two-thirds of the target region (CpG 1-20) had extremely low methylation whereas rest
of the target region (CpG 21-26) had higher methylation. Constitutively, the methylation
pattern and percentage at 96 hpf larvae was not different from those in 3.3 hpf embryos
and adult liver, however, the gene expression was significantly higher at 96 hpf possibly
participating in active cellular proliferation at this stage. Therefore, like c-Jun, the
unmethylated cytosines in the gene body are permissive to c-Myca transcription, but the
actual expression is also regulated by other transcriptional factors. Although the c-Myc
expression was changed after high doses of BaP or BPDE exposures (Fields et al. 2004;
Qin and Meng 2010; Zhang and Shiverick 1997; Akerman et al. 2004; Lu et al. 2009),
BaP at 100 μg/L did not affect zebrafish c-Myca expression or exon methylation (Figure
46).
We found that the CpG methylation status of the target sequences was linked to the
CpG content within them. For example, the LCP in vasa was highly methylated after de
novo methylation; some ICPs, like RASSF1 CGI-1 and c-Myca gene body, were
hypomethylated and some ICPs, like RASSF1 CGI-2 and TERT, were hypermethylated;
the LCP in c-Jun gene body was unmethylated. This agrees with the earlier study that
showed a similar relationship between CpG contents and methylation outcome in
human promoters (Weber et al. 2007). They proposed the reason for this relationship
may be that the DNMTs preferentially methylate the low density CpG sites but not the
rich CGIs. By comparing the constitutive DNA methylation and expression in the 5
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genes, we noticed that hypermethylated promoters in vasa and TERT are associated
with low mRNA expression (Figure 53). In contrast, hypomethylation in RASSF1 CGI-1,
intragenic c-Jun and c-Myc are linked to high mRNA expression. Although the causal
relationship requires further study, it is interesting to find how CpG methylation patterns
may predict the magnitude of gene expression. In this study, we did not find the positive
correlation between intragenic methylation and gene regulation (Zhang et al. 1999;
Zilberman et al. 2007). Both c-Jun and c-Myc have high gene expression with
hypomethylated gene bodies. The high content of unmethylated cytosines may increase
the copy number of mRNA being transcribed as well as improve the mRNA stability
(Bauer et al. 2010; Duan and Antezana 2003).
In this study, we also found that evolutionary CpG loss is apparent in the zebrafish
genome (Table 6). Similar to the finding in mammals, CpG mutations are targeting the
methylated cytosines in zebrafish. For example, lost CpG locations were identified in
both the heavily methylated RASSF1 CGI-2 and TERT promoters. Even the lost CpG
site in c-Myca was located at the end of the target region which had higher methylation.
In summary, BaP is a demethylating agent that causes global DNA hypomethylation
and gene specific loss of methylation in vasa promoter. However, the regions measured
in RASSF1, TERT, c-Jun and c-Myca were resistant to the BaP demethylation effects.
Deeper sequencing of the genomic DNA methylation after BaP treatment might lead to a
better illustration of the differential methylation loci. Further studies are also needed to
measure the long-term impact of early life DNA demethylation on phenotypes.
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Figure 53. Comparison of DNA methylation (A, C, E, yellow bars) and gene expression (B, D,
F, green bars) at 3.3 hpf, 96 hpf and adult female liver. For DNA methylation graphs, bars
represent CpG methylation percentage. For mRNA expression graphs, bars represent
expression of genes which were normalized to internal control 18S rRNA and relative to TERT
expression at the same time-point (2-∆∆CT method, *** P<0.001, **** P<0.0001; n= 3). Because
RASSF1, c-Jun and c-Myca had low methylation in CpG islands, their expression was higher
compared to TERT and vasa, which were highly methylated in their promoters.
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3. BaP effects on zebrafish reproduction and development
BaP is teratogenic to zebrafish development by causing growth retardation and
altering the morphology of head, tail and tail tip. The LC50 for zebrafish embryos is 5.1
μM (1285 μg/L) and the EC50 (the dosage that causes teratogenic changes in 50% of
the animals) is 0.52 μM (131 μg/L) (Weigt et al. 2011). Therefore, the teratogenic index
(LC50/EC50) is 9.81, indicating BaP produces higher incidence of teratogenic than lethal
effects. In this study, we saw delayed hatching, curved tail, abnormal head and
pericardial edema in the embryos exposed to 1, 10 and 100 μg/L BaP from 2.5 to 72 hpf.
However, the deformity percentage (9-18%) was not as severe as reported in a similar
study, which found that 55.0 ± 15.0% of zebrafish embryos were affected by 126 μg/L of
waterborne BaP exposure. The deformities they found were growth retardation and
head and tail abnormalities, which were similar to what we observed (except the cardiac
toxicities).
We also tested the BaP (22.5 ± 2.3 or 42.0 ± 1.9 μg/L) effects on the reproduction
of adult zebrafish. After waterborne BaP (42.0 ± 1.9 μg/L) exposure, unmetabolized BaP
(< 4 ng/ovary) was detected in the zebrafish ovaries, suggesting BaP might affect the
genetic and epigenetic integrity in the oocytes. The egg production was non-significantly
decreased by BaP exposure. However, when the offspring were continuously exposed
to BaP, their survival rate dropped significantly and deformities were observed (Figure
49 and 50). Consistent to our earlier findings, global DNA methylation percentage was
decreased in the 96 hpf larval offspring (Figure 51), which might contribute to the high
mortalities.
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In summary, BaP can distribute to zebrafish gonads and might disrupt the
gametogenesis, resulting in poor health in the offspring. BaP exposure to zebrafish
embryos alone was able to cause teratogenic effects including pericardial edema and
tube heart formation. Therefore, BaP is also a reproductive and developmental toxicant
to zebrafish.
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CHAPTER 6. CONCLUSIONS
Fundulus GNMT cDNA was cloned, and it encodes a protein having high identity
with human and zebrafish GNMT. From the Fundulus embryo studies, we found that
BaP exposure tissue-specifically induced GNMT mRNA expression but decreased
GNMT enzyme activity. However, these effects were not observed in zebrafish,
indicating that the two fish species may respond to BaP exposure differently in terms of
GNMT expression. Similarly, BaP exposure did not change DNMT1 mRNA expression
or enzyme activity in zebrafish. However, direct waterborne BaP treatment in zebrafish
embryos significantly decreased global DNA methylation and gene-specifically reduced
promoter CpG methylation in vasa. As a result, vasa mRNA expression was significantly
induced after BaP exposure. However, the same BaP exposure did not change CpG
island methylation or gene expression in zebrafish RASSF1, TERT, c-Jun and c-Myca.
Therefore, BaP is a potential epigenetic modifier for global and gene specific DNA
methylation status in zebrafish embryos and the alteration is possibly not mediated by
affecting DNMT1 and GNMT activities.
Teratogenic effects (e.g. delayed hatching, pericardial edema, head and tail
deformity) were observed in the BaP-treated zebrafish embryos. After BaP waterborne
exposure to adult zebrafish, unmetabolized BaP can be detected in the ovaries.
Although overall egg production was not affected, the offspring from exposed parents
may be more susceptible to further BaP exposure after fertilization. The survival rate of
the BaP exposed offspring was significantly decreased and deformities were observed.
Furthermore, DNA hypomethylation was detected in the offspring.
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Our study also expands the knowledge of constitutive DNA methylation in the
zebrafish model. We found that evolutionary CpG loss also occurs in the zebrafish
genome and preferentially targets methylated cytosines. The CpG island distributions
and functions of the five genes (vasa, RASSF1, TERT, c-Jun and c-Myc) are conserved
among human, rat, mouse and zebrafish. We confirmed that zygote demethylation and
remethylation are conserved in zebrafish. This study is the first to find an additional
wave of DNA demethylation that occurs during late embryogenesis or early larvae
development in zebrafish. The de novo methylation of TERT occurred rapidly during
early embryogenesis. In vasa promoter though, the methylation pattern was established
at later stages of development. In the five genes, methylation patterns that were
established in early life were maintained consistently in the liver through the life span.
However, evidence for DNA demethylation also occurred in the aging zebrafish (1.5
years old) reflected by reduced methylation in RASSF1 CGI-2.
In conclusion, BaP is a demethylating agent that can cause both global and gene
specific DNA demethylation in vivo. The DNA methylation mechanisms are highly
conserved in zebrafish, which makes it a great model to study chemical induced
epigenetic toxicities.
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Protocol 1. Zebrafish breeding and embryo collection
Fish used for reproduction should meet the following criteria:
1. Fish are healthy without any deformities or diseases.
2. Fish are between 4 to 12 months old with body length longer than 2 cm.
3. Put less than 60 fish in a 10 L tank. The male to female ratio is about 1:2. Males
and females should have been born from different parents and grown up in
separate tanks before they are combined.
4. Do not use egg-bound female fish.
5. If no, few eggs or high percentage of deformed eggs are produced in a tank,
change one or both sexes of the fish.
6. It is critical to pair the breeders at about 3-months old. Fish not matched with
suitable mates grow smaller in size and their secondary sex characteristics
(redness in males and round belly in females (not too round)) develop later and
are less obvious.
7. Newly selected breeders lay more unfertilized eggs in the beginning.
Day 1 (after 4:00 pm)
1. Put a mesh Tupperware into the bottom of the tank to prevent the parental fish
from eating the eggs. A mesh Tupperware is made by sewing a plastic mesh
(pore size: 0.3 x 0.4 cm) with fish lines and plastic zip ties to the cut-open lid
(Figure 54).
2. Set up the sign “no food” on top of the spawning tank.
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Figure 54. Mesh Tupperware.

Day 2
1. Light is turned on at 8:00 am. Allow the fish to spawn for 0.5 -1 hour without any
disturbance.
2. Take out the mesh Tupperware carefully. Feed the parental fish.
3. Pour the water into a fish net (net cloth mesh: 0.1 x 0.1 cm) to gather the eggs.
4. Immerse and shake the eggs inside the net in clean zebrafish water to filter
through small dead embryos (opaque) and debris.
5. Put the eggs in a fish finger bowl and use a plastic pipette to remove bigger dead
embryos and debris.
6. Transfer the eggs to a mesh basket (Figure 55) half-immersed in a fish bowl.

Figure 55. Mesh basket.
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7. Rinse the eggs several times by dipping the mesh basket in several changes of
zebrafish water until all the debris is gone.
8. Transfer the eggs into a Petri dish.
9. Add 50 ml autoclaved, oxygenated (pump air in with an air stone) zebrafish water
(0.06 g Instant Ocean and 0.05 g sodium bicarbonate in 1 L of water) with 0.4
ppm of methylene blue (20 μl stock methylene blue (0.1%) to 50 ml zebrafish
water).
10. Sort out and stage the fertilized eggs (Kimmel et al. 2005) under a dissecting
microscope for further usage.
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Protocol 2. Zebrafish larvae raising protocol
Day 0
•

Fish (~50) are raised in Petri dishes (80mm X 15mm) in an 818 Low Temp
Illuminated Incubator (Precision Scientific, Chennai, India.) which keeps the
temperature at 28.5ºC and a light-dark cycle at 14:10.

•

Add methylene blue to the autoclaved zebrafish water (final concentration is 0.4
ppm) to avoid fungus infection.

•

Remove all dead embryos at the end of the day because some zebrafish
embryos die off during the first day post fertilization.

Day 1
•

Remove dead embryos in the morning.

•

Change the methylene blue water with new autoclaved zebrafish water.

Day 2-4
•

Zebrafish are kept in an 818 Low Temp Illuminated Incubator without feeding or
water changing.

Day 5-11
•

Healthy larvae (~80-100) are transferred to a 1.5 L tank and put into the Aquatic
Habitats ZF0601 Zebrafish Stand-Alone System (Aquatic Habitats, Apopka, FL).

•

Tape the slots in the divider and cover the draining hole with a 500 micron mesh.

•

Adjust the water flow to 0.1 ml/second. This is a slow, steady drip running 24
hours a day.

•

Larvae are fed twice daily with ArteMac-0 powered food (20-80 micron size, BioMarine, Hawthorne, CA). Add ~0.1g ArteMac to 20 ml DI water in a conical tube
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and mix well. Feed 2 ml of the ArteMac to each tank.
Day 12-14
•

Larvae are fed twice daily with 1 ml of ArteMac-0 powered food and 2 squirts of
live brine shrimp (Salt Creek Inc., Salt Lake City, UT).

Day 15-30
•

Larvae are fed twice daily with 3 squirts of live brine shrimp.

•

Adjust the water flow to 0.5 ml/second. This is a rapid drip, just below a stream.

Day 31-60
•

Larvae are transferred to a 3 L tank.

•

Remove the 500 micron mesh in the draining hole.

•

Larvae are fed twice daily with 2 squirts of live brine shrimp and tropical flake fish
food (Tetramin, Tetra Werke, Germany).

•

Increase water flow to continuous stream.

Day 61-120
•

Larvae are transferred to a 10 L tank.

•

Remove the tape on the divider.

•

Larvae are fed twice daily with 2 squirts of live brine shrimp and tropical flake fish
food (Tetramin, Tetra Werke, Germany).

•

Mature zebrafish are selected for reproduction.
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Protocol 3. Sodium bisulfite PCR
Preparing solutions
3 M NaOH:
0.5132 g NaOH to 4.167 ml autoclaved deionized (DI) H2O
1 M hydroquinone: (fresh made)
0.11 g hydroquinone to 1 ml autoclaved DI H2O
avoid light (wrap the tube with aluminum foil), warm at 50 ºC and vortex
5 M sodium bisulfite solution + hydroquinone solution, pH 5.0: (fresh made)
(calculate 0.5 ml/sample)
For 4 ml of solution:
1.9 g sodium metabisulfite
3 ml autoclaved DI H2O
0.5 ml 3 M NaOH (final pH is ~4.897)
0.5 ml 1 M hydroquinone (keep warm)
Avoid light (wrap the tube with aluminum foil), warm at 50 ºC and vortex.
Day 1 Sodium bisulfite treatment
1. Bring up the volume of genomic DNA (1-1.5 μg) to 18 μl with autoclaved DI water
in 8-well strips.
2. Heat at 95ºC for 20 min in the thermal cycler.
3. Put the samples to ice immediately and chill for 5 min.
4. Add 2 μl of 3 M NaOH (final concentration is 0.3 M) and incubate at 42 ºC for 20
min in the thermal cycler to denature DNA.
5. Transfer the denatured DNA mix to 1.7 ml eppendorf tubes. Add 380 μl of the
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fresh made 5 M sodium bisulfite + hydroquinone solution.
6. Wrap the tubes with aluminum foils and incubate in 50ºC water bath in the dark
for 12-16 hrs. Significant degradation may occur if incubate longer.
Day 2 EZ Bisulfite DNA Clean-up Kit (ZYMO Research)
1. Add 4 volumes of M-Binding Buffer to each volume of a bisulfite-converted
sample.
2. Transfer the mixture into a Zymo-Spin™ IC Column.
3. Centrifuge at 10,000X g for 30 seconds. Discard the flow-through.
4. Add 100 μl of M-Wash Buffer to the column. Centrifuge at 10,000X g for 30
seconds.
5. Add 200 μl of M-Desulphonation Buffer to the column and let stand for 20
minutes at room temperature.
6. Centrifuge at 10,000X g for 30 seconds. Discard the flow-through.
7. Add 200 μl of M-Wash Buffer to the column.
8. Centrifuge at 10,000X g for 30 seconds. Discard the flow-through.
9. Add another 200 μl of M-Wash Buffer.
10. Centrifuge at 10,000X g for 30 seconds. Discard the flow-through.
11. Place the column into a 1.7 ml eppendorf tube.
12. Add 10 μl of M-Elution Buffer to the matrix of the column.
13. Centrifuge for 30 seconds at 10,000X g. Collect the flow-through as the bisulfiteconverted DNA.
14. DNA is ready for immediate use or can be stored at -20°C for later use. For long
term storage, store at -70°C.
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15. Conversion efficiency and recovery of this method is shown in (Table 5 and
13)．
Table 13. Recovery of genomic DNA after sodium bisulifite conversion.
Start amount of DNA (ng)
500
1000
2000
3000

DNA amount after conversion (ng)
324
656
1186
2303

Recovery
64.8%
65.6%
59.3%
76.8%

PCR
General rules for primer design
1. Amplify a DNA fragment no more than 500 bp.
2. Primer length is about 20-30 bp.
3. Avoid CpGs inside of the primer. If you can not avoid CpG, replace C with a C/T
on the forward primer or G/A on the reverse strand.
4. Primers should contain 30% non-CG Cs which are replaced by T in the forward
primer and by A in the reverse primer.
5. Design

with

Methyl

Primer

Express

v1.0

or

MethPrimer

(http://www.urogene.org/methprimer/index1.html).
PCR
1. Use in a 50 μl reaction with 1 μl of the bisulfite-converted DNA (300-600 ng/μl)
and 2 μl of 10 μM forward and reverse primers.
2. For method optimization, try several primer combinations and use published
primers as positive control.
3. It usually works better if annealing temperature is 45-50ºC.
4. It may need longer extension time (2-3 min, at least for the first PCR).
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5. It may need nested/second PCR for best amplification.
6. Try to use hot-start Taq polymerase (activated by heating at 95°C for 10 min).
7. Use the initial PCR program: 94°C 10 min, 1 cycle; 94°C 1 min, 45°C 2 min, 72°C
3 min, 5 cycles; 94°C 0.5 min, 45°C 2 min, 72°C 1.5 min, 35 cycles; 72°C 10 min,
1 cycle.
8. After you get a PCR product, optimize the PCR program, such as increase
annealing temperature, reduce extension time, increase/decrease the amount of
template DNA, primers or adjust cycle numbers. It might be necessary to initially
reduce the annealing temperature to 45°C and set total cycle number at 40.
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Protocol 4. Preparation of high efficient competent DH5α E.coli cells
Preparing CCMB80 buffer
•

10 mM KOAc pH 7.0 (10 ml of a 1 M stock/L (stock: 9.815 g in 0.1 L H2O) )

•

80 mM CaCl2·2H2O (11.8 g/L)

•

20 mM MnCl2·4H2O (4.0 g/L)

•

10 mM MgCl2·6H2O (2.0 g/L)

•

10% glycerol (100 ml/L)

•

adjust pH down to 6.4 with 0.1 M HCl if necessary (~3 ml 0.1 M HCl/L)

•

autoclave and store at 4°C (slight dark precipitate appears not to affect its
function)

Preparing glassware
Detergent should be eliminated in glassware. Avoid washing glassware with
detergent. Fill the glassware with ¾ of DI water and autoclave.
Prechill plasticware and glassware
Prechill centrifuge tubes, pipet tips, and glassware before use.
Preparing seed stocks
1. Spread stock E.coli cells (Invitrogen) on an agar LB plate (without any antibody)
and grow overnight at 37°C until single colonies appear.
2. Pick a single colony into 2 ml of LB medium and incubate overnight at 37°C, 220
RPM.
3. For short term usage, store the culture in 4°C refrigerator. For long term storage,
increase glycerol concentration to 15%, aliquot 1 ml of culture to each eppendorf
tube, quick freeze in dry ice for 5 minutes, and place in -80°C freezer indefinitely.
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Preparing competent cells
1. Inoculate 100 to 250 ml of SOB or LB medium with seed stock E.coli and grow at
37°C, 220 RPM to an OD 600nm of 0.3 (test with biophotometer (Eppendorf,
Hamburg, Germany), no dilution needed). Aim for lower, not higher OD.
2. Transfer 50 ml E. coli culture to each conical tube and centrifuge at 5,000X g at
4°C for 10 min. Discard the medium.
3. Gently resuspend the cells with 1 ml of ice cold CCMB80 buffer.
4. Add 14 ml of ice cold CCMB80 buffer to the cells and mix them gently.
5. Sit on ice for 20 min.
6. Centrifuge at 5,000X g at 4°C and discard the supernatant.
7. Resuspend cells in 2.5 ml of ice cold CCMB80 buffer.
8. Sit on ice for 20 min.
9. Aliquot to chilled 1.7 ml eppendorf tubes or chilled 8-well strips (100 μl/aliquot).
10. Place on dry ice for 5 min and store at -80°C indefinitely.
Test competence (optional)
1. Add 2.5 μl pUC19 control (Invitrogen, 100 pg/μl) to 100 μl of cells.
2. Proceed by following the Cloning Protocol until single colonies grow on the plate.
3. Calculate transformation efficiency. Transformation efficiency (# transformants/μg
DNA) = (# of colonies x 106 pg x volume of transformants x dilution factor)/(pg
pUC19 DNA x μg x X μl plated).
4. The expected transformation efficiency should be between 5x108 and 5x109
cfu/µgDNA.
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Protocol 5. High speed ethidium bromide gel electrophoresis
Preparing gel electrophoresis buffer (20x sodium boric acid buffer)
1. Dissolve 8 g sodium hydroxide (NaOH) with 700 ml nanopure H2O.
2. Add 53 g boric acid (H3BO3, electrophoresis grade).
3. Bring up to 1 L with nanopure H2O (add boric acid to adjust the final pH to 8.0,
usually not needed).
4. Store the stock buffer at room temperature.
5. Dilute stock buffer to 1x with nanopure H2O for use.
Preparing 1% agarose gel
1. Add 10 g agarose to 50 ml 20X sodium boric acid buffer.
2. Bring up to 1 L with nanopure H2O.
3. Heat and stir until solution turns clear.
4. Divide solutions into 50 ml conical tubes for future usage.
Gel electrophoresis
1. Melt the 1% agarose gel in microwave. Add 1 μl ethidium bromide to every 50 ml
of gel.
2. Pour the gel in to the casting tray, insert the comb, and let the gel solidify.
3. Take out the comb carefully and place the gel into the gel box.
4. Mix samples with 6X loading dye.
5. Load the samples and markers to the wells.
6. Run the gel at 300 V for 8 min or 200 V for 15 min or 100 V for 36 min.
7. Image by using VersaDoc Gel Imaging System (Bio-Rad, Hercules, CA).
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Protocol 6. Transformation of E.coli competent cell
SOB Medium
For 200 mL, mix the following broth and Mg solution at 100:1 ratio in a sterile
environment.
Broth
Bacto-tripton

4g

Yeast extract

1g

5 M NaCl

0.4 mL

3 M KCl

0.167 mL

Add nanopure water up to 200 mL.
Autoclave
Mg solution
MgSO4·7H2O

2.465 g

MgCl2·6H2O

2.033 g

Add nanopure water up to 10 mL.
Autoclave
SOC Medium
Mix SOB medium and the following glucose solution at 100:1 in a sterile
environment.
Glucose

3.603 g

Add nanopure water up to 10mL.
Autoclave
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Cloning
1. Gently pipette 100 μl competent cells to the bottom of culture tube.
2. Add DMSO 1 μl (optional).
3. Add 5 μl of pGEM T easy vector ligased with the target DNA fragment.
4. Mix gently and chill on ice for 30 min.
5. Heat shock at 37ºC for 30 sec (optional).
6. Chill on ice for 2 min.
7. Add 1 ml SOC medium.
8. Incubate at 37ºC, 220 RPM for 45-60 min in an Excella® Benchtop Incubator
Shaker (New Brunswick Scientific, Edison, NJ).
9. Spread 20 µl X-gal (50 mg/ml) and 20 µl IPTG (100 mM) on to the LB agar plates
with ampicillin or carbenicillin (100 μg/ml) and keep them upside down for 15 min
at room temperature.
10. Centrifuge the E.coli cells at 3,000X g for 5 min. Suck out the majority of the
supernatant until leaving about 100 μl of LB in the culture tube.
11. Resuspend the E.coli and spread the 100 μl from each transformation on the prewarmed selective agar plates.
12. Incubate plates upside down at 37ºC over night (12-16 hrs).
13. Store the plates at 4ºC until use.
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Protocol 7. Isolate DNA from 3.3 hpf zebrafish embryos
Sample storage
1. Put embryos in cryovials and rinse with 100% ethanol.
2. Suck out ethanol and add new 100% ethanol.
3. Snap freeze in liquid nitrogen for 5 min.
4. Store in -80ºC for later use.
Method 1. Phenol/chloroform extraction
Preparing solutions
Proteinase K storage buffer (50 mM Tris-HCl pH 8.0, 10 mM CaCl2)
0.3029 g Tris-HCl
0.0555 g CaCl2
Adjust pH to 8.0 with 1 M HCl
Add autoclaved DI H2O to 50 ml
Proteinase K reaction buffer (50 mM Tris-HCl pH 8.0, 100 mM NaCl and 1% SDS)
0.3029 g Tris-HCl
1.4612 g EDTA
0.2922 g NaCl
0.5 g SDS
25 ml 100 mM Tris-HCl (pH 8.0)
Adjust pH to 8.0 with 1 M HCl
Add autoclaved DI H2O to 50 ml
125 μg/μl proteinase K
12.5 mg proteinase K
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100 μl proteinase K storage buffer
DNA extraction
1. Homogenize pooled samples in 300 μl proteinase K buffer for 2 min with a pestle
motor.
2. Add 700 μl proteinase K buffer and 14.5 μl 125 μg/μl proteinase K.
3. Incubate at 56 ºC overnight.
4. Add 4 μl RNase A (100 mg/ml) and let stand in room temperature for 5 min.
5. Centrifuge at 12,000X g for 10 min at room temperature.
6. Divide the supernatant equally into two 1.7 ml eppendorf tubes.
7. Add an equal volume of phenol:chloroform:isoamyl-alcohol (25:24:1) (SigmaAldrich) to each tubes (about 600 μl).
8. Mix for 30 sec and let stand for 10 min at room temperature.
9. Centrifuge at 12,000X g at 4 ºC for 15 min.
10. Transfer the aqueous layer (top) to a new tube.
11. Add an equal volume of chloroform:isoamyl-alcohol (24:1) (Sigma-Aldrich), mix
well and let stand at room temperature for 5 min.
12. Centrifuge at 12,000X g at 4 ºC for 10 min.
13. Transfer aqueous layer (top) to a new tube.
14. Add an equal volume of ice cold isopropanol (Sigma-Aldrich). Mix well.
15. Centrifuge at 12,000X g at 4 ºC for 10 min.
16. Discard the supernatant and wash with ice cold 70% ethanol.
17. Centrifuge at 8,000X g at 4 ºC for 5 min.
18. Discard the supernatant. Dissolve the DNA-pellet in 100 μl TE buffer.
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19. Add 4 μl RNase A (100 mg/ml) and let stand at room temperature for 5 min.
20. Purify DNA with DNA Clean & Concentrator kit (ZYMO Research). Add 2X
volume of DNA binding buffer.
21. Transfer mixture to a provided Zymo-Spin Column in a collection tube.
22. Centrifuge at 12,000X g for 30 sec. Discard the flow-through.
23. Add 200 μl of Wash Buffer to the column. Centrifuge at 12,000X g for 30 sec.
Discard the flow-through.
24. Repeat the wash step.
25. Add 20 or 30 μl TE buffer or water to the column matrix.
26. Transfer the column to a 1.7 ml eppendorf tube and centrifuge 12,000X g for 30
sec to elute the DNA.
Method 2. DNA extraction with DNAzol (Molecular Research Center, Cincinnati,
OH)
1. Homogenize pooled samples in 300 μl DNAzol for 2 min with a pestle motor.
2. Add 700 μl DNAzol, 14.5 μl 125 μg/μl proteinase K and 15 μl polyacryl carrier
(Molecular Research Center).
3. Incubate at room temperature overnight.
4. Add 4 μl RNase A (100 mg/ml) and store at room temperature for 5 min.
5. Centrifuge at 12,000X g at 4 ºC for 10 min.
6. Transfer the supernatant to a new tube. Add 500 μl 100% ethanol.
7. Mix samples by inverting tubes 8 times and store at room temperature for 3 min
to precipitate DNA.
8. Centrifuge at 10,000X g at 4 ºC for 5 min.
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9. Discard liquid. Wash the DNA pellet twice with 1.0 ml of 75% ethanol.
10. Centrifuge at 1,000X g at 4 ºC for 2 min.
11. Dissolve the DNA-pellet in 100 μl TE buffer.
12. Add 4 μl RNase A (100 mg/ml) and let stand at room temperature for 5 min.
13. Purify DNA with DNA Clean & Concentrator kit (ZYMO Research). Add 2X
volume of DNA binding buffer.
14. Transfer mixture to a provided Zymo-Spin Column in a collection tube.
15. Centrifuge at 12,000X g for 30 sec. Discard the flow-through.
16. Add 200 μl of Wash Buffer to the column. Centrifuge at 12,000X g for 30 sec.
Discard the flow-through.
17. Repeat the wash step.
18. Add 20 or 30 μl TE buffer or water to the column matrix.
19. Transfer the column to a 1.7 ml eppendorf tube and centrifuge 12,000X g for 30
sec to elute the DNA.
Method 3. DNA extraction with Qiagen DNeasy Blood & Tissue Easy Kit (Qiagen)
1. Homogenize pooled samples in 180 μl Buffer ALT for 2 min with a pestle motor.
2. Add 14.5 μl 125 μg/μl proteinase K and incubate overnight at 56 ºC.
3. Add 4 μl RNase A (100 mg/ml) and let stand at room temperature for 5 min.
4. Centrifuge at 12,000X g at room temperature for 10 min.
5. Transfer the supernatant to a new tube.
6. Vortex for 15 sec. Add 200 μl Buffer AL to the sample and vortex. Add 200 μl
100% ethanol and mix again by vortexing.
7. Load the mixture to the DNeasy Mini spin column placed in a collection tube.
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8. Centrifuge at 6,000X g for 1 min. Discard flow-through.
9. Add 500 μl Buffer AW1 to the column and centrifuge at 6,000X g for 1 min.
Discard flow-through.
10. Add 500 μl Buffer AW2 to the column and centrifuge at 16,000X g for 5 min.
11. Place the DNeasy Mini spin column in a new 1.7 ml eppendorf tube. Pipet 20-50
μl Buffer AE onto the DNeasy membrane.
12. Incubate at room temperature for 1 min. Centrifuge for 1 min at 6,000X g.
13. Put the DNeasy Mini spin column in a new 1.7 ml eppendorf tube. Pipet another
20-50 μl Buffer AE onto the DNeasy membrane.
14. Incubate at room temperature for 1 min. Centrifuge for 1 min at 6,000X g.
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Protocol 8. In situ hybridization probe synthesis
Day 1 Cut circular plasmid DNA to linear DNA
1. Select the right DNA cutting enzyme and RNA polymerase.
•

If DNA fragment is inserted in forward position and you want a sense
probe, use SP6 cutting enzymes for digestion and T7 polymerase for
probe synthesis.

•

If DNA fragment is inserted in forward position and you want an anti-sense
probe, use T7 cutting enzymes for digestion and Sp6 polymerase for
probe synthesis.

•

If DNA fragment is inserted in reverse position and you want sense probe,
use T7 cutting enzymes for digestion and Sp6 polymerase for probe
synthesis.

•

If DNA fragment is inserted in reverse position and you want an anti-sense
probe, use SP6 cutting enzymes for digestion and T7 polymerase for
probe synthesis.

•

Cutting enzymes should leave a 5’ overhang. The best T7 cutting enzyme
is NcoI and the best SP6 cutting enzymes are SpeI and NdeI.

•

Check the enzyme recognition cites of the DNA insert with NEBcutter V2.0
(http://tools.neb.com/NEBcutter2/index.php). Make sure the digestion
enzyme will not cut the DNA insert.

2. Set up the digestion mixture (total volume is 50 μl)
5 μl buffer
5 μl DNA cutting enzyme (New England Biolabs, Ipswich, MA)
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X μl plasmid DNA (total amount is 5 μg)
(40-X) μl autoclaved
3. Incubate at 37 ºC overnight.
Day 2 Clean up linear DNA and synthesize probe
Purify linear DNA with DNA Clean & Concentrator Kit (ZYMO Research)
1. Add 2X volume of DNA binding buffer to the linear DNA.
2. Transfer mixture to a provided Zymo-Spin Column in a collection tube.
3. Centrifuge at 12,000X g for 30 sec. Discard the flow-through.
4. Add 200 μl of Wash Buffer to the column. Centrifuge at 12,000X g for 30 sec.
Discard the flow-through.
5. Repeat the wash step.
6. Add 12 μl DEPC water (incubate 500 μl DEPC with 500 ml of DI water overnight
and autoclave) to the column matrix.
7. Transfer the column to a 1.7 ml eppendorf tube and centrifuge at 12,000X g for
30 sec to elute the DNA.
8. Quantitate the DNA concentration with Nano-drop (Thermo Scientific).
Check the quality of linear DNA by gel electrophoresis
1. Prepare 1% agarose gel with sodium boric acid buffer (Appendix Protocol 5).
2. Mix 1 μl linear or plasmid DNA with 1 μl 6X loading dye and 4 μl autoclaved DI
water.
3. Load the samples and marker to the wells.
4. Run the gel at 200 V for 15 min.
5. High quality linear DNA should have a sharp, bright band that migrates further
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compare to its original plasmid DNA.
Transcribe cRNA probe
1. Set up the reaction mixture (total volume is 20 μl)
2 μl 10X polymerase buffer (Roche)
2 μl digoxigenin RNA mix (Roche)
1 μl RNase inhibitor
2 μl 100 mM dithiothreitol (DTT, fresh made)
2 μl T7/Sp6 polymerase (Roche)
X μl linear DNA (total amount is 1 μg)
(20-X) μl DEPC water
2. Incubate at 37 ºC for 2-4 hours in a thermal cycler.
Remove DNA template
1. Add 2 μl RNase-free DNase (Qiagen) to remove template DNA.
2. Incubate at 37 ºC for 15 min in a thermal cycler.
3. Terminate reaction by incubating at 64 ºC for 10 min.
Purify cRNA probe with Illustra Probe Quant G-50 Micro Columns (GE Healthcare,
Pittsburgh, PA)
1. Add 25 μl DEPC water to cRNA probe.
2. Vortex the spin column for 30 sec.
3. Break the tip of the spin column and put it on a collection tube.
4. Centrifuge at 800X g for 1 min. If column is too dry after centrifuge, add 200 μl
DEPC water to the column and repeat the centrifuge in a lower speed.
5. Place the column to a 1.7 ml eppendorf tube.
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6. Apply probe to the center of the resin. Avoid adding probe to the side of the
column.
7. Centrifuge at 1,000X g for 2 min.
8. Quantify the cRNA probe with Nano-drop.
Check the quality of cRNA probe by gel electrophoresis
1. Prepare 1% agarose gel with sodium boric acid buffer (Appendix Protocol 5).
2. Mix 4 μl purified cRNA probe with 1 μl 6X loading dye and 1 μl DEPC water.
3. Load the samples and marker to the wells.
4. Run the gel at 200 V for 15 min.
5. High quality linear DNA should have a sharp and bright band with the size slightly
longer than the DNA insert to the plasmid (enzymes cut a short fragment of
vector DNA with the insert DNA). Sometimes it is acceptable to have a second
but weaker band.
Store the cRNA probe
1. Dilute the probe to 20 ng/ μl with hybridization buffer (-) (20X SSC (pH 6.0)
12.5 ml, formamide 25 ml, 10% Tween 20 0.5 ml (0.01%), DEPC water
12 ml).
2. Store at -20 or -80 ºC.
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Protocol 9. BaP extraction from zebrafish ovary
1. Ovary is weighed and homogenized in 3 ml CH2Cl2 in a glass disposable
culture tube (12X77 mm, Fisher Scientific) with a Tissue Tearor (Biospec
Products, Bartlesville, OK) for 3 min.
2. Add 20 μl surrogate standard internal standard (contains napthalene d8,
acenaphthalene d10, phenanthrene d10, chrysene d12 and perylene d12; all
compounds were at 0.2 mg/L in stock solution, use 20 μl, which is 0.004
μg/compound/sample). Cover the tube with aluminum foil to reduce CH2Cl2
evaporation.
3. Centrifuge at 3,000X g at 4ºC for 5 min.
4. Use Pasteur pipette to suck out the CH2Cl2 layer in the bottom.
5. Add 1 ml CH2Cl2 to the tissue layer and break it with a Pasteur pipette. Add
another 1 ml of CH2Cl2. Vortex and centrifuge at 3,000X g at 4ºC for 5 min.
6. Repeat step 4 and 5.
7. Combine the CH2Cl2 extracts and purify with a Na2SO4 (2 g) column.
- Activate Na2SO4 in an oven.
- Insert glass wool in a Pasteur pipette.
- Add 2 g activated Na2SO4 to the Pasteur pipette.
- Add CH2Cl2 to pack the column.
- Transfer the CH2Cl2 extracts to the column.
- Collect the filtered CH2Cl2 extracts.
- Add CH2Cl2 to wash the column.
8. Combine CH2Cl2 extracts and purify with an alumina (1.5 g) column.

219

- Deactivate alumina (multiply the amount weighed out in grams times 0.01
and add the resulting number as milliliter DI water to the alumina.
- Rotate alumina in a flask slowly for at least one hour for deactivation.
- Insert glass wool in a Pasteur pipette.
- Add 1.5 g deactivated alumina and 0.5 g activated Na2SO4 to the Pasteur
pipette.
- Add CH2Cl2 to pack the column.
- Transfer the CH2Cl2 extracts to the column.
- Collect the purified CH2Cl2 extracts.
- Add CH2Cl2 to wash the column.
9. Combine all the CH2Cl2 extracts and blow down with nitrogen gas.
10. Dissolve the residue with 180 μl hexane.
11. Transfer the hexane solution to an insert and put it in a GC vial.
12. Add internal standard d12 benzo(a)pyrene and d10 fluorene (2 mg/L in stock
solution, use 20 μl, which is 0.04 μg/sample).
13. Analysis was performed by gas chromatography (Agilent 6890) coupled with
mass spectrometry (Agilent 5973N) in selected ion monitoring mode.
Standard curves were constructed with 0.02, 0.08, 0.2, 1, and 2 μg/mL of all
non-deuterated compounds prepared in hexane.
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